Note: Descriptions are shown in the official language in which they were submitted.
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
CONJUGATES FOR TREATING DISEASES
TECHNICAL FIELD
The present disclosure relates to pyrrolobenzodiazepine (PBD) prodrugs and
conjugates
thereof. The present disclosure also relates to pharmaceutical compositions of
the conjugates
described herein, methods of making and methods of using the same.
BACKGROUND
The mammalian immune system provides a means for the recognition and
elimination
of pathogenic cells, such as tumor cells, and other invading foreign
pathogens. While the
immune system normally provides a strong line of defense, there are many
instances where
pathogenic cells, such as cancer cells, and other infectious agents evade a
host immune
response and proliferate or persist with concomitant host pathogenicity.
Chemotherapeutic
agents and radiation therapies have been developed to eliminate, for example,
replicating
neoplasms. However, many of the currently available chemotherapeutic agents
and radiation
therapy regimens have adverse side effects because they lack sufficient
selectivity to
preferentially destroy pathogenic cells, and therefore, may also harm normal
host cells, such as
cells of the hematopoietic system, and other non-pathogenic cells. The adverse
side effects of
these anticancer drugs highlight the need for the development of new therapies
selective for
pathogenic cell populations and with reduced host toxicity.
Researchers have developed therapeutic protocols for destroying pathogenic
cells by
targeting cytotoxic compounds to such cells. Many of these protocols utilize
toxins conjugated
to antibodies that bind to antigens unique to or overexpressed by the
pathogenic cells in an
attempt to minimize delivery of the toxin to normal cells. Using this
approach, certain
immunotoxins have been developed consisting of antibodies directed to specific
antigens on
pathogenic cells, the antibodies being linked to toxins such as ricin,
Pseudomonas exotoxin,
Diptheria toxin, and tumor necrosis factor. These immunotoxins target
pathogenic cells, such
as tumor cells, bearing the specific antigens recognized by the antibody
(Olsnes, S., Immunol.
Today, 10, pp. 291-295, 1989; Melby, E.L., Cancer Res., 53(8), pp. 1755-1760,
1993; Better,
M.D., PCT Publication Number WO 91/07418, published May 30, 1991).
Another approach for targeting populations of pathogenic cells, such as cancer
cells or
foreign pathogens, in a host is to enhance the host immune response against
the pathogenic cells
to avoid the need for administration of compounds that may also exhibit
independent host
toxicity. One reported strategy for immunotherapy is to bind antibodies, for
example,
genetically engineered multimeric antibodies, to the surface of tumor cells to
display the
1
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
constant region of the antibodies on the cell surface and thereby induce tumor
cell killing by
various immune-system mediated processes (De Vita, V.T., Biologic Therapy of
Cancer, 2d ed.
Philadelphia, Lippincott, 1995; Soulillou, J.P., U.S. Patent 5,672,486).
However, these
approaches have been complicated by the difficulties in defining tumor-
specific antigens.
Folate plays important roles in nucleotide biosynthesis and cell division,
intracellular
activities which occur in both malignant and certain normal cells. The folate
receptor has a high
affinity for folate, which, upon binding the folate receptor, impacts the cell
cycle in dividing
cells. As a result, folate receptors have been implicated in a variety of
cancers (e.g., ovarian,
endometrial, lung and breast) which have been shown to demonstrate high folate
receptor
expression. In contrast, folate receptor expression in normal tissues is
limited (e.g., kidney,
liver, intestines and placenta). This differential expression of the folate
receptor in neoplastic
and normal tissues makes the folate receptor an ideal target for small
molecule drug
development. The development of folate conjugates represents one avenue for
the discovery of
new treatments that take advantage of differential expression of the folate
receptor. There is a
great need for the development of folate conjugates, methods to identify
folate receptor positive
cancers, and methods to treat patients with folate receptor positive cancers.
SUMMARY
In one aspect, the present disclosure provides conjugates comprising a binding
ligand, a
linker and a drug, having the formula B-(AA)zi-L2-(L3)z2-(AA)z3-(L1)z4-(1-
,4)z5-D1-L5-D2,
B-(AA)z10-L2-D2, B-(AA)1 1 L2 D1 L5 D1 2
L (AA)z12-B or
B-L1-AA-L1-AA-L1-12-(L3)z6-(L4)z7-(AA)z8-(L4)z9-D1-L5-D2,
wherein each of B, AA, L1, L2, L3, L4, L5, D1, D2, z 1, z2, z3, z4, z5, z6,
z7, z8, z9, z10, z 1 1 and
z12 are defined as described herein; or a pharmaceutically acceptable salt
thereof.
In another aspect, the disclosure provides pharmaceutical compositions
comprising a
therapeutically effective amount of the conjugates described herein, or a
pharmaceutically
acceptable salt thereof, and at least on excipient.
In another aspect, the disclosure provides a method of treating abnormal cell
growth in a
mammal, including a human, the method comprising administering to the mammal
any of the
conjugates or compositions described herein.
The conjugates of the present disclosure can be described as embodiments in
any of the
following enumerated clauses. It will be understood that any of the
embodiments described
herein can be used in connection with any other embodiments described herein
to the extent
that the embodiments do not contradict one another.
2
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
1. A conjugate comprising a binding ligand, a linker and a drug, having
the formula B-
(AA)zi-L2-(L3)z2-(AA)z3-(Li)z4-(L4)z5-D1-L5-D2,
B-(AA)zio-L2-D2, B-(AA)11 L2 D1 L5 D1 L2 (AA)z12-B or
B-L1-AA-L1-AA-L1-L2-(L3)z6-(L4)z7-(AA)z8-(L4)z9-D1-L5-D2,
wherein
each zl, z10, zll and z12 is each independently 2, 3, 4 or 5;
z2 is 0, 1 or 2;
z3 is 0, 1, 2, 3 or 4;
z4 is 0, 1 or 2; and
z5 is 0, 1 or 2
z6 is 0, 1 or 2;
z7 is 0, 1 or 2;
z8 is 0, 1, 2, 3 or 4;
z9 is 0, 1 or 2;
B is of the formula I
R40 CO2H
vi r R3 Ri R2 el N---.\----'-'-i *
H
R5 0
R6
/- 2'\ 3->
H2N X X
I
wherein
R1 and R2 in each instance are independently selected from the group
consisting of H,
D, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -OR', -SR7 and -NR7R7',
wherein each
hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl and C2_C6 alkynyl is independently
optionally
substituted by halogen, -0R8, -SR8, -NR8R8', -C(0)R8, -C(0)0R8 or -C(0)NR8R8';
R3, R4, R5 and R6 are each independently selected from the group consisting of
H, D,
halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -CN, -NO2, -NCO, -0R9, -
SR9, -NR9R9',
-C(0)R9, -C(0)0R9 and -C(0)NR9R9', wherein each hydrogen atom in C1-C6 alkyl,
C2-C6
alkenyl and C2_C6 alkynyl is independently optionally substituted by halogen, -
0R10, -Se,
-NR10R10', -C(0)R10, -C(0)0R1 or -C(0)NR10R10';
each R7, R7', R8, R8', R9, R9', R1 and R10' is independently H, D, C1-C6
alkyl, C2-C6
alkenyl or C2_C6 alkynyl;
X1 is -NR11-, =N-, -N=, -C(R11)= or =C(R11)-;
3
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
X2 is -NR11'- or =N-;
X3 is -NR11--, -N= or -C(R11')=;
X4 is -N= or -C=;
X5 is NR12 or CR12R12';
Y1 is H, D, -0R13, -SR13 or -NR13R13' when X1 is -N= or -C(R11)=, or Y1 is =0
when
X1 is -NR11-, =N- or =C(R11)-;
Y2 is H, D, C1-C6 alkyl, C2-C6 alkenyl, -C(0)R14, -C(0)0R14, -C(0)NR14R14'
when X4
is -C=, or y2 is absent when X4 is -N=;
R11, R11', R11-, R12, R12', R13, R13', R14 and R14' are each independently
selected from the
group consisting of H, D, C1-C6 alkyl, -C(0)R15, -C(0)0R15 and -C(0)NR15R15';
R15 and R15' are each independently H or C1-C6 alkyl;
m is 1, 2, 3 or 4;
AA is an amino acid;
L1 is a linker of the formula II
R160
I 1
* N *
S,CR17R1T) n
R18
II
wherein
R16 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, -C(0)R19, -C(0)0R19 and -C(0)NR19R19', wherein each hydrogen atom in
C1-C6 alkyl,
C2-C6 alkenyl and C2_C6 alkynyl is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, and C2_C6 alkynyl, -0R20, -0C(0)R20, -0C(0)NR20R20', -
0S(0)R20
,
-0S(0)2R20, -SR20, -S(0)R20, -S(0)2R20, -S(0)NR20R20', -S(0)2NR20R20', -
0S(0)NR20R20',
-0S(0)2NR2 R2 ', -NR20R20', -NR20C(0)R21, -NR20C(0)0R21, -NR20C(0)NR21R21',
-NR205(0)R21, -NR205(0)2R21, -NR205(0)NR21R21', -NR205(0)2NR21R21', -C(0)R20
,
-C(0)0R2 or -C(0)NR20R20';
each R17 and R17' is independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R22, -0C(0)R22,
-0C(0)NR22R22', -0S(0)R22, -0S(0)2R22, -5R22, -S(0)R22, -S(0)2R22, -
S(0)NR22R22',
-S(0)2NR22R22', -0S(0)NR22R22', -0S(0)2NR22R22', -NR22R22', -NR22C(0)R23,
-NR22C(0)0R23, -NR22C(0)NR23R23', -NR225(0)R23, -NR225(0)2R23, -
NR225(0)NR23R23',
4
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR22S(0)2NR23R23', -C(0)R22, -C(0)0R22, and -C(0)NR22R22', wherein each
hydrogen atom
in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is independently
optionally
substituted by halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -0R24, -
0C(0)R24,
-0C(0)NR24R24', -0S(0)R24, -0S(0)2R24, -SR24, -S(0)R24, -S(0)2R24, -
S(0)NR24R24',
-S(0)2NR24R24', -0S(0)NR24R24', -0S(0)2NR24R24', -NR24R24', -NR24C(0)R25,
-NR24C(0)0R25, -NR24C(0)NR25R25', -NR245(0)R25, -NR245(0)2R25, -
NR245(0)NR25R25',
-NR245(0)2NR25R25', -C(0)R24, -C(0)0R24 or -C(0)NR24R24'; or R17 and R17' may
combine to
form a C4-C6 cycloalkyl or a 4- to 6- membered heterocycle, wherein each
hydrogen atom in
C4-C6 cycloalkyl or 4- to 6- membered heterocycle is independently optionally
substituted by
halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R24, -0C(0)R24,
-0C(0)NR24R24', -0S(0)R24, -0S(0)2R24, -5R24, -S(0)R24, -S(0)2R24, -
S(0)NR24R24',
-S(0)2NR24R24', -0S(0)NR24R24', -0S(0)2NR24R24', -NR24R24', -NR24C(0)R25,
-NR24C(0)0R25, -NR24C(0)NR25R25', -NR245(0)R25, -NR245(0)2R25, -
NR245(0)NR25R25',
-NR245(0)2NR25R25', -C(0)R24, -C(0)0R24 or -C(0)NR24R24';
R18 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R26, -0C(0)R26, -0C(0)NR26R26', -0S(0)R26, -0S(0)2R26, -5R26, -
S(0)R26,
-S(0)2R26, -S(0)NR26R26', -S(0)2NR26R26', -0S(0)NR26R26', -0S(0)2NR26R26', -
NR26R26',
-NR26C(0)R27, -NR26C(0)0R27, -NR26C(0)NR27R27', -NR26C(=NR26")NR27R27',
-NR265(0)R27, -NR265(0)2R27, -NR26S(0)NR27R27', -NR26S(0)2NR27R27', -C(0)R26,
-C(0)0R26 and -C(0)NR26R26', wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl
and 5- to 7-
membered heteroaryl is independently optionally substituted by halogen, C1-C6
alkyl, C2-C6
alkenyl, -(CH2)p0R28, -(CH2)p(OCH2)q0R28, -(CH2)p(OCH2CH2)q0R28, -0R29, -
0C(0)R29,
-0C(0)NR29R29', -0S(0)R29, -0S(0)2R29, -(CH2)p0S(0)20R29, -0S(0)20R29, -5R29,
-S(0)R29, -S(0)2R29, -S(0)NR29R29', -S(0)2NR29R29', -0S(0)NR29R29', -
0S(0)2NR29R29',
-NR29R29', -NR29C(0)R30, -NR29C(0)0R30, -NR29C(0)NR30R30', -NR295(0)R30
,
-NR295(0)2R30, -NR295(0)NR30R30', -NR295(0)2NR30R30', -C(0)R29, -C(0)0R29 or
-C(0)NR29R29';
each R19, R19', R20, R20', R21, R21', R22, R22', R23, R23', R24, R24', R25,
R25', R26, R26', R26',
R29, R29', R3 and R30' is independently selected from the group consisting of
H, D, C1-C7 alkyl,
C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl
and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C7 alkyl, C2-
C7 alkenyl,
5
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10
aryl, or 5- to 7-
membered heteroaryl is independently optionally substituted by halogen, -OH, -
SH, -NH2 or -
CO2H;
R27 and R27' are each independently selected from the group consisting of H,
C1-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q
(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
R28 is a H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3-
to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl or sugar;
n is 1, 2, 3, 4 or 5;
p is 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5;
L2 is a releasable linker;
L3 is selected from the group consisting of C1-C6 alkyl, -(CR39R39'),C(0)-,
-(CR39R39'),OC(0)-, -NR39R39'C(0)(CR39R39'),-, -(CH2),NR39-, -
(0CR39R39'CR39R39'),C(0)-,
and -(0CR39R39'CR39R39'CR39R39')- ,C(0)-,
wherein
each R39 and R39' is independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -Ole, -0C(0)R40
,
-0C(0)NR40R40', -0S(0)R40, -0S(0)2R40, -Se, -S(0)R40, -S(0)2R40, -
S(0)NR40R40',
-S(0)2NR4 R4 ', -0S(0)NR4 R4 ', -0S(0)2NR4 R4 ', -Nee', -NR40C(0)R41,
-NR40C(0)0R41, -NR40C(0)NR41 R41 ' , -NR405 (0)R41 , -NR405 (0)2R41 , -NR405
(0)NR41R41' ,
-NR405 (0)2NR41R
41', -C(0)R40,
C(0)0R4 and -C(0)NR40R40';
R40, R40', R41 and R41' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
r in each instance is 1, 2, 3, 4, or 5;
L4 is selected from the group consisting of -C(0)(CR44R44')t-,
-NR42CR43R43'CR43R43'(OCR44R44'CR44R44')t-, -
NR42CR43R43'CR43R43'(OCR44R44'CR44R44')c,
-NR42CR43R43'CR43R43'(OCR44R44'CR44R44')tC(0)-,-
NR42CR43R43'CR43R43'(CR44=CR44')t-, and
-NR42C6-C10 aryl(Ci-C6 alky1)0C(0)-;
wherein
R42 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
6
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R45, -0C(0)R45, -0C(0)NR45R45', -0S(0)R45,
-0S(0)2R45, -SR45, -S(0)R45, -S(0)2R45, -S(0)NR45R45', -S(0)2NR45R45', -
0S(0)NR45R45',
-0S(0)2NR45R45', -NR45R45', -NR45C(0)R46, -NR45C(0)0R46, -NR45C(0)NR46R46',
-NR455(0)R46, -NR455(0)2R46, -NR455(0)NR46R46', -NR455(0)2NR46R46', -C(0)R45,
-C(0)0R45 or -C(0)NR45R45',
each R43, R43', R44 and R44 is independently selected from the group
consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each
hydrogen atom in
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is
independently optionally
substituted by halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R47, -
0C(0)R47,
-0C(0)NR47R47', -0S(0)R47, -0S(0)2R47, -5R47, -S(0)R47, -S(0)2R47, -
S(0)NR47R47',
-S(0)2NR47R47', -0S(0)NR47R47', -0S(0)2NR47R47', -NR47R47', -NR47C(0)R48,
-NR47C(0)0R48, -NR47C(0)NR48R48', -NR475(0)R48, -NR475(0)2R48, -
NR475(0)NR48R48',
-NR475(0)2NR48R48', -C(0)R47, -C(0)0R47 or -C(0)NR47R47';
R45, R45', R46, R46', R47, R47', R48 and R48' are each independently selected
from the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl;
t is in each instance 1, 2, 3, 4, or 5;
L5 is selected from the groups consisting of C1-C10 alkyl, -(CR49=CR49').-,
-(CR49R49')õC(0)-,-CH2CH2(OCR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- and
-CH2CH2(0CR49R49'CR49R49'CR49R49')uC(0)-, wherein
each R49 and R49' is independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each
hydrogen atom in Ci-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently
optionally substituted
by halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to
7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R50, -0C(0)R50
,
-0C(0)NR50R50', -0S(0)R50, -0S(0)2R50, -5R50, -S(0)R50, -S(0)2R50, -
S(0)NR50R50',
-S(0)2NR5 R5 ', -0S(0)NR5 R5 ', -0S(0)2NR5 R5 ', -NR50R50', -NR50C(0)R51,
-NR50C(0)0R51, -NR5 C(0)NR51R51', -NR505(0)R51, -NR505(0)2R51, -
NR505(0)NR51R51',
-NR505(0)2NR51R51', -C(0)R50, -C(0)0R5 or -C(0)NR50R50';
R50, R50', R51 and R51' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl;
7
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
u is in each instance 0, 1, 2, 3, 4 or 5;
D1 is a PBD prodrug; and
D2 is a DNA binding agent;
or a pharmaceutically acceptable salt thereof.
2. The conjugate of clause 1, wherein D1 is of the formula III
,R2a
µ......fioa 0
" R9a O
R5 0 ¨ R1 a
. N
----
NNR3aR4a
, / 0 o
Rua 1
R7a
III
wherein
K- 2a;
R3a and R4a are each independently selected from the group consisting of H, D,
Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
11a la
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R; -C(0)OR,
and -C(0)NR1 laR1 la' ; wherein each hydrogen atom in Cl-C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl,
C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-
membered
heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl,
C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 7-
membered heteroaryl,
_calla, _
OC(0)R11a; _
OC(0)NR1 laR1 la' ; -
OS(0)R
1
1a _os(o)2R11a,
_sR1 la; _s(0)R11a; _s(0)2R11a; _
S(0)NR1 laR1 la'; _
S (0)2NR1 laR1 la' ; _OS (0)NR1 laR1 la';
-OS (0)2NR1 laR1 la'; _NR1laR1 la'; _NR1lac(0)R12a; _NR1lac(0)0R12a;
_NR1lac(0)NR12aR12a';
_NR1las(0)R12a; _NR1las(0)2R12a; _NR1 las (0)NR12aR12a' ;
-NR 1 laS(0)2NR12aR12a'; _c(0)R1 la;
-C(0)0R11a or -C(0)NR1 laR1 la' ;
or Ria is a bond; or R4a is a bond;
R5a, R6a and R7a are each independently selected from the group consisting of
H, D, Ci-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R13a, -C(0)0R13a and-C(0)NR13a-
rsK 13a'
, wherein
each hydrogen atom in Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR14a;
_oc(o)R14a,
-0C(0)NR14aR14a'; _
OS(0)R14a; _
OS (0)2R14a; _sR14a; _s(0)R14a; _s(0)2R14a; _
S(0)NR14aR14a';
-S(0)2NR14aR14a'; -OS(0)NR14aR14a'; -OS(0)2NRi4aRi4a', _NRi4aRi4a.',
_Neac(0)Ri5a,
-NR14aC(0)0R15a, -NR14aC(0)NRisaRisa', _Neas(o)Risa, _Neas(0)2Risa,
8
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR14aS(0)NR15aRi5a', -NR14aS(0)2NR15aRi5a', -C(0)Ri4a, -C(0)0R14a or -
C(0)NR14aR14a';
wherein R6a and R7a taken together with the atoms to which they are attached
optionally
combine to form a 3- to 7-membered heterocycloalkyl, or R5a and R6a taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl or 5- to 7-membered heteroaryl, wherein each hydrogen atom in
3- to 7-
membered heterocycloalkyl or 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R16a, -
0C(0)R16a,
-0C(0)NR16aR16a', 0s(0)R16a, 0s(0)2R16a, sR16a, s(0)R16a, s(0)2,,K16a,
S(0)NR16aR16a',
-S(0)2NR16aR16a', OS(0)NR16aR16a', OS(0)2NR16aR16a', NR16aR16a',
NR16ac(0)R17a,
-NR16aC(0)CH2CH2-, -NR16aC(0)0R17a, -NR16aC(0)NR17aRi7a', -NR16aS(0)R17a,
-NR16aS(0)2R17a, -NR16aS(0)NR17aRi7a', -NR16aS(0)2NR17aRi7a', -C(0)R16a, -
C(0)0R16a
or -C(0)NR16aR16a', and wherein one hydrogen atom in 5- to 7-membered
heteroaryl is
optionally a bond, or R5a is a bond;
R8a and R9a are each independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
0R18a,
-0C(0)R18a, -0C(0)NR18aR18a', 0s(0)R18a, 0s(0)2R18a, sR18a, s(0)R18a,
s(0)2R18a,
-S(0)NR18aR18a', -S(0)2NR18aR18a', -0S(0)NR18aR18a', -0S(0)2NR18aR18a', -
NR18aR18a',
-NR18aC(0)R19a, -NR18aC(0)0R19a, -NR18aC(0)NR19aR19a', -NR18aS(0)R19a, -
NR18aS(0)2R19a,
-NR18aS(0)NR19aR19a', -NR18aS(0)2NR19aR19a', -C(0)R18a, -C(0)0R18a and -
C(0)NR18aR18a',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -ORma, -
0C(0)R2Oa,
-0C(0)NR20aR20a', 0s(0)R20a, 0s(0)2R20a, sR20a, s(0)R20a, s(0)2,,K20a,
S(0)NR20aR20a',
-S(0)2NR2thR2a', -OS(0)NR20aR20a',
OS(0)2NRmaRma', -NR20aR20a', NR2Oac(0)R21a,
-NR2thC(0)0R21a, -NR2OaC(0)NR2iaR2ia', NR2oas(0)R2ia, NR2oas(0)2R2ia,
-NR2thS(0)NR21aR2la', NR20aS(0)2NR21aR2la', c(0)R20a, C(0)0R2Oa or -
C(0)NR20aR20a';
R10a is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R22a, -0C(0)R22a, -0C(0)NR22aR22a', 0s(0)R22a, 0s(0)2R22a,
sR22a,
-S(0)R22a, -S(0)2R22a, -S(0)NR22aR22a',
S(0)2NR22aR22a', 0S(0)NR22aR22a',
-OS(0)2NR22aR22a', NR22aR22a', NR22ac(0)R23a, NR22aC(0)0R23a, -
NR22aC(0)NR23aR23a',
-NR22aS(0)R23a, -NR22aS(0)2R23a, -NR22aS(0)NR23aR23a', -NR22aS(0)2NR23aR23a, -
C(0)R22a,
9
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
-C(0)0R23a and -C(0)NR22aR22a'; wherein each hydrogen atom in C1-C6 alkyl, C2-
C6 alkenyl,
C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10
aryl and 5- to 7-
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-
membered heteroaryl, -OR24a; _OC(0)R24a; _OC(0)NR24aR24a'; _OS(0)R24a; _OS
(0)2R24a,
_sR24a; _s (0)R24a; _s (0)2R24a; -S(0)NR24aR24a'; _S(0)2NR24aR24a';
_OS(0)NR24aR24a';
-OS(0)2NR24aR24a'; _NR24aR24a'; _NR24ac(0)R25a; _NR24aC(0)0R25a, -
NR24aC(0)NR25aR25a';
_NR24as(0)R25a; _NR24as(0)2R25a; _NR24as
(0)NR25aR25a'; _NR24as(0)2NR25aR25a'; _c(0)R24a;
-C(0)0R24a or -C(0)NR24aR24a'; and
each Ri la, Ri la', Ri2a, Ri2a.', Ri3a, Ri3a.', Ri4a, RiLta', ea, ea', Ri6a,
Ri6a.', Ri7a, Ri7a.', R18a;
R18a'; R19a; R19a'; R20a; R20a'; R21a; R2la'; R22a; R22a'; R23a; R23a'; R24a;
R24a'; R25a and R25a is
independently selected from the group consisting of H, D, Cl-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl,
and 5- to 7-
membered heteroaryl;
provided that at least two of Rla, RLia and R5a are a bond, or when R5a and
R6a taken
together with the atoms to which they are attached optionally combine to form
a 3- to 7-
membered heterocycloalkyl or 5- to 7-membered heteroaryl, one hydrogen atom in
5- to 7-
membered heteroaryl is a bond and one of Ria or R4a is a bond; or a
pharmaceutically
acceptable salt thereof.
3. The conjugate of clause 1 or 2, wherein D2 is a minor groove binding
drug; or a
pharmaceutically acceptable salt thereof.
4. The conjugate of any one of clauses 1 to 3, wherein D2 is of the
formula selected from
the group consisting of
R11b Dp2b
R12b R1 Ob
cjIN
.....,.....L/
R9b C)---1 µ 0 ¨R1 b
0 R4C
0¨R2C
R8b = C21
R8b z
- R1C
N'\ 0 NR3bR4b
R6b/ 9 411.
"' - NR5c R3
WI' ,s.:..-
*0 ORle
lei I-N
I I-N-I . elei
N \ SI * N
N N ' ,
N
Cl/
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0 *0 0
0 _______________________________
N
HN
0 and
CI
0
HN
wherein
Rib, R2b, R3b
a tc are each independently selected from the group consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R13b, -
C(0)0R13b,
and -C(0)NR13bR13b', wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-
membered heteroaryl, -0R13b, -0C(0)R13b,
-0C(0)NR13bR13b', os(0)R13b, os(0)2R13b, sR13b, s(0)R13b, s(0)2R13b,
S(0)NR13bR13b',
-S(0)2NR13bR13b', OS(0)NR13bR13b',
OS(0)2NR13bR13b', NR13bR13b', NR13bc(0)R14b,
-NR13bC(0)0R14b, -NR13bC(0)NR14bR14W, NR13bs(0)R14b, NR13bs(0)2R14b,
-NR13bS(0)NR14bR14b', NR13bS(0)2NRi4bR14b', c(0)R13b, C(0)0R13b or -
C(0)NR13bR13b'; or
any one of Rib,K 2- b,
R3- and R4b is a bond;
R5b, R6b and R7b are each independently selected from the group consisting of
H, D, C1-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R15b, -C(0)0R15b, and -
C(0)NR15bR15b',
wherein each hydrogen atom in Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -L4H, -
L3H, -0R15b,
-0C(0)R15b, -0C(0)NR15bR15b', os(0)R15b, os(0)2R15b, sR15b, s(0)R15b,
s(0)2R15b,
-S(0)NR15bR15b',
S(0)2NR15bR15b', OS(0)NR15bR151)', OS(0)2NR15bR15b',
NR15bR15b',
-NR15bC(0)R16b, -NR15bC(0)0R16b, -NR15bC(0)NR16bR16b', NR15bs(0)R16b,
NR15bs(0)2R16b,
11
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR15bS(0)NR16bR16b', _NR15bs(0)2NR16bR16W, _c(0)R15b, _C(0)0R15b or -
C(0)NR15bR15b';
wherein R6b and R7b taken together with the atoms to which they are attached
optionally
combine to form a 3- to 7-membered heterocycloalkyl, or R5b and R6b taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl or 5- to 7-membered heteroaryl, wherein each hydrogen atom in
3- to 7-
membered heterocycloalkyl and 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R17b, -
0C(0)R17b,
-0C(0)NR17bR17b', _OS(0)R'b, -os(o)2R17b, _sR17b, _s(0)R17b, _s(0)2R17b, _
S(0)NR17bR17b'
,
-S(0)2NR17bR17b', _OS(0)NR17bR17b', _OS(0)2NR17bR17b', _NR17bR17b',
_NR17bc(0)R18b,
-NR171)C(0)0R18b, _NR17bc(0)NR18bR181D', _NR17bs(0)R18b, _NR17bs(0)2R18b,
-NR17bS(0)NR18bR18b', _NR17bs(0)2NR18bR18W, _c(0)R17b, _C(0)0R17b or -
C(0)NR17bR17b; or
any one of R5b, R6b or R7b is a bond;
R8b and R9b are each independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -0R19b, -0C(0)R19b,
-0C(0)NR19bR19b', _OS(0)R19b, -os(o)2R19b, _sR19b, _s(0)R19b, _s(0)2R19b, _
S(0)NR19bR19b',
-S(0)2NR19bR19W, _OS(0)NR19bR19b', _OS(0)2NR19bR19b', _NR19bR19b',
_NR19bc(0)R20b,
-NR19bC(0)0R20b, _NR19bc(0)NR2ObR2Ob', _NR19bs(0)R20b, _NR19bs(0)2R20b,
-NR19bS(0)NR2obR2ow, _NRobs(0)2NR2obR2ce, _c(0)Rob, _C(0)0R19b and -
C(0)NR19bR19b',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR21b,
_OC(0)R211'
,
-0C(0)NR21bR2lb', _OS(0)R211'
, _OS(0)2R211'
, _sR21b, _s(0)R21b, _s(0)2R21b, _
S(0)NR21bR2lb',
-S(0)2NR21bR2lb', _OS(0)NR21bR2lb', _OS(0)2NR21bR2lb', _NR21bR2lb',
_NR211)c(0)R22b,
-NR21bC(0)0R22b, _NR2lbc
(0)NR22bR22b', _NR211)s(0)R22b, _NR2lbs(0)2R22b,
-NR2lbS(0)NR22bR22b', _NR2lbs
(0)2NR22bR22b', _c(0)R21b, _
C(0)0R2lb or -C(0)NR21bR21b;
R10b, Rllb and R12b are each independently selected from the group consisting
of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R23b, -
0C(0)R23b,
-0C(0)NR23bR23b', _
OS(0)R23b, -os(o)2R23b, _sR23b, _s(0)R23b, _s(0)2R23b, _
S(0)NR23bR23b',
-S(0)2NR23bR23b', _OS(0)NR23bR23b', -OS(0)2NR23bR23b', _NR23bR23b',
_NR23bc(0)R24b,
-NR23bC(0)0R24b, _NR23bc
(0)NR24bR24b', _NR23bs(0)R24b, _NR23bs(0)2R24b,
12
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR2"s(o)NR24bR24w, _NR23bs(0)2NR24b R24b', _c(0)R23b,
C(0)0R23b and -C(0)NR23bR23b',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R2', -
0C(0)R2'
,
-0C(0)NR25bR25b',
OS(0)R25b, -OS(0)2R2', _sR25b, -S(0)R2',
-S(0)2R2',
S(0)NR25bR25b',
-S(0)2NR25bR25b',
OS(0)NR25bR25b',
OS(0)2NR25bR25b', _NR25bR25b', _NR25bc(0)R261'
,
-NR25bC(0)0R261'
, _NR25bc(0)NR26bR26b', _NR25bs(0)R261'
, _NR251'
s(0)2R261'
,
-NR25bS(0)NR26bR26w, _NR25bs(0)2NR26bR26w, _c(0)R25b, _
C(0)0R25b or -C(0)NR25bR25b, or
Ruth and R1 lb taken together with the carbon atoms to which they are attached
optionally
combine to form a C6-C10 aryl, or R1 lb and R12b taken together with the
carbon atom to which
they are attached optionally combine to form an exo-methylene; or R12b is
absent;
each R13b, R13b', R14b, R14b', R15b, R15b', R16b, R16b', R17b, R17b', R18b,
R18b', R19b, R19b',
R2ob, R2ow, R2ib, R2lb', R22b, R22b', R23b, R23b', R24b, R24b', R25b, R25b',
R26b and R26b' is
independently selected from the group consisting of H, D, C1-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, C1-
C6 alkyl(C6-C10
aryl) and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C6-C10
aryl, C1-C6
alkyl(C6-C10 aryl) and 5- to 7-membered heteroaryl is independently optionally
substituted by
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
OH, -SH,
-NH2, -503H, -C(0)0H and -C(0)NH2;
provided that one of Rib, R2b, R3b, R4b, R5b, R6b and K-.7b
is a bond;
Ric, - 2c
K and R5c are each independently selected from the group
consisting of H, D, C1-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R6c, -C(0)0R6c and -
C(0)NR6cR6c', wherein
each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R7c, -
OC(0)R7c, -0C(0)NR7cR7c', -0S(0)R7c, -0S(0)2R7c, -SR7c, -S(0)R7c, -S(0)2R7c,
-S(0)20R7c, -S(0)NR7cR7c', -S(0)2NR7cR7c', -OS(0)NR7cR7c', -OS(0)2NR7cR7c', -
NR7cR7c',
-NR7cC(0)R8c, -NR7cC(0)0R8c, -NR7cC(0)NR8cR8c', -NR7cS(0)R8c, -NR7cS(0)2R8c,
-NR7cS(0)NR8cR8c', -NR7cS(0)2NR8cR8c', -C(0)R7c, -C(0)0R7c or -C(0)NR7cR7c';
or when J is
cR13c=, R-5
c is absent; provided that one of Ric or R2c is a bond;
13
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R3c and R4c are each independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -0R9c, -0C(0)R9c, -
0C(0)NR9cR9c,
-0S(0)R9c, -0S(0)2R9c, -SRw, -S(0)R9c, -S(0)2R9c, -S(0)NR9cR9c, -S(0)2NR9cR9c,
-OS(0)NR9cR9c, -OS(0)2NR9cR9c, -NR9cR9c, -NR9cC(0)R1 c, -NR9cC(0)0R1 c,
-NR9cC(0)NRiocRioc, _NR9cs(0)Rioc, _NR9cs(0)2Rioc,_N-K9c=-=
S(0)NRiocRioc
-NR9cS(0)2NRiocRioc,_c(0)-K9c,
C(0)0R9c and -C(0)NR9cR9c, wherein each hydrogen atom
in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OW lc, -0C(0)R,
-0C(0)NRiicRiic, _os(0)Ri lc, _os(0)2Ri lc, _sRi lc, _s(0)Ri lc, _s(0)2Ri lc,
_
S(0)NRiicRiic,
-S(0)2NR1icRi lc',
OS (0)NR11cR1 lc',
OS(0)2NR11cRllc', _NR11cRllc', _NR1lcc(0)R12c,
_NR1lcc(0)0R12c, _NR11cC(0)NRi2cRi2c, _NR1ics(0)Ri2c, _NR1ics(0)2Ri2c,
-NR 1 lcS(0)NR12cRi2c,
K S(0)2NR12cR12C, _c(0)R1lc,
C(0)0R1lc or -C(0)NR1icRilc;
J is -C(0)-, -CR13c= or -(CR13cRl3c')_
each R6c, R6c, R7c, R7c, R8c, R8c, R9c, R9c, Rioc, Rioc, Ri2c, Ri2c,
Ri3c and
Ri3c is independently selected from the group consisting of H, D, C1-C7 alkyl,
C2-C7 alkenyl,
C2_C7alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl
and 5- to 7-
membered heteroaryl;
Rld is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R2', -SR2d and -NR2dR2d',
R2d and R2d' are each independently selected from the group consisting of H,
D, Cl-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in Cl-C6
alkyl, C2-C6
alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl,
C6-C10 aryl and 5-
to 7-membered heteroaryl is optionally substituted by -0R3d, -SR3d, and -
NR3dR3d';
R3d and R3d' are each independently selected from the group consisting of H,
D, Cl-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl and 5- to 7-membered heteroaryl;
Rie is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl, wherein each hydrogen atom in Cl-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
14
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-
membered heteroaryl, -0R2e, -0C (0)R2e, - OC(0)NR2eR2e';
OS (0)R2e, -OS(0)2R2e, -SR2e,
-S(0)R2e, -S(0)2R2e, -S(0)NR2eR2e',
S(0)2NR2eR2e' ;
OS(0)NR2eR2e' ; _OS (0)2NR2eR2e',
_NR2eR2e', _NRec (0)-K 3e;
NR2eC(0)0R3e, -NR2eC(0)NR3eR3e', -NR2eS(0)R3e, -NR2eS(0)2R3e,
-NR2eS(0)NR2eR2e',
K (0)2NR3eR3e', -C(0)R2e, -C(0)0R2e or -C(0)NR2eR2e;
each R2e,R 'e ;
2 R3e and R3e' is independently selected from the group
consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein each
hydrogen atom in
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is optionally
substituted by
-0R4e, -SR4e or -NR4eR4e'
R4e and We' are independently selected from the group consisting of H, D, C1-
C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl
and 5- to 7-membered heteroaryl;
v is 1, 2 or 3; and
* is a covalent bond;
or a pharmaceutically acceptable salt thereof.
5. The conjugate of any one of clauses 1 to 4, wherein each AA is
independently selected
from the group consisting of L-lysine, L-asparagine, L-threonine, L-serine, L-
isoleucine, L-
methionine, L-proline, L-histidine, L-glutamine, L-arginine, L-glycine, L-
aspartic acid, L-
glutamic acid, L-alanine, L-valine, L-phenylalanine, L-leucine, L-tyrosine, L-
cysteine, L-
tryptophan, L-phosphoserine, L-sulfo-cysteine, L-arginosuccinic acid, L-
hydroxyproline, L-
phosphoethanolamine, L-sarcosine, L-taurine, L-carnosine, L-citrulline, L-
anserine, L-1,3-
methyl-histidine, L-alpha-amino-adipic acid, D-lysine, D-asparagine, D-
threonine, D-serine, D-
isoleucine, D-methionine, D-proline, D-histidine, D-glutamine, D-arginine, D-
glycine, D-
aspartic acid, D-glutamic acid, D-alanine, D-valine, D-phenylalanine, D-
leucine, D-tyrosine, D-
cysteine, D-tryptophan, D-citrulline and D-carnosine, or a pharmaceutically
acceptable salt
thereof.
6. The conjugate of any one of clauses 1 to 5, wherein R16 is H; or a
pharmaceutically
acceptable salt thereof.
7. The conjugate of any one of clauses 1 to 6, wherein each R17 and
R17' is independently
selected from the group consisting of H, C1-C6 alkyl and -0R22, wherein each
hydrogen atom in
C1-C6 alkyl is independently optionally substituted by -0R24; or R17 and R17'
may combine to
form a C4-C6 cycloalkyl or a 4- to 6- membered heterocycle, wherein each
hydrogen atom in
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
c4-c6 cycloalkyl or 4- to 6- membered heterocycle is independently optionally
substituted by
halogen, C1-C6 alkyl or -0R24; or a pharmaceutically acceptable salt thereof.
8. The conjugate of any one of clauses 1 to 7, wherein R18 is selected from
the group
consisting of H, C1-C6 alkyl, 5- to 7-membered heteroaryl, -0R26, -
NR26C(0)R27,
-NR26C(0)NR27R27', -NR26C(=NR26-)NR27R27', and -C(0)NR26R26', wherein each
hydrogen
atom in C1-C6 alkyl and 5- to 7-membered heteroaryl is independently
optionally substituted by
C1-C6 alkyl, -0R29, -(CH2)p0S(0)20R29, -0S(0)20R29, or -C(0)NR29R29';
each R26, R26', R26-, R29 and R29'
is independently H or C1-C7 alkyl, wherein each
hydrogen atom in C1-C7 alkyl, is independently optionally substituted by
halogen, -OH, -SH,
-NH2 or -CO2H;
R27 and R27' are each independently selected from the group consisting of H,
C1-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q-
(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
n is 2, 3, 4 or 5;
p is 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5;
or a pharmaceutically acceptable salt thereof.
9. The conjugate of any one of clauses 1 to 8, wherein each L1 is selected
from the group
consisting of
R16
R16
R160 I ?I
(H2C R16
0
*11\1;tf?
*N*
*
0yr )n Cy )n 0 )n
)n HN
HN,0 HC:o). HN HN
OH , 1 HO,, ), and HO, ,>, ' HOOH = '10H 'OH
R27 oriOH
HO
OH HO OH
OH
OH ,
wherein R16 is H, and * is a covalent bond; or a pharmaceutically acceptable
salt thereof.
10. The conjugate of any one of clauses 1 to 9, wherein R1 and R2 in each
instance are H;
R3, R4, R5 and R6 are H; X1 is ¨NR11-; X2 is =N-; X3 is -N=; X4 is ¨N=; X5 is
NR12; y1 is is =0;
Y2 is absent; Riland R12 are H; m is 1, 2, 3 or 4; and * is a covalent bond;
or a pharmaceutically
acceptable salt thereof.
11. The conjugate of any one of clauses 1 to 10, having the formula
16
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
0 CO2H
oz444)z5-D -L5-D2
N (AA)zi -1-2-0-3)z2-(ANz3-(
0 =
H 0
NN
H2NNN
0 CO2H
0 N
1_1-AA-L1-AA-L1-L2-(L3)z6-(0),7-(AA),8-(0),9-D1-L5-D2
NN 0
H2NNN
0 CO2H
NAA)z10-1-
2 D2
O
NN 0
H2NNN or
CO2H o
O oo2H
FIN NN N 2 0
ANzil-L2-131-L5-131-L -(AA)zi2 0
0 H
0
).. H
H NNNH2
H2N N
or a pharmaceutically acceptable salt thereof.
12. The conjugate of
any one of clauses 1 to 11, having the formula
0 CO2H
0 N (Aink),4_
L2_ Di _ L5_ D2
H N N 0
H2NNN
0 CO2H
)(AA)4_1_2_L3_AA_Li_o_Di_L5_D2
0
0
NN =
H2NNN
0 CO2H
N/\/(AA)4-L2-L3-(AA)2-Di_L5_D2
0 =H H N N 0
H2NNN
17
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
0 CO2H CO2 H 0
-1-2-(AA)4N
0 AA)4-L2-D1-L5-D1 0
0 0
41I [\11
I H H
H2N N N
NH2
0 CO2H
0
0
0 CO2H
o
HN Ll -AA- L 1 -AA-Li - L2- L3-
(AA)2- L4-D1 -L5-D2
0
H2NNN
0 CO2H
0
NL1-AA-L1-AA-Ll-L2-L3-(AA)2-L4-D1-L5-D2
NN 0
H2NNN
0 CO2H
0 O N
Li AA Li AA L1 L2 L3 L4 (AA)2 L4 D1 L5 D2
0
H2NNN
0 CO2H
0NAIALILLLLDLD2
=
NN 0
H2NNN
0 CO2H
Li
0 _AA-L1-AA-L1-L2-L3_(AA)2-D1-L5-
D2
H N N 0
H2NNIe
or
0 CO2H
0
j
H N
H2NNN
or a pharmaceutically acceptable salt thereof.
13. The conjugate of any one of clauses 1 to 12, wherein the sequence of -
(AA)4- is -Asp-
18
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
Arg-Asp-Asp-; or a pharmaceutically acceptable salt thereof.
14. The conjugate of any one of clauses 1 to 13, wherein the sequence of -
(AA)2- is Val-
CIT; or a pharmaceutically acceptable salt thereof.
15. The conjugate of any one of clauses 1 to 14, wherein L2 is selected
from the group
consisting of
CO2H 0 CO2H
x6
y6 ) )
* * *
0 0
R31 R31
CO2H
CO2H 0
* X6 ) *NI
0
N S *
N*
R31 0
CO2H CO2H
*NI 0 *N 0
R36 R36
0 and 0
wherein
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
X6 is C1-C6 alkyl or C6-C10 aryl(Ci-C6 alkyl), wherein each hydrogen atom in
C1-C6
alkyl and C6-C10 aryl(Ci-C6 alkyl) is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -0R34, -0C(0)R34, -0C(0)NR34R34', -
0S(0)R34,
-0S(0)2R34, -5R34, -S(0)R34, -S(0)2R34, -S(0)NR34R34', -S(0)2NR34R34', -
0S(0)NR34R34',
-0S(0)2NR34R34', -NR34R34', -NR34C(0)R35, -NR34C(0)0R35, -NR34C(0)NR35R35',
19
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR34S(0)R35, -NR34S(0)2R35, -NR34S(0)NR35R35', -NR34S(0)2NR35R35', -C(0)R34,
-C(0)0R34 or -C(0)NR34R34';
each R32, R32', R", R"', R34, R34', R" and R"' are independently selected from
the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl;
R36 is independently selected from the group consisting of H, D, C1-C6 alkyl,
C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-
C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally
substituted by halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R37, -0C(0)R37,
-0C(0)NR37R37', -0S(0)R37, -0S(0)2R37, -5R37, -S(0)R37, -S(0)2R37, -
S(0)NR37R37',
-S(0)2NR37R37', -0S(0)NR37R37', -0S(0)2NR37R37', -NR37R37', -NR37C(0)R38,
-NR37C(0)0R38, -NR37C(0)NR38R38', -NR375(0)R38, -NR375(0)2R38, -
NR375(0)NR38R38',
-NR375(0)2NR38R38', -C(0)R37, -C(0)0R37 or -C(0)NR37R37';
R37, R37', R38 and R38' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl; and
* is a covalent bond;
or a pharmaceutically acceptable salt thereof.
16. The conjugate of any one of clauses 1 to 15, wherein L2 is of the
formula
CO2H 0
S X6 )
''N S *
I
R31
wherein
R31 is H; and X6 is C1-C6 alkyl; or a pharmaceutically acceptable salt
thereof.
17. The conjugate of any one of clauses 1 to 15, wherein L2 is of the
formula
CO2H 0
* )
NC=SSX6 *
0
1
R31
wherein
R31 is H; and X6 is C6-C10 aryl(Ci-C6 alkyl); or a pharmaceutically acceptable
salt thereof.
18. The conjugate of any one of clauses 1 to 15, wherein L2 is of the
formula
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
CO2H
* N 0
R36 N*
0
wherein
R36 is independently selected from the group consisting of H, D, C1-C6 alkyl,
C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-
C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally
substituted by halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R37, -0C(0)R37,
-0C(0)NR37R37', -0S(0)R37, -0S(0)2R37, -SR37, -S(0)R37, -S(0)2R37, -
S(0)NR37R37',
-S(0)2NR37R37', -0S(0)NR37R37', -0S(0)2NR37R37', -NR37R37', -NR37C(0)R38,
-NR37C(0)0R38, -NR37C(0)NR38R38', -NR375(0)R38, -NR375(0)2R38, -
NR375(0)NR38R38',
-NR375(0)2NR38R38', -C(0)R37, -C(0)0R37 or -C(0)NR37R37';
R37, R37', R38 and R38' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl; and
* is a covalent bond.
19. The conjugate of any one of clauses 1 to 15, wherein R36 is H; or a
pharmaceutically
acceptable salt thereof.
20. The conjugate of any one of clauses 1 to 15, 18 or 19, wherein the
linker is of the
formula
CO2H CO2H
H 0 0 ) 0 CO H
H Fidll , 2
riThr N
0
0
0
0 *
1),
NH 0
NH - NH 0 N)cr IRINA 10
H N
0 H
sOH
HO" HO" OH
HO's) HO" 1-1049Th
OH HO HO
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
21. The conjugate of any one of clauses 1 to 15, 18 or 19, wherein the
linker is of the
formula
21
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H
HO2C O2C
0 CO2H 0
H ?1 7, H jj .- jrvs
1 - N
*Nõ./...N N , 11/---li a 11
H 8 =,), o -, 1
'1
0N s 1,H 0 0 >----
0
0 NH NH
0 NH OH
0H _____\= HN¨cr
.,
Ohl NH
, pH o' ,s 0 4.
0
*
HO
ss' .' HO ,
'
HO\
HO 0
HO
HO OH
OH
OH ,
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
22. The conjugate of any one of clauses 1 to 16, wherein the linker is of
the formula
CO2H CO2H
H 0
1 H ,r H 0 CO2H 0
S¨S0)*
\ 0 0
(J\ NH 0-- NH (J\ NH
,õOH .õOH .õOH
,,. õOH µ,. õOH
H0"' H0" HO's ' HO'' '
HO HO/ HO/
OH HO HO ,
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
23. The conjugate of any one of clauses 1 to 16, wherein the linker is of
the formula
HN NH
2
NH
CO2H
CO2H H 0 jcH 0 LH
1 z H z H z
H 0 0 0
CO2H CO2H S
/
S
CD
11 *
0 ,
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
24. The conjugate of any one of clauses 1 to 15 or 16, wherein the linker
is of the formula
22
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
H N N H2 *
CO2H
171 0 4H H CO2H 10
--s/
---- CO2H 0 --
CO2H
,
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
25. The conjugate of any one of clauses 1 to 15, 18 or 19, wherein the
linker is of the
formula
CO2H CO2H H
co 2H H 0 H 0 H 0 CO2H fNI.r*
*Nr
J\ 0
0 NH 0-:;-'-µNH ¨ (-) NH
OH .,õOH
HO'''''(:)H HO'sµ..'µ\ F1 HO'sss.'"()H
HO
HO
HO/'
OH HO HO ,
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
26. The conjugate of any one of clauses 1 to 15, 18 or 19, wherein the
linker is of the
formula
H Ny NH2
NH
CO2H
IT! 0 H 0 H
* NJ.1\1 NN N CO____24H
CO2H
0 -CO2H 0 0N---\___\_)__
- -S 0
,--NH2
R <NH
NH HN
0
-----\ 0 0
0 ,
wherein * is a bond; or a pharmaceutically acceptable salt thereof.
23
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
27. The conjugate of any one of clauses 1 to 15, 18 or 19, wherein the
linker is of the
formula
HNy NH2
NH
CO2H
171 9 ,cH 0
H
*NN NkANJciNCO2F-4
CO2H 0 -CO2H 0
NH FIN............
0
R NH
-----\ 0 0
slit
11
0 ,
wherein * is a bond, or a pharmaceutically acceptable salt thereof.
28. The conjugate of any one of clauses 1 to 15, 18 or 19, wherein the
linker is of the
formula
0 H
N 0
CO2H CO2H
O ) ) ?-1 -02C
H- - H, n _H0CO2H HN
N..)1\1='NLNS ___/ µ CO2H
. N
N 0
H 0 zõ,,,... H 0 e......, H
----\
-::.-NNH -;.--NNH \ NH 0
HO'''" HO'''' HOµµ''µC)H
HOi.
HOl HO/
OH HO HO
wherein * is a bond, or a pharmaceutically acceptable salt thereof.
29. The conjugate of any of clauses 1-28, wherein ¨D1-L5-D2 is of the
formula
24
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R71, R6b
R3.1., R (1)
N,4b 0 \...õN/
= R5b
Rai)
D2a
2' Oa 0 "
R9a
R9b
c..-IN 1110 -I-5 -C) 2bel-0 R1 ObR- R12b
R1113
R8a
R5 ---
N'\NR3aR4a, / 0 o
Rua 1
R7a ,
wherein R2a, R3a, R4a, R8a, R9a, R10a, R2b, R3b, K,--.4b,
R8b and R9b are H; or a pharmaceutically
acceptable salt thereof.
30. The conjugate of any of clause 29, wherein R2a, R3a, R4a, R8a, R9a,
R10a, R2b, R3b, R4b, R8b
and R9b are H, L5 is Ci-C10 alkyl or -(CR49R49').C(0)-, each R49 and R49' is
H, and u is 1, 2, 3,
or 4; or a pharmaceutically acceptable salt thereof.
31. The conjugate of any of clauses 1-28, wherein -D1-L5-D2 is of the
formula
R5
1 ,
III
R3c N-:-.-=0,,.
......R2a
µ_....il Oa 0
C1R9ao 0:L5-0
_ .
N
R8a 0 R
4c 0
RN5 '-- ii2c
'\ NR3aR4a
, / 0 0
Rua 1
R7a
wherein R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a, R10a, R2c, R3c, R4c, -5c
K are H; or a pharmaceutically
acceptable salt thereof.
32. The conjugate of any of clause 31, wherein, L5 is C1-C10 alkyl or -
(CR49R49')uC(0)-,
wherein each R49 and R49' is H, and u is 1, 2, 3, 4 or 5; or a
pharmaceutically acceptable salt
thereof.
33. The conjugate of any of clauses 1-28, wherein -D1-L5-D2 is of the
formula
D 2a
µ.....il Oa 0 "
R8a c.
R
R9a 0 SI 0_1_5_0 ,INI
NI H
5a :
, - I N
N'\
R6a/ 0 NR3aR4a
N
0 = el \
i
R7a N=N
N
wherein, R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a and K- 10a
are H; or a pharmaceutically acceptable
salt thereof.
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
34. The conjugate of clause 33, wherein, L5 is Ci-Cio alkyl or
¨(CR49R49').C(0)-, wherein
each R49 and R49' is H, and u is 1, 2, 3, 4 or 5; or a pharmaceutically
acceptable salt thereof.
35. The conjugate of any of clauses 1-28, wherein ¨D1-L5-D2 is of the
formula
ORle
0
R8a
R5 CI
N'\ 0 NR3aR4a
o
R6a/
R7a
wherein, R2a, R3a; R4a; R5a; R6a; R7a; R8a; R9a; Rioa and Rie are H;
or a pharmaceutically
acceptable salt thereof.
36. The conjugate of clause 35, wherein L5 is C1-C10 alkyl or
¨(CR49R49').C(0)-, wherein
each R49 and R49' is H, and u is 1, 2, 3, 4 or 5; or a pharmaceutically
acceptable salt thereof.
37. The conjugate of any of claims 1-28, wherein ¨D1-L5-D2 is of the
formula
0
_R2a o R1 d
JR10a 0
R9a
N\-4¨CN
ciN N H
R8a
R5
N'\ 0 NR3aR4a
/ 0
Roa
R7a
wherein R2a, R3a; R4a; R5a; R6a; R7a; R8a; R9a; Rioa; Rid are H;
or a pharmaceutically acceptable
salt thereof.
38. The conjugate of clause 37, wherein L5 is Cl-Cio alkyl or
¨(CR49R49').C(0)-, wherein
each R49 and R49' is H, and u is 1, 2, 3, 4 or 5; or a pharmaceutically
acceptable salt thereof.
39. The conjugate of any of clauses 1-28, wherein ¨D1-L5-D2 is of the
formula
R2a
0 "
" R9a c,1
R5a
0_0_0 40 0 1
R8a N N"--\ 0 NR3aR4a 0
/ /II..
Roa
R7a 0
wherein R2a, R3a; R4a; R5a; R6a; R7a; R8a; R9a and Rioa are H;
or a pharmaceutically acceptable
salt thereof.
40. The conjugate of clause 39, wherein L5 is Cl-Cio alkyl or
¨(CR49R49').C(0)-, wherein
each R49 and R49' is H, and u is 1, 2, 3, 4 or 5; or a pharmaceutically
acceptable salt thereof.
41. The conjugate of any of clauses 1-28, wherein ¨D1-L5-D2 is of the
formula
26
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
CI
20 a 0 N--../."¨C1
Oa 0 "
R9a
R5a
0 ¨L5 ¨H
R8a
N'\NR3aR4a
R6a/ 0 o
Fea
wherein R2a, R3a; R4a; R5a; R6a; R7a; R8a; R9a and Rioa are H;
or a pharmaceutically acceptable
salt thereof.
42. The conjugate of clause 41, wherein L5 is Ci-Cio alkyl or
¨(CR49R49').C(0)-, wherein
each R49 and R49' is H, and u is 1, 2, 3, 4 or 5; or a pharmaceutically
acceptable salt thereof.
43. The conjugate of any of clauses 1-28, wherein ¨D1-L5-D2 is of the
formula
R7b R6b
R3,1,3 ,R4b 0 (!)
RN)
R5b
D2a
R5a ....
R9a 0¨L5-0 Si R9b
R1 Ob"-- R12b
R2b -0 R1113
R8a
NR3a
/ 0 o
R6a
R7a
wherein R2a, R3a; R5a; R6a; R7a; R8a; R9a, Rioa, R2b, R3b, R4b, R5b, R6b, R7b,
R8b, R9b, R10b, Rib and
Ri2b are H;
or a pharmaceutically acceptable salt thereof.
44. The conjugate of clause 43, wherein L5 is C1-C10 alkyl or
¨(CR49R49')õC(0)-, wherein each R49 and R49' is H, and u is 1, 2, 3, 4 or 5;
or a
pharmaceutically acceptable salt thereof.
45. A conjugate of the formula
27
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
H2N
)7-NH
1µ1O
N N
\I"
HN
qo
HN
0
NH
HO:):)¨FNH
'OH 0 '¨0O21-1
HO OH NH
0
HO, NH HN
H CD \--CO2H
HO OH NH
0
H(3, F3--rNH CO2H
OO
HO¨I
HN
0
0
0
0
O
NH
HN
0
0
0 N
H2N
0
0
515,õNH
NH
0
or a pharmaceutically acceptable salt thereof.
28
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
46. A pharmaceutical composition comprising a therapeutically effective
amount of a
conjugate according to any one of clauses 1-45, or a pharmaceutically
acceptable salt thereof,
and at least on excipient.
47. A method of treating abnormal cell growth in a mammal, including a
human, the
method comprising administering to the mammal a conjugate of any one of
clauses 1-45.
48. The method of clause 47, wherein the abnormal cell growth is cancer
49. The method of clause 48. wherein the cancer is lung cancer, bone
cancer, pancreatic
cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular
melanoma, uterine
cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach
cancer, colon cancer,
breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of
the endometrium,
carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva,
Hodgkin's Disease,
cancer of the esophagus, cancer of the small intestine, cancer of the
endocrine system, cancer of
the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal
gland, sarcoma of soft
tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic
or acute leukemia,
lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter,
renal cell
carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous
system (CNS),
primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary
adenoma, or a
combination of one or more of the foregoing cancers. In another embodiment of
said method,
said abnormal cell growth is a benign proliferative disease, including, but
not limited to,
psoriasis, benign prostatic hypertrophy or restinosis.
50. Use of a conjugate according to any one of clauses 1-45 in the
preparation of a
medicament for the treatment of cancer.
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows that EC1629 (=) dosed at 2 [tmol/kg TIVV for two weeks decreases
KB
tumors in test animals compared to untreated control (=). The dotted line
indicates the last
dosing day.
FIG. 2 shows that EC1744 (N) dosed at 2 [tmol/kg TIVV for two weeks decreases
KB
tumors in test animals compared to untreated control (=). FIG. 2 also shows
and that EC1788
(A) dosed at 0.2 [tmol/kg TIVV for two weeks decreases KB tumors in test
animals compared to
untreated control (=), and that EC1788 gave a complete response. The dotted
line indicates the
last dosing day.
FIG. 3 shows that EC1884 (d) dosed at 2 [tmol/kg TIVV for two weeks decreases
KB
29
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
tumors in test animals compared to untreated control (a). FIG. 3 also shows
and that EC1879
(c) dosed at 2 p.mol/kg TIVV for 1 week decreases KB tumors in test animals
compared to
untreated control (a), and that EC1879 gave a partial response. FIG. 3 also
shows and that
EC1788 (b) dosed at 0.4 p.mol/kg BIVV for 2 weeks decreases KB tumors in test
animals
compared to untreated control (a), and that EC1788 gave a complete response,
and cure. The
dotted line indicates the last dosing day.
FIG. 4 shows that EC1879 ( A ) dosed at 2 p.mol/kg TIVV for two weeks
decreases KB
tumors in test animals compared to untreated control (N),and that EC1879 gave
a complete
response in 5/5 test animals, and cure in 5/5 test animals. The dotted line
indicates the last
dosing day.
FIG. 5 shows that EC1744 (=) dosed at 2 p.mol/kg TIVV for two weeks decreases
MDA-
MB-231 tumors in test animals compared to untreated control (N), and that
EC1744 gave a
complete response in 5/5 test animals, and cure in 4/5 test animals. The
dotted line indicates
the last dosing day.
DEFINITIONS
As used herein, the term "alkyl" includes a chain of carbon atoms, which is
optionally
branched and contains from 1 to 20 carbon atoms. It is to be further
understood that in certain
embodiments, alkyl may be advantageously of limited length, including C1-C12,
C1-C10, C1-C9,
C1-C8, C1-C7, C1-C6, and C1-C4, Illustratively, such particularly limited
length alkyl groups,
including C1-C8, C1-C7, C1-C6, and C1-C4, and the like may be referred to as
"lower alkyl."
Illustrative alkyl groups include, but are not limited to, methyl, ethyl, n-
propyl, isopropyl, n-
butyl, isobutyl, sec-butyl, tert-butyl, pentyl, 2-pentyl, 3-pentyl, neopentyl,
hexyl, heptyl, octyl,
and the like. Alkyl may be substituted or unsubstituted. Typical substituent
groups include
cycloalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, aryloxy,
mercapto, alkylthio,
arylthio, cyano, halo, carbonyl, oxo, (=0), thiocarbonyl, 0-carbamyl, N-
carbamyl, 0-
thiocarbamyl, N-thiocarbamyl, C-amido, N-amido, C-carboxy, 0-carboxy, nitro,
and amino, or
as described in the various embodiments provided herein. It will be understood
that "alkyl" may
be combined with other groups, such as those provided above, to form a
functionalized alkyl.
By way of example, the combination of an "alkyl" group, as described herein,
with a "carboxy"
group may be referred to as a "carboxyalkyl" group. Other non-limiting
examples include
hydroxyalkyl, aminoalkyl, and the like.
As used herein, the term "alkenyl" includes a chain of carbon atoms, which is
optionally
branched, and contains from 2 to 20 carbon atoms, and also includes at least
one carbon-carbon
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
double bond (i.e. C=C). It will be understood that in certain embodiments,
alkenyl may be
advantageously of limited length, including C2-C12, C2-C9, C2-C8, C2-C7, C2-
C6, and C2-C4.
Illustratively, such particularly limited length alkenyl groups, including C2-
C8, C2-C7, C2-C6,
and C2-C4 may be referred to as lower alkenyl. Alkenyl may be unsubstituted,
or substituted as
described for alkyl or as described in the various embodiments provided
herein. Illustrative
alkenyl groups include, but are not limited to, ethenyl, 1-propenyl, 2-
propenyl, 1-, 2-, or 3-
butenyl, and the like.
As used herein, the term "alkynyl" includes a chain of carbon atoms, which is
optionally
branched, and contains from 2 to 20 carbon atoms, and also includes at least
one carbon-carbon
triple bond (i.e. CC). It will be understood that in certain embodiments
alkynyl may each be
advantageously of limited length, including C2-C12, C2-C9, C2-C8, C2-C7, C2-
C6, and C2-C4.
Illustratively, such particularly limited length alkynyl groups, including C2-
C8, C2-C7, C2-C6,
and C2-C4 may be referred to as lower alkynyl. Alkenyl may be unsubstituted,
or substituted as
described for alkyl or as described in the various embodiments provided
herein. Illustrative
alkenyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-
propynyl, 1-, 2-, or 3-
butynyl, and the like.
As used herein, the term "aryl" refers to an all-carbon monocyclic or fused-
ring
polycyclic groups of 6 to 12 carbon atoms having a completely conjugated pi-
electron system.
It will be understood that in certain embodiments, aryl may be advantageously
of limited size
such as C6-C10 aryl. Illustrative aryl groups include, but are not limited to,
phenyl, naphthalenyl
and anthracenyl. The aryl group may be unsubstituted, or substituted as
described for alkyl or as
described in the various embodiments provided herein.
As used herein, the term "cycloalkyl" refers to a 3 to 15 member all-carbon
monocyclic
ring, an all-carbon 5-member/6-member or 6-member/6-member fused bicyclic
ring, or a
multicyclic fused ring (a "fused" ring system means that each ring in the
system shares an
adjacent pair of carbon atoms with each other ring in the system) group where
one or more of
the rings may contain one or more double bonds but the cycloalkyl does not
contain a
completely conjugated pi-electron system. It will be understood that in
certain embodiments,
cycloalkyl may be advantageously of limited size such as C3-C13, C3-C6, C3-C6
and C4-C6.
Cycloalkyl may be unsubstituted, or substituted as described for alkyl or as
described in the
various embodiments provided herein. Illustrative cycloalkyl groups include,
but are not limited
to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclopentadienyl,
cyclohexyl,
cyclohexenyl, cycloheptyl, adamantyl, norbornyl, norbornenyl, 9H-fluoren-9-yl,
and the like.
As used herein, the term "heterocycloalkyl" refers to a monocyclic or fused
ring group
having in the ring(s) from 3 to 12 ring atoms, in which at least one ring atom
is a heteroatom,
31
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
such as nitrogen, oxygen or sulfur, the remaining ring atoms being carbon
atoms.
Heterocycloalkyl may optionally contain 1, 2, 3 or 4 heteroatoms.
Heterocycloalkyl may also
have one of more double bonds, including double bonds to nitrogen (e.g. C=N or
N=N) but
does not contain a completely conjugated pi-electron system. It will be
understood that in
certain embodiments, heterocycloalkyl may be advantageously of limited size
such as 3- to 7-
membered heterocycloalkyl, 5- to 7-membered heterocycloalkyl, and the like.
Heterocycloalkyl
may be unsubstituted, or substituted as described for alkyl or as described in
the various
embodiments provided herein. Illustrative heterocycloalkyl groups include, but
are not limited
to, oxiranyl, thianaryl, azetidinyl, oxetanyl, tetrahydrofuranyl,
pyrrolidinyl, tetrahydropyranyl,
piperidinyl, 1,4-dioxanyl, morpholinyl, 1,4-dithianyl, piperazinyl, oxepanyl,
3,4-dihydro-2H-
pyranyl, 5,6-dihydro-2H-pyranyl, 2H-pyranyl, 1, 2, 3, 4-tetrahydropyridinyl,
and the like.
As used herein, the term "heteroaryl" refers to a monocyclic or fused ring
group of 5 to
12 ring atoms containing one, two, three or four ring heteroatoms selected
from nitrogen,
oxygen and sulfur, the remaining ring atoms being carbon atoms, and also
having a completely
conjugated pi-electron system. It will be understood that in certain
embodiments, heteroaryl
may be advantageously of limited size such as 3- to 7-membered heteroaryl, 5-
to 7-membered
heteroaryl, and the like. Heteroaryl may be unsubstituted, or substituted as
described for alkyl
or as described in the various embodiments provided herein. Illustrative
heteroaryl groups
include, but are not limited to, pyrrolyl, furanyl, thiophenyl, imidazolyl,
oxazolyl, thiazolyl,
pyrazolyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, purinyl,
tetrazolyl, triazinyl,
pyrazinyl, tetrazinyl, quinazolinyl, quinoxalinyl, thienyl, isoxazolyl,
isothiazolyl, oxadiazolyl,
thiadiazolyl, triazolyl, benzimidazolyl, benzoxazolyl, benzthiazolyl,
benzisoxazolyl,
benzisothiazolyl and carbazoloyl, and the like.
As used herein, "hydroxy" or 'hydroxyl" refers to an -OH group.
As used herein, "alkoxy" refers to both an -0-(alkyl) or an -0-(unsubstituted
cycloalkyl)
group. Representative examples include, but are not limited to, methoxy,
ethoxy, propoxy,
butoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the
like.
As used herein, "aryloxy" refers to an -0-aryl or an -0-heteroaryl group.
Representative
examples include, but are not limited to, phenoxy, pyridinyloxy, furanyloxy,
thienyloxy,
pyrimidinyloxy, pyrazinyloxy, and the like, and the like.
As used herein, "mercapto" refers to an -SH group.
As used herein, "alkylthio" refers to an -S-(alkyl) or an -S-(unsubstituted
cycloalkyl)
group. Representative examples include, but are not limited to, methylthio,
ethylthio,
propylthio, butylthio, cyclopropylthio, cyclobutylthio, cyclopentylthio,
cyclohexylthio, and the
like.
32
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
As used herein, "arylthio" refers to an -S-aryl or an -S-heteroaryl group.
Representative
examples include, but are not limited to, phenylthio, pyridinylthio,
furanylthio, thienylthio,
pyrimidinylthio, and the like.
As used herein, "halo" or "halogen" refers to fluorine, chlorine, bromine or
iodine.
As used herein, "trihalomethyl" refers to a methyl group having three halo
substituents,
such as a trifluoromethyl group.
As used herein, "cyano" refers to a -CN group.
As used herein, "sulfinyl" refers to a -S(0)R" group, where R" is any R group
as
described in the various embodiments provided herein, or R" may be a hydroxyl
group.
As used herein, "sulfonyl" refers to a -S(0)2R" group, where R" is any R group
as
described in the various embodiments provided herein, or R" may be a hydroxyl
group.
As used herein, "S-sulfonamido" refers to a -S(0)2NR"R" group, where R" is any
R
group as described in the various embodiments provided herein.
As used herein, "N-sulfonamido" refers to a -NR"S(0)2R" group, where R" is any
R
group as described in the various embodiments provided herein.
As used herein, "0-carbamyl" refers to a -0C(0)NR"R" group, where R" is any R
group as described in the various embodiments provided herein.
As used herein, "N-carbamyl" refers to an R"OC(0)NR"- group, where R" is any R
group as described in the various embodiments provided herein.
As used herein, "0-thiocarbamyl" refers to a -0C(S)NR"R" group, where R" is
any R
group as described in the various embodiments provided herein.
As used herein, "N-thiocarbamyl" refers to a R"OC(S)NR"- group, where R" is
any R
group as described in the various embodiments provided herein.
As used herein, "amino" refers to an -NR"R" group, where R" is any R group as
described in the various embodiments provided herein.
As used herein, "C-amido" refers to a -C(0)NR"R" group, where R" is any R
group as
described in the various embodiments provided herein.
As used herein, "N-amido" refers to a R"C(0)NR"- group, where R" is any R
group as
described in the various embodiments provided herein.
As used herein, "nitro" refers to a ¨NO2 group.
As used herein, "bond" refers to a covalent bond.
As used herein, "optional" or "optionally" means that the subsequently
described event
or circumstance may but need not occur, and that the description includes
instances where the
event or circumstance occurs and instances in which it does not. For example,
"heterocycle
group optionally substituted with an alkyl group" means that the alkyl may but
need not be
33
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
present, and the description includes situations where the heterocycle group
is substituted with
an alkyl group and situations where the heterocycle group is not substituted
with the alkyl
group.
As used herein, "independently" means that the subsequently described event or
circumstance is to be read on its own relative to other similar events or
circumstances. For
example, in a circumstance where several equivalent hydrogen groups are
optionally substituted
by another group described in the circumstance, the use of "independently
optionally" means
that each instance of a hydrogen atom on the group may be substituted by
another group, where
the groups replacing each of the hydrogen atoms may be the same or different.
Or for example,
where multiple groups exist all of which can be selected from a set of
possibilities, the use of
"independently" means that each of the groups can be selected from the set of
possibilities
separate from any other group, and the groups selected in the circumstance may
be the same or
different.
As used herein, the term "pharmaceutically acceptable salt" refers to those
salts which
counter ions which may be used in pharmaceuticals. Such salts include:
(1) acid addition salts, which can be obtained by reaction of the free base of
the parent
conjugate with inorganic acids such as hydrochloric acid, hydrobromic acid,
nitric acid,
phosphoric acid, sulfuric acid, and perchloric acid and the like, or with
organic acids
such as acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methane
sulfonic
acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric
acid, citric acid,
succinic acid or malonic acid and the like; or
(2) salts formed when an acidic proton present in the parent conjugate either
is replaced
by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an
aluminum ion; or
coordinates with an organic base such as ethanolamine, diethanolamine,
triethanolamine, trimethamine, N-methylglucamine, and the like.
Pharmaceutically acceptable salts are well known to those skilled in the art,
and any such
pharmaceutically acceptable salt may be contemplated in connection with the
embodiments
described herein
As used herein, "amino acid" (a.k.a. "AA") means any molecule that includes an
alpha-
carbon atom covalently bonded to an amino group and an acid group. The acid
group may
include a carboxyl group. "Amino acid" may include molecules having one of the
formulas:
R' __ - ...
..
)K
H ,'
; XH
H2N COOH HN COOH
34
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
wherein R' is a side group and (I) includes at least 3 carbon atoms. "Amino
acid" includes
stereoisomers such as the D-amino acid and L-amino acid forms. Illustrative
amino acid groups
include, but are not limited to, the twenty endogenous human amino acids and
their derivatives,
such as lysine (Lys), asparagine (Asn), threonine (Thr), serine (Ser),
isoleucine (Ile),
methionine (Met), proline (Pro), histidine (His), glutamine (Gin), arginine
(Arg), glycine (Gly),
aspartic acid (Asp), glutamic acid (Glu), alanine (Ala), valine (Val),
phenylalanine (Phe),
leucine (Leu), tyrosine (Tyr), cysteine (Cys), tryptophan (Trp), phosphoserine
(PSER), sulfo-
cysteine, arginosuccinic acid (ASA), hydroxyproline, phosphoethanolamine
(PEA), sarcosine
(SARC), taurine (TAU), carnosine (CARN), citrulline (CIT), anserine (ANS), 1,3-
methyl-
histidine (ME-HIS), alpha-amino-adipic acid (AAA), beta- alanine (BALA),
ethanolamine
(ETN), gamma-amino-butyric acid (GABA), beta-amino- isobutyric acid (BAIA),
alpha-amino-
butyric acid (BABA), L-allo-cystathionine (cystathionine- A; CYSTA-A), L-
cystathionine
(cystathionine-B; CYSTA-B), cystine, allo-isoleucine (ALLO- ILE), DL-
hydroxylysine
(hydroxylysine (I)), DL-allo-hydroxylysine (hydroxylysine (2)), ornithine
(ORN), homocystine
(HCY), and derivatives thereof. It will be appreciated that each of these
examples are also
contemplated in connection with the present disclosure in the D-configuration
as noted above.
Specifically, for example, D-lysine (D-Lys), D-asparagine (D-Asn), D-threonine
(D-Thr), D-
serine (D-Ser), D-isoleucine (D-Ile), D-methionine (D-Met), D-proline (D-Pro),
D-histidine (D-
His), D-glutamine (D-Gln), D-arginine (D-Arg), D-glycine (D-Gly), D-aspartic
acid (D-Asp),
D-glutamic acid (D-Glu), D-alanine (D-Ala), D-valine (D-Val), D-phenylalanine
(D-Phe), D-
leucine (D-Leu), D-tyrosine (D-Tyr), D-cysteine (D-Cys), D-tryptophan (D-Trp),
D-citrulline
(D-CIT), D-carnosine (D-CARN), and the like. In connection with the
embodiments described
herein, amino acids can be covalently attached to other portions of the
conjugates described
herein through their alpha-amino and carboxy functional groups (i.e. in a
peptide bond
configuration), or through their side chain functional groups (such as the
side chain carboxy
group in glutamic acid) and either their alpha-amino or carboxy functional
groups. It will be
understood that amino acids, when used in connection with the conjugates
described herein,
may exist as zwitterions in a conjugate in which they are incorporated.
As used herein, "sugar" refers to carbohydrates, such as monosaccharides,
disaccharides, or oligosaccharides. In connection with the present disclosure,
monosaccharides
are preferred. Non-limiting examples of sugars include erythrose, threose,
ribose, arabinose,
xylose, lyxose, allose, altrose, glucose, mannose, galactose, ribulose,
fructose, sorbose,
tagatose, and the like. It will be undertsood that as used in connection with
the present
disclosure, sugar includes cyclic isomers of amino sugars, deoxy sugars,
acidic sugars, and
combinations thereof. Non-limiting examples of such sugars include,
galactosamine,
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
glucosamine, deoxyribose, fucose, rhamnose, glucuronic acid, ascorbic acid,
and the like. In
some embodiments, sugars for use in connection with the present disclosure
include
HOHO
HO_ii) n HO
HO CO2H
0 F1 HF010 HO\c) HI-01C\)&1020H
-.0
___________________________________________ and 0 .
,
As used herein, "prodrug" refers to a compound that can be administered to a
subject in
a pharmacologically inactive form which then can be converted to a
pharmacologically active
form through a normal metabolic process, such as hydrolysis of an oxazolidine.
It will be
understood that the metabolic processes through which a prodrug can be
converted to an active
drug include, but are not limited to, one or more spontaneous chemical
reaction(s), enzyme-
catalyzed chemical reaction(s), and/or other metabolic chemical reaction(s),
or a combination
thereof. It will be appreciated that understood that a variety of metabolic
processes are known
in the art, and the metabolic processes through which the prodrugs described
herein are
converted to active drugs are non-limiting. A prodrug can be a precursor
chemical compound of
a drug that has a therapeutic effect on a subject.
Au used herein, the term "therapeutically effective amount" refers to an
amount of a
drug or pharmaceutical agent that elicits the biological or medicinal response
in a subject (i.e. a
tissue system, animal or human) that is being sought by a researcher,
veterinarian, medical
doctor or other clinician, which includes, but is not limited to, alleviation
of the symptoms of
the disease or disorder being treated. In one aspect, the therapeutically
effective amount is that
amount of an active which may treat or alleviate the disease or symptoms of
the disease at a
reasonable benefit/risk ratio applicable to any medical treatment. In another
aspect, the
therapeutically effective amount is that amount of an inactive prodrug which
when converted
through normal metabolic processes to produce an amount of active drug capable
of eliciting
the biological or medicinal response in a subject that is being sought.
It is also appreciated that the dose, whether referring to monotherapy or
combination
therapy, is advantageously selected with reference to any toxicity, or other
undesirable side
effect, that might occur during administration of one or more of the
conjugates described
herein. Further, it is appreciated that the co-therapies described herein may
allow for the
administration of lower doses of conjugates that show such toxicity, or other
undesirable side
effect, where those lower doses are below thresholds of toxicity or lower in
the therapeutic
window than would otherwise be administered in the absence of a cotherapy.
As used herein, "administering" includes all means of introducing the
conjugates and
compositions described herein to the host animal, including, but are not
limited to, oral (po),
36
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
intravenous (iv), intramuscular (im), subcutaneous (sc), transdermal,
inhalation, buccal, ocular,
sublingual, vaginal, rectal, and the like. The conjugates and compositions
described herein may
be administered in unit dosage forms and/or formulations containing
conventional nontoxic
pharmaceutically-acceptable carriers, adjuvants, and/or vehicles.
As used herein "pharmaceutical composition" or "composition" refers to a
mixture of
one or more of the conjugates described herein, or pharmaceutically acceptable
salts, solvates,
hydrates thereof, with other chemical components, such as pharmaceutically
acceptable
excipients. The purpose of a pharmaceutical composition is to facilitate
administration of a
conjugate to a subject. Pharmaceutical compositions suitable for the delivery
of conjugates
described and methods for their preparation will be readily apparent to those
skilled in the art.
Such compositions and methods for their preparation may be found, for example,
in
'Remington's Pharmaceutical Sciences', 19th Edition (Mack Publishing Company,
1995).
A "pharmaceutically acceptable excipient" refers to an inert substance added
to a
pharmaceutical composition to further facilitate administration of a conjugate
such as a diluent
or. a carrier.
DETAILED DESCRIPTION
In each of the foregoing and each of the following embodiments, it is to be
understood
that the formulae include and represent not only all pharmaceutically
acceptable salts of the
conjugates, but also include any and all hydrates and/or solvates of the
conjugate formulae. It is
appreciated that certain functional groups, such as the hydroxy, amino, and
like groups form
complexes and/or coordination conjugates with water and/or various solvents,
in the various
physical forms of the conjugates. Accordingly, the above formulae are to be
understood to
include and represent those various hydrates and/or solvates. It is also to be
understood that the
non-hydrates and/or non-solvates of the conjugate formulae are described by
such formula, as
well as the hydrates and/or solvates of the conjugate formulae.
The conjugates described herein can be expressed by the generalized
descriptors B, L
and Drug, where B is a cell surface receptor binding ligand (a.k.a. a "binding
ligand"), L is a
linker that may include a releasable portion (i.e. a releasable linker) and L
may be described by
one or more of the groups AA, L1, L2, L3, L4 or L5 as defined herein, and Drug
represents one
or more drugs (e.g. D1 and D2) covalently attached to the conjugate.
The conjugates described herein can be described according to various
embodiments
including but not limited to
B-(AA)zi-L2-(L3)z2-(AA)z3-(Li)z4-(L4)z5_D1-L5-D2
B-L1-AA-L1-AA-L1_,- 2_
L (L3)z6-(L4)z7-(AA)z8-(Liz9-Dl_L5_D2
37
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
B-(AA)z10-L2-D2
B-(AA)11 L2 D1 L5 D1 L2 (AA)z12-B
B-(AA)4-L2-D1-L5-D2
B-(AA)4-L2-L3-AA L1 L4 D1 L5 D2
B-(AA)4-L2-L3-(AA)2-D1-L5-D2
B-(AA)4-L2-D2
B-(AA)4 L2 D1 L5 D1 L2 (AA)4-B
B-L1-AA L1 AA L1 L2 D1 L5 D2
B - Ll - AA - Ll - AA Ll L2 L3 (AA)2-L4-D1-L5-D2
B-L1-AA-L1-AA L1 L2 L3 L4 (AA)2-L4-D1-L5-D2
B-L1-AA L1 AA L1 L2 L3 L4 D1 L5 D2
B-L1-AA-L1-AA-L1-L2-L3-(AA)2-D1-L5-D2
B-L1-AA L1 AA L1 L2 L3 D1 L5 D2
wherein B, AA, L1, L2, L3, L4, L5, D1 and D2 are defined by the various
embodiments described
herein, and z 1 is 2, 3, 4 or 5; z2 is 0, 1 or 2; z3 is 0, 1, 2, 3 or 4; z4 is
0, 1 or 2; z5 is 0, 1 or 2;
yl is 0, 1 or 2; y2 is 0, 1 or 2; y3 is 0, 1, 2, 3 or 4; and y4 is 0, 1 or 2.
As used herein, the term cell surface receptor binding ligand (aka a "binding
ligand"),
generally refers to compounds that bind to and/or target receptors that are
found on cell
surfaces, and in particular those that are found on, over-expressed by, and/or
preferentially
expressed on the surface of pathogenic cells. Illustrative ligands include,
but are not limited to,
vitamins and vitamin receptor binding compounds.
Illustrative vitamin moieties include carnitine, inositol, lipoic acid,
pyridoxal, ascorbic
acid, niacin, pantothenic acid, folic acid, riboflavin, thiamine, biotin,
vitamin B12, and the lipid
soluble vitamins A, D, E and K. These vitamins, and their receptor-binding
analogs and
derivatives, constitute the targeting entity covalently attachment to the
linker. Illustrative biotin
analogs that bind to biotin receptors include, but are not limited to,
biocytin, biotin sulfoxide,
oxybiotin, and the like).
In some embodiments, the B is folate or derivative thereof. In some
embodiments, the B
is of the formula I
R4 0 CO2H
R3
vi y1 22 R *
X4 0
mx5 R5
R6
H2N3(2X3-)
38
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
wherein
R1 and R2 in each instance are independently selected from the group
consisting of H,
D, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -OR', -SR7 and -NR7R7',
wherein each
hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl and C2_C6 alkynyl is independently
optionally
substituted by halogen, -0R8, -SR8, -NR8R8', -C(0)R8, -C(0)0R8 or -C(0)NR8R8';
R3, R4, R5 and R6 are each independently selected from the group consisting of
H, D,
halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -CN, -NO2, -NCO, -0R9, -
SR9, -NR9R9', -
C(0)R9, -C(0)0R9 and -C(0)NR9R9', wherein each hydrogen atom in C1-C6 alkyl,
C2-C6
alkenyl and C2_C6 alkynyl is independently optionally substituted by halogen, -
0R10, -
-NRioRicr, _c(0)-K, _ io C(0)0R1 or -C(0)NR10R10';
each R7, R7', R8, R8', R9, R9', R1 and R10' is independently H, D, C1-C6
alkyl, C2-C6
alkenyl or C2_C6 alkynyl;
X1 is -NR11-, -N=, -C(R11)= or =C(R11)-;
X2 is -NR11'- or =N-;
X3 is -NR11"-, -N= or -C(R11')=;
X4 is -N= or -C=;
X5 is NR12 or CR12R12';
y1 is H, D, -0R13, -5R13 or -NR13R13' when X1 is -N= or -C(R11)=, or y1 is =0
when
X1 is -NR11-, =N- or =C(R11)-;
Y2 is H, D, C1-C6 alkyl, C2-C6 alkenyl, -C(0)R14, -C(0)0R14, -C(0)NR14R14'
when X4
is -C=, or y2 is absent when X4 is -N=;
R11, R11', R11", R12, R12', R13, R13', R14 and R14'
are each independently selected from the
group consisting of H, D, C1-C6 alkyl, -C(0)R15, -C(0)0R15 and -C(0)NR15R15';
R15 and R15' are each independently H or C1-C6 alkyl;
m is 1, 2, 3 or 4; and
* is a covalent bond.
It will be appreciate that when B is described according to the formula I,
that both the
D- and L- forms are contemplated. In some embodiments, B is of the formula Ia
or lb
R4 0 CO2H
R3
vi
R5 *
0
mx5
2 R6
H2N X X
or
Ia
39
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R4 0 CO2H
Y1 v2 R3 N *
)(4&x50
X1 R5
R6
=
H 2 N X2 )(3
lb
where each of R1, R2, R3, R4, R5, R6, y1, y2, X1, X2, X3, X4, X5, m and * are
as defined for the
formula I.
In some embodiments described herein, R1 and R2 are H. In some embodiments
described herein, m is 1. In some embodiments described herein, R3 is H. In
some embodiments
described herein, R4 is H. In some embodiments described herein, R5 is H. In
some
embodiments described herein, R6 is H. In some embodiments described herein,
R3, R4, R5 and
R6 are H. In some embodiments described herein, X1 is ¨NR11, and R11 is H. In
some
embodiments described herein, X2 is =N-. In some embodiments described herein,
X3 is ¨N=.
In some embodiments described herein, X4 is ¨N=. In some embodiments described
herein, X1
is ¨NR11, and R11 is H; X2 is =N-; X3 is ¨N=; and X4 is ¨N=. In some
embodiments described
herein, X5 is NR12, and R12 is H. In some embodiments, y1 is =O. In some
embodiments, Y2 is
absent. In some embodiments, B is of the formula Ic
0 CO2H
0 N \./\ *
H N N 0
H2NNN
Ic
wherein * is defined for formula I.
In some embodiments, B is of the formula Id
0 CO2H
0 N *
H N NN 0
H2 N
Id
wherein * is defined for formula I.
It will be appreciated that in certain embodiments, the conjugates described
herein can
be represented by the exemplary formulae
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
0 CO2H
0
N )(AA)zi-L2-(1-3)z2-(AA)z3-(1_1)z4-(1-4)z5-D1-L5-D2
HNI N N lei H 0
I H
H2NN 1\r
0 CO2H
1 AA-L1-AA-Ll-L2-(L31 -(L41 -AA) ( 41 Di 1 5 n2
0 0
H 0
H N NN
I H
H2NNI\r
0 CO2H
0 N i_(AA)zio-L2-D2
0
H 0
HNI NN
I H
H2N N 1\r
CO2H o
0 CO2H
0 ykii_L2_01_0_01_1_2_(AA),-THN io 0
0 0
NN)-
1
NH
H1\1).NN 0 H
H N N NH2
H2N N I\1
0 CO2H
0 N(AA)4_1_2_Di_o_D2
0
H
HNINN 0
I H
H2NNN
0 CO2H
(AA)4-L2-L3-AA-L1-L4-D1-L5-D2
0
1.10
HNII\IN
I H
H2NNIe
0 CO2H
0 N(AA)4-L2-L3-(AA)2-D1-L5-D2
H 0
HNI N N
I H
H2NN 1\r
O c02H CO2H 0
FIN1 NN 40 AA)4-L2-01-L5-01-L2-(AA)4yN
0
Fl H NH
io NN ,_NH
)..
O o
H H
H2N N 1\K N N NH2
41
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0 CO2H
0
i_AA-L1-AA-L1-L2-D1-L5-D2
HNI-
NN 0
2lN IN IN
0 CO2H
NL1-AA-L1-AA-L1-L2-L3-(AA)2-L4-D1-L5-D2
0
H N !NN 0
H2NNN
0 CO2H
0
NN 0
H2NNN
0 CO2H
0 i N
Li_AA_Li_AA L1 L2 L3 L4 (AA)2-0-D1-0-D2
0
NN
H2N1\11\1
0 CO2H
0 NILAALLLLDLD
H
NN 0
H2NNN
0 CO2H
0
NN 0
H2NNIe
or
0 CO2H
0 =
Li _AA_Li _AA_L -L2-L3-Di-L5-D2
N
NN 0
H2NNN
or a pharmaceutically acceptable salt thereof.
The linker for connected B and Drug in the conjugates described herein can be
represented by the groups AA, L1, L2, L3, L4 or L5.
AA is an amino acid as defined herein. In certain embodiments, AA is a
naturally
occurring amino acid. In certain embodiments, AA is in the L-form. In certain
embodiments,
AA is in the D-form. It will be appreciated that in certain embodiments, the
conjugates
42
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
described herein will comprise more than one amino acid as portions of the
linker, and the
amino acids can be the same or different, and can be selected from a group of
amino acids. It
will be appreciated that in certain embodiments, the conjugates described
herein will comprise
more than one amino acid as portions of the linker, and the amino acids can be
the same or
different, and can be selected from a group of amino acids in D- or L-form. In
some
embodiments, each AA is independently selected from the group consisting of L-
lysine, L-
asparagine, L-threonine, L-serine, L-isoleucine, L-methionine, L-proline, L-
histidine, L-
glutamine, L-arginine, L-glycine, L-aspartic acid, L-glutamic acid, L-alanine,
L-valine, L-
phenylalanine, L-leucine, L-tyrosine, L-cysteine, L-tryptophan, L-
phosphoserine, L-sulfo-
cysteine, L-arginosuccinic acid, L-hydroxyproline, L-phosphoethanolamine, L-
sarcosine, L-
taurine, L-carnosine, L-citrulline, L-anserine, L-1,3-methyl-histidine, L-
alpha-amino-adipic
acid, D-lysine, D-asparagine, D-threonine, D-serine, D-isoleucine, D-
methionine, D-proline, D-
histidine, D-glutamine, D-arginine, D-glycine, D-aspartic acid, D-glutamic
acid, D-alanine, D-
valine, D-phenylalanine, D-leucine, D-tyrosine, D-cysteine, D-tryptophan, D-
citrulline and D-
carnosine.
In some embodiments, each AA is independently selected from the group
consisting of
L-asparagine, L-arginine, L-glycine, L-aspartic acid, L-glutamic acid, L-
glutamine, L-cysteine,
L-alanine, L-valine, L-leucine, L-isoleucine, L-citrulline, D-asparagine, D-
arginine, D-glycine,
D-aspartic acid, D-glutamic acid, D-glutamine, D-cysteine, D-alanine, D-
valine, D-leucine, D-
isoleucine and D-citrulline. In some embodiments, each AA is independently
selected from the
group consisting of Asp, Arg, Val, Ala, Cys and CIT. In some embodiments, each
AA is
independently selected from the group consisting of Asp, Arg, Val, Ala, D-Cys
and CIT. In
some embodiments, each AA is independently selected from the group consisting
of Asp, Arg,
Val, Ala and CIT. In some embodiments, zl is 4 and the sequence of AA therein
is -Asp-Arg-
Asp-Asp-. In some embodiments, z3 is 2 and the sequence of AA therein is Val-
Ala. In some
embodiments, z3 is 2 and the sequence of AA therein is Val-CIT. In some
embodiments, zl is 4
and the sequence of AA therein is -Asp-Arg-Asp-Asp-, and z3 is 2 and the
sequence of AA
therein is Val-Ala. In some embodiments, zl is 4 and the sequence of AA
therein is -Asp-Arg-
Asp-Asp-, and z3 is 2 and the sequence of AA therein is Val-CIT.
In some embodiments, z8 is 3. In some embodiments, z8 is 2. In some
embodiments, z8
is 2, and the sequence of AA therein is Val-Ala. In some embodiments, z10 is
5. In some
embodiments, z10 is 4. In some embodiments, z10 is 3. In some embodiments, z10
is 4 and the
sequence of AA therein is -Asp-Arg-Asp-Asp-. In some embodiments, zll is 5. In
some
embodiments, zll is 4. In some embodiments, zll is 3. In some embodiments, zll
is 4 and the
sequence of AA therein is -Asp-Arg-Asp-Asp-. In some embodiments, z12 is 5. In
some
43
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
embodiments, z12 is 4. In some embodiments, z12 is 3. In some embodiments, z12
is 4 and the
sequence of AA therein is -Asp-Asp-Arg-Asp-. In some embodiments, zll is 4 and
z12 is 4. In
some embodiments, zll is 4 and the sequence of AA therein is -Asp-Arg-Asp-Asp-
, and z12 is
4 and the sequence of AA therein is -Asp-Asp-Arg-Asp-. In some embodiments, z8
is 2, and the
sequence of AA is -Glu-Glu-, wherein the amino acids are covalently attached
at their alpha-
amino functionality and their side chain carboxylate.
L1 can be present or absent in the conjugates described herein. When L1 is
present, L1
can be any group covalently attaching portions of the linker to the binding
ligand, portions of
the linker to one another, or to D1, or to D2. It will be understood that the
structure of L1 is not
particularly limited in any way. It will be further understood that L1 can
comprise numerous
functionalities well known in the art to covalently attach portions of the
linker to the binding
ligand, portions of the linker to one another, or to D1, or to D2, including
but not limited to,
alkyl groups, ether groups, amide groups, carboxy groups, sulfonate groups,
alkenyl groups,
alkynyl groups, cycloalkyl groups, aryl groups, heterocycloalkyl, heteroaryl
groups, and the
like. In some embodiments, L1 is a linker of the formula II
R160
I 1
* N *
S,CR17R17') n
R18
II
wherein
R16 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, -C(0)R19, -C(0)0R19 and -C(0)NR19R19', wherein each hydrogen atom in
C1-C6 alkyl,
C2-C6 alkenyl and C2_C6 alkynyl is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, and C2_C6 alkynyl, -0R20, -0C(0)R20, -0C(0)NR20R20'; -
0S(0)R20
,
-0S(0)2R20; _sR20; _s(0)R20; _s(0)2-K20; _ S(0)NR2oR20', _
S(0)2NR2oR20', _
OS(0)NR2 R20',
-OS(0)2NR2oR2u; _NR20R20'; _NR20c (0)R2t; _NR20c
(0)0R21, -NR20C(0)NR21R21';
-NR205(0)R21, -NR205(0)2R21, -NR205(0)NR21R21'; _NR205(0)2NR21R21'; _c(0)R20
;
-C(0)0R2 or -C(0)NR20R20';
each R17 and R17' is independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R22, -0C(0)R22,
-0C(0)NR22R22', _
OS(0)R22, -OS(0)2R22,
_5
R22, _s(0)R22, _s(0)27., _22
K S(0)NR22R22',
-S(0)2NR22R22', _OS(0)NR22R22', -OS(0)2NR22R22', _NR22R22', _NR22c(0)R23, _
NR22c(o)0R23, -NR22c(o)NR23R23', _NR225
(0)R23, _NR22s(0)2R23, _N-R 22-
S(0)NR23R23',
44
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR22S(0)2NR23R23', -C(0)R22, -C(0)0R22, and -C(0)NR22R22', wherein each
hydrogen atom
in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is independently
optionally
substituted by halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, -0R24, -
0C(0)R24,
-0C(0)NR24R24', -0S(0)R24, -0S(0)2R24, -SR24, -S(0)R24, -S(0)2R24, -
S(0)NR24R24',
-S(0)2NR24R24', -0S(0)NR24R24', -0S(0)2NR24R24', -NR24R24', -NR24C(0)R25,
-NR24C(0)0R25, -NR24C(0)NR25R25', -NR245(0)R25, -NR245(0)2R25, -
NR245(0)NR25R25',
-NR245(0)2NR25R25', -C(0)R24, -C(0)0R24 or -C(0)NR24R24'; or R17 and R17' may
combine to
form a C4-C6 cycloalkyl or a 4- to 6- membered heterocycle, wherein each
hydrogen atom in
C4-C6 cycloalkyl or 4- to 6- membered heterocycle is independently optionally
substituted by
halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R24, -0C(0)R24,
-0C(0)NR24R24', -0S(0)R24, -0S(0)2R24, -5R24, -S(0)R24, -S(0)2R24, -
S(0)NR24R24',
-S(0)2NR24R24', -0S(0)NR24R24', -0S(0)2NR24R24', -NR24R24', -NR24C(0)R25,
-NR24C(0)0R25, -NR24C(0)NR25R25', -NR245(0)R25, -NR245(0)2R25, -
NR245(0)NR25R25',
-NR245(0)2NR25R25', -C(0)R24, -C(0)0R24 or -C(0)NR24R24';
R18 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R26, -0C(0)R26, -0C(0)NR26R26', -0S(0)R26, -0S(0)2R26, -5R26, -
S(0)R26,
-S(0)2R26, -S(0)NR26R26', -S(0)2NR26R26', -0S(0)NR26R26', -0S(0)2NR26R26', -
NR26R26',
-NR26C(0)R27, -NR26C(0)0R27, -NR26C(0)NR27R27', -NR26C(=NR26")NR27R27',
-NR265(0)R27, -NR265(0)2R27, -NR26S(0)NR27R27', -NR26S(0)2NR27R27', -C(0)R26,
-C(0)0R26 and -C(0)NR26R26', wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl
and 5- to 7-
membered heteroaryl is independently optionally substituted by halogen, C1-C6
alkyl, C2-C6
alkenyl, -(CH2)p0R28, -(CH2)p(OCH2)q0R28, -(CH2)p(OCH2CH2)q0R28, -0R29, -
0C(0)R29,
-0C(0)NR29R29', -0S(0)R29, -0S(0)2R29, -(CH2)p0S(0)20R29, -0S(0)20R29, -5R29,
-S(0)R29, -S(0)2R29, -S(0)NR29R29', -S(0)2NR29R29', -0S(0)NR29R29', -
0S(0)2NR29R29',
-NR29R29', -NR29C(0)R30, -NR29C(0)0R30, -NR29C(0)NR30R30', -NR295(0)R30
,
-NR295(0)2R30, -NR295(0)NR30R30', -NR295(0)2NR30R30', -C(0)R29, -C(0)0R29 or
-C(0)NR29R29';
each R19, R19', R20, R20', R21, R21', R22, R22', R23, R23', R24, R24', R25,
R25', R26, R26', R26',
R29, R29', R3 and R30' is independently selected from the group consisting of
H, D, C1-C7 alkyl,
C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl
and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C7 alkyl, C2-
C7 alkenyl,
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
C2_07 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10
aryl, or 5- to 7-
membered heteroaryl is independently optionally substituted by halogen, -OH, -
SH, -NH2 or -
CO2H;
R27 and R27' are each independently selected from the group consisting of H,
C1-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q-
(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
R28 is a H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3-
to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl or sugar;
n is 1, 2, 3, 4 or 5;
p is 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
It will be appreciate that when L1 is described according to the formula II,
that both the
R- and S- configurations are contemplated. In some embodiments, L1 is of the
formula IIa or IIb
R160 R160
1 I I I
*Nr * *N*
i
R17R17.) n ,(,,oR17R17') n
R18 R18
or
IIa Ilb
where each of R16, R17, R17', R18, n and * are as defined for the formula II.
In some embodiments, each L1 is selected from the group consisting of
16
R16 0
R0
R16 0
R16 R16 ,
I ii *11\1 li
*11\1 I * * 1\1 i * I un
* N.2 * * 1\1.2* *
:
H 0: c.00HH HO-..p
(HOCH)n HO HO
OH COH
1 OH HO
R18 HO OH HO ,
HO OH ,
, , ,
46
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
HOHO
HOHO
0 H ON i40 HFHO
HON _k
\_ 00H ,E13,
R16 0
I Ol R16 00H
0 0
*fX * I Oi
*
0
*HN ' m(LTO
N
() )13
[ i p
t _I- NH
HO 0 HO 0 ....-
I õN
HO OH vr-N , _-N, *rN* '
HO- -OH , OH ' 7 n I õN ' 0
I
R16
*rN*
0 I iR
R._
*rN*
01
R16
HO 002H HO OH 0 HO
Hi6e2 HI80:(-5)2H
HO SO H
1460zZ:OH
O,2 -
LOo
0 0 0 0
[( i)7r0 ( ir0 0 P I C")
P [ CND
, _.õ.. NH HN, 0 0
Cr0
-)-
NH _.. NH ,(
_...NH
*rN* ' *rN* , (in ' H
0 I 0 IR16 *rN* * ( N * *r N*
:
R16 0 I 0 I 0 I
R16 R16
R16
R16 0 R16 0
R16 o R16 n
R16 R16 0
I I O
* I I
1 il
j *
0* *N il *N * *N*,
*N1, *
Oy( )11 0(; L ok- )n Cy )n Oy(-- )11
(H2C)n HN HN 1-11\1 I-11\
HN0 HOOH k
HN
) HO,) OH .
I , OH ' HOõ,)'''OH '
HO /..,OH
' .'OH ,
H ' HO, ) =
'OH ,
R27 HO ,OH HO O
,OH HO HO
Hy
OH H01"."
OH OOH
OOH
OH
R16 R16 R16 R16 HO
I 9 I *N 011 N I O I V
*N* u *N 0' b
* * *
*
HN
Ok-)n Oy( )n 0)n Oy; ) n
HN _.-N,
HN HN
HO,, =,0H
iiõ...
HOOH
f.
HO,
HU 0 . 'OH , HO, ),
= 'OH and
N
HO OOH F1 ' H0 (:) '
HO 'r *rY*
OH OH OH 0 R1.6
.
,
and combinations thereof,
47
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
wherein
R16 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, -C(0)R19, -C(0)0R19 and -C(0)NR19R19', wherein each hydrogen atom in
C1-C6 alkyl,
C2-C6 alkenyl and C2_C6 alkynyl is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, and C2_C6 alkynyl, -0R20, -0C(0)R20, -0C(0)NR20R20', -
0S(0)R20, -
OS (0)2R2 , -SR20, -S(0)R2 , -S(0)2R2 , -S(0)NR2 R2 ', -S(0)2NR2 R2 ', -
0S(0)NR2 R2 ',
-0S(0)2NR2 R2 ', -NR20R20', -NR20C(0)R21, -NR20C(0)0R21, -NR20C(0)NR21R21',
-NR20S(0)R21, -NR20S(0)2R21, -NR20S(0)NR21R21', -NR20S(0)2NR21R21', -C(0)R20
,
-C(0)0R2 or -C(0)NR20R20';
R18 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R26, -0C(0)R26, -0C(0)NR26R26', -0S(0)R26, -0S(0)2R26, -5R26, -
S(0)R26,
-S(0)2R26, -S(0)NR26R26', -S(0)2NR26R26', -0S(0)NR26R26', -0S(0)2NR26R26', -
NR26R26',
-NR26C(0)R27, -NR26C(0)0R27, -NR26C(0)NR27R27', -NR26C(=NR26")NR27R27',
-NR265(0)R27, -NR265(0)2R27, -NR26S(0)NR27R27', -NR26S(0)2NR27R27', -C(0)R26,
-C(0)0R26 and -C(0)NR26R26', wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl
and 5- to 7-
membered heteroaryl is independently optionally substituted by halogen, C1-C6
alkyl, C2-C6
alkenyl, -(CH2)p0R28, -(CH2)p(OCH2)q0R28, -(CH2)p(OCH2CH2)q0R28, -0R29, -
0C(0)R29,
-0C(0)NR29R29', -0S(0)R29, -0S(0)2R29, -(CH2)p0S(0)20R29, -0S(0)20R29, -5R29,
-S(0)R29, -S(0)2R29, -S(0)NR29R29', -S(0)2NR29R29', -0S(0)NR29R29', -
0S(0)2NR29R29',
-NR29R29', -NR29C(0)R30, -NR29C(0)0R30, -NR29C(0)NR30R30', -NR295(0)R30
,
-NR295(0)2R30, -NR295(0)NR30R30', -NR295(0)2NR30R30', -C(0)R29, -C(0)0R29 or
-C(0)NR29R29';
each each R19, R19', R20, R20', R21, R21', R26, R26', R26'', R29, R29', R3
and R30' is
independently selected from the group consisting of H, D, C1-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl, wherein each hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl,
C2_C7
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or
5- to 7-membered
heteroaryl is independently optionally substituted by halogen, -OH, -SH, -NH2
or -CO2H;
R27 and R27'
are each independently selected from the group consisting of H, Ci-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q-
(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
R28 is H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3-
to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl or sugar;
48
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
n is 1, 2, 3, 4 or 5;
pis 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments, each L1 is selected from the group consisting of
R16
R160 R160
I Il R16
11i
* 0 * *NI ,1 I * * N ,, .* \i
*
o(,)n oy;)n o >n i
(H2C)n HN
HN0 1 H0,4OH HN HN HO OH ' HO,,
'OH ,),, and HO .
' , ,
'OH
R27 \OH
OH HO ,OH HOI
..."
OH
OH ,
wherein R16 is defined as described herein, and * is a covalent bond.
In some embodiments, R16 is H. In some embodiments, R18 is selected from the
group
consisting of H, 5- to 7-membered heteroaryl, -0R26, -NR26C(0)R27, -
NR26C(0)NR27R27',
-NR26C(=NR26'')NR27R27', and -C(0)NR26R26', wherein each hydrogen atom 5- to 7-
membered
heteroaryl is independently optionally substituted by halogen, C1-C6 alkyl, C2-
C6 alkenyl,
-(CH2)p0R28, -(CH2)p(OCH2)q0R28, -(CH2)p(OCH2CH2)q0R28, -0R29, -0C(0)R29,
-0C(0)NR29R29', -0S(0)R29, -0S(0)2R29, -(CH2)p0S(0)20R29, -0S(0)20R29, -5R29,
-S(0)R29, -S(0)2R29, -S(0)NR29R29', -S(0)2NR29R29', -0S(0)NR29R29', -
0S(0)2NR29R29',
1 5 -NR29R29', -NR29C(0)R30, -NR29C(0)0R30, -NR29C(0)NR30R30', -NR295(0)R30
,
-NR295(0)2R30, -NR295(0)NR30R30', -NR295(0)2NR30R30', -C(0)R29, -C(0)0R29 or
-C(0)NR29R29';
each R26, R26', R26'', R29, R29', R30 and K-30'
is independently selected from the group
consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl,
wherein each
hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl,
3- to 7-
membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is
independently
optionally substituted by halogen, -OH, -SH, -NH2 or -CO2H;
R27 and R27' are each independently selected from the group consisting of H,
C1-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q-
(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
R28 is a H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3-
to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl or sugar;
49
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
n is 1, 2, 3, 4 or 5;
pis 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments, R18 is selected from the group consisting of H, 5- to 7-
membered
heteroaryl, -0R26, -NR26C(0)R27, -NR26C(0)NR27R27', -NR26C(=NR26-)NR27R27'
,
and -C(0)NR26R26', wherein each hydrogen atom 5- to 7-membered heteroaryl is
independently
optionally substituted by -(CH2)p0R28, -0R29, -(CH2)p0S(0)20R29 and
-0S(0)20R29,
each R26, R26', K26"
and R29 is independently H or C1-C7 alkyl, wherein each hydrogen
atom in C1-C7 alkyl is independently optionally substituted by halogen, -OH, -
SH, -NH2 or
-CO2H;
R27 and R27' are each independently selected from the group consisting of H,
-(CH2)p(sugar), -(CH2)p(OCH2CH2)q(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
15R28 =
is H or sugar;
n is 1, 2, 3, 4 or 5;
pis 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments, each L1 is selected from the group consisting of
H 0
H 0 H H
* 1 O
* * I '
* Nj I\1
* I r
*
I\1*
HO,,
,.)OH
OH HO
'p
(HOCH)n HO
OH , , COH ,
,
1 ,
R18 HO: OH HO OH HO" HO OH
HO HO
HO HO
0:8 wn H
H.O
H 0 0 H
00H 6-0
H 0 H 00H
0
0
*IX, ÚO
* * HN ' * 0
)p [ ] ril(0
HO 0
HO J.0 , N 1 P
,
, ) (r
NH
_ n ,
HO OH
HO- -OH ......N, '
* r- y *
OH
-n I õN
0 H
0 H
*ry*
0 H
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
HO 002H HO OH Ho HO
1-10/e2o Fil802-5)2H
1460 FzilL-OH
HON.
0 HOZido
0
0 0
( iL)7r0 (L30
[ OID
[ OP
[ CND
,
, HN
l,
,_õ,...NH CrO 0 '
-)
7 n
*r*(N*NH NH NH
n(." n(3- nCe "Th *ry * 7
0 H 0 H *(:N* * (' N*
01 I 0 I 0 I
H
H
H H H 0
H
HO o
I m I ID
H o
'N. õ r\i,())1 * * 1 I õ
1 0
* j * * * N r, * * N,.
I II
* *
NI,
Oy( )n OyC )ri 0 )n ()ye )1-1
Oy(;)n
(H2C)n HN HN HN
HN HN
HN /0 H0,40H ' HOo...
\OH HF1 0L
,,c)10 ' Ho
FIFI ,,
I OH HOõ.
;'''OH ' '= ''OH ' ./OH
'
R27 HO
õOH
\OH HO HO
OH H019*
OH OOH
OOH
OH
HO
H 0 H H H
I *N
1 9 I I ,S'
0' b
*Nj * U *NJ
*NJ* *
*
HN
c(-- )n
Oy( )n 0y;: )n Oy; )n )p
...- NI
HN HN \
HN 1 õN
HO,, ',cm
...,
\O ,
HO,) OH
HO, ).,OH \
= 'OH
HO, ).,OH = 'OH and (N
HO H
OOH HO ' HO= = ' ...-,0
HO y
*ry*
OH OH OH H
=
,
and combinations thereof,
wherein
R18 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R26, -0C(0)R26, -0C(0)NR26R26', -0S(0)R26, -0S(0)2R26, -SR26, -
S(0)R26,
-S(0)2R26, -S(0)NR26R26', -S(0)2NR26R26', -0S(0)NR26R26', -0S(0)2NR26R26', -
NR26R26',
-NR26C(0)R27, -NR26C(0)0R27, -NR26C(0)NR27R27', -NR26C(=NR26-)NR27R27',
-NR265(0)R27, -NR265(0)2R27, -NR26S(0)NR27R27', -NR26S(0)2NR27R27', -C(0)R26,
-C(0)0R26 and -C(0)NR26R26', wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl
and 5- to 7-
51
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
membered heteroaryl is independently optionally substituted by halogen, C1-C6
alkyl, C2-C6
alkenyl, -(CH2)p0R28, -(CH2)p(OCH2)q0R28, -(CH2)p(OCH2CH2)q0R28, -0R29, -
0C(0)R29,
-0C(0)NR29R29', -0S(0)R29, -0S(0)2R29, -(CH2)p0S(0)20R29, -0S(0)20R29, -5R29,
-S(0)R29, -S(0)2R29, -S(0)NR29R29', -S(0)2NR29R29', -0S(0)NR29R29', -
0S(0)2NR29R29',
-NR29R29', -NR29C(0)R30, -NR29C(0)0R30, -NR29C(0)NR30R30', -NR295(0)R30
,
-NR295(0)2R30, -NR295(0)NR30R30', -NR295(0)2NR30R30', -C(0)R29, -C(0)0R29 or
-C(0)NR29R29';
each R26, R26', R26-, R29, R29', R3 and R30' is independently selected from
the group
consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl,
wherein each
hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl,
3- to 7-
membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is
independently
optionally substituted by halogen, -OH, -SH, -NH2 or -CO2H;
R27 and R27' are each independently selected from the group consisting of H,
C1-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q
(sugar) and -(CH2)p(OCH2CH2CH2)q(sugar);
R28 is a H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3-
to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl or sugar;
n is 1, 2, 3, 4 or 5;
pis 1,2,3,4or5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments, R18 is selected from the group consisting of H, 5- to 7-
membered
heteroaryl, -0R26, -NR26C(0)R27, -NR26C(0)NR27R27', -NR26C(=NR26-)NR27R27',
and -C(0)NR26R26', wherein each hydrogen atom 5- to 7-membered heteroaryl is
independently
optionally substituted by halogen, C1-C6 alkyl, C2-C6 alkenyl, -(CH2)p0R28,
-(CH2)p(OCH2)q0R28, -(CH2)p(OCH2CH2)q0R28, -0R29, -0C(0)R29, -0C(0)NR29R29',
-0S(0)R29, -0S(0)2R29, -(CH2)p0S(0)20R29, -0S(0)20R29, -5R29, -S(0)R29, -
S(0)2R29,
-S(0)NR29R29', -S(0)2NR29R29', -0S(0)NR29R29', -0S(0)2NR29R29', -NR29R29', -
NR29C(0)R30
,
-NR29C(0)0R30, -NR29C(0)NR30R30', -NR295(0)R30, -NR295(0)2R30, -
NR295(0)NR30R30', -
NR295(0)2NR30R30', -C(0)R29, -C(0)0R29 or -C(0)NR29R29';
each R26, R26', R26-, R29, R29', R3 and R30' is independently selected from
the group
consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl,
wherein each
hydrogen atom in C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl,
3- to 7-
52
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is
independently
optionally substituted by halogen, -OH, -SH, -NH2 or -CO2H;
R27 and R27' are each independently selected from the group consisting of H,
C1-C9
alkyl, C2-C9 alkenyl, C2_C9 alkynyl, C3_C6 cycloalkyl, -(CH2)p(sugar), -
(CH2)p(OCH2CH2)q-
(sugar) and -(CH2)p(OCH2CH2CH2) q(sugar);
R28 is a H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3-
to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl or sugar;
n is 1, 2, 3, 4 or 5;
pis 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments, R18 is selected from the group consisting of H, 5- to 7-
membered
heteroaryl, -0R26, -NR26C(0)R27, -NR26C(0)NR27R27', -NR26C(=NR26")NR27R27',
and -C(0)NR26R26', wherein each hydrogen atom 5- to 7-membered heteroaryl is
independently
,
optionally substituted by -(CH2)p0R28, -0R29, -(CH2)p0S(0)2OR29 and
-OS(0)20R29,
each R26, R26', R26"
and R29 is independently H or C1-C7 alkyl, wherein each hydrogen
atom in C1-C7 alkyl is independently optionally substituted by halogen, -OH, -
SH, -NH2 or
-CO2H;
R27 and R27' are each independently selected from the group consisting of H,
-(CH2)p(sugar), -(CH2)p(OCH2CH2)q(sugar) and -(CH2)p(OCH2CH2CH2) q(sugar);
R28 is H or sugar;
n is 1, 2, 3, 4 or 5;
pis 1, 2, 3, 4 or 5;
q is 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments of the conjugates described herein, L1 is present. In some
embodiments of the conjugates described herein, L1 is absent. In some
embodiments, z4 is 0. In
some embodiments, z4 is 1. In some embodiments, z4 is 2.
30L2 =
is a releasable linker. As used herein, the term "releasable linker" refers to
a linker
that includes at least one bond that can be broken under physiological
conditions, such as a pH-
labile, acid-labile, base-labile, oxidatively labile, metabolically labile,
biochemically labile, or
enzyme-labile bond. It is appreciated that such physiological conditions
resulting in bond
breaking do not necessarily include a biological or metabolic process, and
instead may include
a standard chemical reaction, such as a hydrolysis reaction, for example, at
physiological pH, or
53
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
as a result of compartmentalization into a cellular organelle such as an
endosome having a
lower pH than cytosolic pH.
It is understood that a cleavable bond can connect two adjacent atoms within
the
releasable linker and/or connect other linkers or B, D1 and/or D2, as
described herein, at either
or both ends of the releasable linker. In the case where a cleavable bond
connects two adjacent
atoms within the releasable linker, following breakage of the bond, the
releasable linker is
broken into two or more fragments. Alternatively, in the case where a
cleavable bond is
between the releasable linker and another moiety, such as another linker, a
drug or binding
ligand, the releasable linker becomes separated from the other moiety
following breaking of the
bond.
The lability of the cleavable bond can be adjusted by, for example,
substituents at or
near the cleavable bond, such as including alpha-branching adjacent to a
cleavable disulfide
bond, increasing the hydrophobicity of substituents on silicon in a moiety
having silicon-
oxygen bond that may be hydrolyzed, homologating alkoxy groups that form part
of a ketal or
acetal that may be hydrolyzed, and the like.
Illustrative releasable linkers described herein include linkers that include
hemiacetals
and sulfur variations thereof, acetals and sulfur variations thereof,
hemiaminals, aminals, and
the like, and can be formed from methylene fragments substituted with at least
one heteroatom,
1-alkoxyalkylene, 1-alkoxycycloalkylene, 1-alkoxyalkylenecarbonyl, 1-
alkoxycycloalkylenecarbonyl, and the like. Illustrative releasable linkers
described herein
include linkers that include carbonylarylcarbonyl,
carbonyl(carboxyaryl)carbonyl,
carbonyl(biscarboxyaryl)carbonyl, haloalkylenecarbonyl, and the like.
Illustrative releasable
linkers described herein include linkers that include alkylene(dialkylsily1),
alkylene(alkylarylsily1), alkylene(diarylsily1), (dialkylsilyl)aryl,
(alkylarylsilyl)aryl,
(diarylsilyl)aryl, and the like. Illustrative releasable linkers described
herein include
oxycarbonyloxy, oxycarbonyloxyalkyl, sulfonyloxy, oxysulfonylalkyl, and the
like. Illustrative
releasable linkers described herein include linkers that include
iminoalkylidenyl,
carbonylalkylideniminyl, iminocycloalkylidenyl, carbonylcycloalkylideniminyl,
and the like.
Illustrative releasable linkers described herein include linkers that include
alkylenethio,
alkylenearylthio, and carbonylalkylthio, and the like.
In some embodiments, L2 is selected from the group consisting of
54
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
CO2H o CO2H
X6 )
S X6 )
*NI * *NI *
R31 R31
CO2H
CO2H 0
*Ns 0
N*
R31 0
CO2H CO2H
*NI 0 *N 0
R36 R36
0 and 0
wherein
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
X6 is C1-C6 alkyl or C6-C10 aryl(Ci-C6 alkyl), wherein each hydrogen atom in
Ci-C6
alkyl and C6-C10 aryl(Ci-C6 alkyl) is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -0R34, -0C(0)R34, -0C(0)NR34R34', -
0S(0)R34,
-0S(0)2R34, -5R34, -S(0)R34, -S(0)2R34, -S(0)NR34R34', -S(0)2NR34R34', -
0S(0)NR34R34',
-0S(0)2NR34R34', -NR34R34', -NR34C(0)R35, -NR34C(0)0R35, -NR34C(0)NR35R35',
-NR345(0)R35, -NR345(0)2R35, -NR34S(0)NR35R35', -NR34S(0)2NR35R35', -C(0)R34,
-C(0)0R34 or -C(0)NR34R34';
each R32, R32', R33, R33', R34, R34', R35 and R35' are independently selected
from the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl;
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R36 is independently selected from the group consisting of H, D, C1-C6 alkyl,
C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-
C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally
substituted by halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R37, -0C(0)R37,
-0C(0)NR37R37', -0S(0)R37, -0S(0)2R37, -SR37, -S(0)R37, -S(0)2R37, -
S(0)NR37R37',
-S(0)2NR37R37', -0S(0)NR37R37', -0S(0)2NR37R37', -NR37R37', -NR37C(0)R38,
-NR37C(0)0R38, -NR37C(0)NR38R38', -NR375(0)R38, -NR375(0)2R38, -
NR375(0)NR38R38',
-NR375(0)2NR38R38', -C(0)R37, -C(0)0R37 or -C(0)NR37R37';
R37, R37', R38 and R38' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl; and
* is a covalent bond.
In some embodiments, R31 is H. In some embodiments, R36 is H. In some
embodiments,
X6 is C1-C6 alkyl. In some embodiments, X6 is C1-C6 alkyl. C6-C10 aryl(Ci-C6
alkyl).
In some embodiments, L2 is
CO2H 0
)*
S 0
I
R31
wherein
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -5R32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
X6 is C1-C6 alkyl or C6-C10 aryl(Ci-C6 alkyl), wherein each hydrogen atom in
Ci-C6
alkyl and C6-C10 aryl(Ci-C6 alkyl) is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -0R34, -0C(0)R34, -0C(0)NR34R34', -
0S(0)R34,
-0S(0)2R34, -5R34, -S(0)R34, -S(0)2R34, -S(0)NR34R34', -S(0)2NR34R34', -
0S(0)NR34R34',
56
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-0S(0)2NR"Rw, -NR"R"', -NR34C(0)R35, -NR34C(0)0R35, -NR34C(0)NR35R35',
-NR34S(0)R35, -NR34S(0)2R35, -NR34S(0)NR35R35', -NR34S(0)2NR35R35', -C(0)R34
,
-C(0)0R34 or -C(0)NR34R34';
each R32, R32', R", R"', R34, R34', R" and R"' are independently selected from
the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond.
In some embodiments, R31 is H, and X6 is C1-C6 alkyl. In some embodiments, R31
is H,
and X6 is C6-C10 aryl(Ci-C6 alkyl).
In some embodiments, L2 is
CO2H 0
f x6 )
*N/\/S \S/ \ *
0
1
R31
wherein
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -5R32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
X6 is C1-C6 alkyl or C6-C10 aryl(Ci-C6 alkyl), wherein each hydrogen atom in
C1-C6
alkyl and C6-C10 aryl(Ci-C6 alkyl) is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -0R34, -0C(0)R34, -0C(0)NR34R34', -
0S(0)R34,
-0S(0)2R34, -5R34, -S(0)R34, -S(0)2R34, -S(0)NR34R34', -S(0)2NR34R34', -
0S(0)NR34R34',
-0S(0)2NR34R34', -NR34R34', -NR34C(0)R35, -NR34C(0)0R35, -NR34C(0)NR35R35',
-NR345(0)R35, -NR345(0)2R35, -NR34S(0)NR35R35', -NR34S(0)2NR35R35', -C(0)R34
,
-C(0)0R34 or -C(0)NR34R34';
each R32, R32', R33, R33', R34, R34', R35 and R35' are independently selected
from the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
57
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
* is a covalent bond.
In some embodiments, R31 is H, and X6 is C1-C6 alkyl. In some embodiments, R31
is H,
and X6 is C6-C10 aryl(Ci-C6 alkyl).
In some embodiments, L2 is
CO2H 0
S x6 )
*NI S *
R31
wherein
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
X6 is C1-C6 alkyl or C6-C10 aryl(Ci-C6 alkyl), wherein each hydrogen atom in
C1-C6
alkyl and C6-C10 aryl(Ci-C6 alkyl) is independently optionally substituted by
halogen, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C io aryl, 5- to 7-membered heteroaryl, -0R34, -0C(0)R34, -0C(0)NR34R34', -
0S(0)R34,
-0S(0)2R34, -5R34, -S(0)R34, -S(0)2R34, -S(0)NR34R34', -S(0)2NR34R34', -
0S(0)NR34R34',
-0S(0)2NR34R34', -NR34R34', -NR34C(0)R35, -NR34C(0)0R35, -NR34C(0)NR35R35',
-NR345(0)R35, -NR345(0)2R35, -NR345(0)NR35R35', -NR345(0)2NR35R35', -C(0)R34,
-C(0)0R34 or -C(0)NR34R34';
each R32, R32', R33, R33', R34, R34', R35 and R35' are independently selected
from the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond.
In some embodiments, R31 is H, and X6 is C1-C6 alkyl. In some embodiments, R31
is H,
and X6 is C6-C10 aryl(Ci-C6 alkyl).
In some embodiments, L2 is
58
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
CO2H
* N S S 0 *
I 11
R31 0
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
CO2H
* N SS() *
I I I
R31 0
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -5R32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
59
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
CO2H
=
_
=
0
* *
I
R31 0
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
0
*
CO2H 0)
S
* N s 0
I
R31
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -5R32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
0
*
CO2H 0)
, 0
*
N S S
I
R31
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
0
*
_CO2H 0)
=
_
:
* S
I
R31
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
61
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
*
'0
0
CO2H
S
*
I
R31
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -5R32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
62
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
*
ICIO
CO2H
S
* N S IS
I
R31
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -SR32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR325(0)R33, -NR325(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
*
0
0
CO 2H
_ 2
_
_
z
S
*
I
R31
R31 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R32, -0C(0)R32, -0C(0)NR32R32', -0S(0)R32,
-0S(0)2R32, -5R32, -S(0)R32, -S(0)2R32, -S(0)NR32R32', -S(0)2NR32R32', -
0S(0)NR32R32',
63
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-0S(0)2NR32R32', -NR32R32', -NR32C(0)R33, -NR32C(0)0R33, -NR32C(0)NR33R33',
-NR32S(0)R33, -NR32S(0)2R33, -NR32S(0)NR33R33', -NR32S(0)2NR33R33', -C(0)R32,
-C(0)0R32 or -C(0)NR32R32';
each R32, R32', R33 and R33' are independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R31 is H.
In some embodiments, L2 is
CO2H
* N 0
I
R36 N*
0
R36 is independently selected from the group consisting of H, D, C1-C6 alkyl,
C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-
C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally
substituted by halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R37, -0C(0)R37,
-0C(0)NR37R37', -0S(0)R37, -0S(0)2R37, -5R37, -S(0)R37, -S(0)2R37, -
S(0)NR37R37',
-S(0)2NR37R37', -0S(0)NR37R37', -0S(0)2NR37R37', -NR37R37', -NR37C(0)R38,
-NR37C(0)0R38, -NR37C(0)NR38R38', -NR375(0)R38, -NR375(0)2R38, -
NR375(0)NR38R38', -
NR375(0)2NR38R38', -C(0)R37, -C(0)0R37 or -C(0)NR37R37';
R37, R37', R38 and R38' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R36 is H.
In some embodiments, L2 is
CO2H
?
_õ...-;.........õ0,.S
* N 0
I
R36 N*
0
R36 is independently selected from the group consisting of H, D, C1-C6 alkyl,
C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-
C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally
substituted by halogen,
64
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R37, -0C(0)R37,
-0C(0)NR37R37', -0S(0)R37, -0S(0)2R37, -SR37, -S(0)R37, -S(0)2R37, -
S(0)NR37R37',
-S(0)2NR37R37', -0S(0)NR37R37', -0S(0)2NR37R37', -NR37R37', -NR37C(0)R38,
-NR37C(0)0R38, -NR37C(0)NR38R38', -NR375(0)R38, -NR375(0)2R38, -
NR375(0)NR38R38',
-NR375(0)2NR38R38', -C(0)R37, -C(0)0R37 or -C(0)NR37R37';
R37, R37', R38 and R38' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R36 is H.
In some embodiments, L2 is
CO2H
* N S
0
I
R36 N*
0
R36 is independently selected from the group consisting of H, D, C1-C6 alkyl,
C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-
C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently optionally
substituted by halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R37, -0C(0)R37,
-0C(0)NR37R37', -0S(0)R37, -0S(0)2R37, -5R37, -S(0)R37, -S(0)2R37, -
S(0)NR37R37',
-S(0)2NR37R37', -0S(0)NR37R37', -0S(0)2NR37R37', -NR37R37', -NR37C(0)R38,
-NR37C(0)0R38, -NR37C(0)NR38R38', -NR375(0)R38, -NR375(0)2R38, -
NR375(0)NR38R38',
-NR375(0)2NR38R38', -C(0)R37, -C(0)0R37 or -C(0)NR37R37';
R37, R37', R38 and R38' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl; and
* is a covalent bond. In some embodiments, R36 is H.
L3 can be present or absent in the conjugates described herein. When L3 is
present, L3
can be any group covalently attaching portions of the linker to one another,
or to D1, or to D2. It
will be understood that the structure of L3 is not particularly limited in any
way. It will be
further understood that L3 can comprise numerous functionalities well known in
the art to
covalently attach portions of the linker to one another, or to D1, or to D2,
including but not
limited to, alkyl groups, ether groups, amide groups, carboxy groups,
sulfonate groups, alkenyl
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
groups, alkynyl groups, cycloalkyl groups, aryl groups, heterocycloalkyl,
heteroaryl groups, and
the like. In some embodiments, L3 is selected from the group consisting of C1-
C6 alkyl,
¨(CR39R39'),C(0)-, ¨(CR39R39'),OC(0)-, ¨NR39R39'C(0)(CR39R39'),-, ¨(CH2),NR39-
,
¨(0CR39R39'CR39R39'),C(0)-, and ¨(0CR39R39'CR39R39'CR39R39')- ,C(0)-,
wherein
each R39 and R39' is independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R40, -0C(0)R40
,
-0C(0)NR40R40r, -0S(0)R40, -0S(0)2R40, _se, _s(0)R40, _s(0)2R40,
_S(0)NR40R40',
-S(0)2NR4 R4cr, -OS(0)NR4oR4cr, -OS(0)2NR
40R40r, _Neer, _NR40c (0)R4i,
-NR40C(0)0R41, _NR40c (0)NR41R41'; _NR405(o)R41; _NR405(0)2R41;
_NR405(0)NR41R41';
-NR405(0)2NR41R41'; _c(o)R40; _
C(0)0R4 and -C(0)NR40R
40';
R40; R40'; R41 and K-41'
are each independently selected from the group consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl, and 5- to 7-membered heteroaryl; and
r in each instance is 1, 2, 3, 4, or 5. In some embodiments of the conjugates
described
herein, L3 is present. In some embodiments of the conjugates described herein,
L3 is absent. In
some embodiments, z2 is 0. In some embodiments, z2 is 1. In some embodiments,
z2 is 2. In
some embodiments, z6 is 0. In some embodiments, z6 is 1. In some embodiments,
z6 is 2. In
some embodiments, r is 5. In some embodiments, r is 4. In some embodiments, r
is 3. In some
embodiments, r is 5, each R39 is H, and each R39' is H. In some embodiments, r
is 4, each R39 is
H, and each R39' is H. In some embodiments, r is 3, each R39 is H, and each
R39' is H.
In some embodiments, L3 i5¨(CR39R39'),C(0)-. In some embodiments, L3 is
¨(CR39R39'),C(0)-, r is 5, each R39 is H, and each R39' is H. In some
embodiments, L3 is
¨(CR39R39'),C(0)-, r is 4, each R39 is H, and each R39' is H. In some
embodiments, L3 is
¨(CR39R39'),C(0)-, r is 3, each R39 is H, and each R39' is H.
In some embodiments, L3 is ¨(CR39R39'),OC(0)-, r is 5, each R39 is H, and each
R39' is
H. In some embodiments, L3 is ¨(CR39R39'),OC(0)-, r is 4, each R39 is H, and
each R39' is H. In
some embodiments, L3 is ¨(CR39R39'),OC(0)-, r is 3, each R39 is H, and each
R39' is H.
In some embodiments, L3 is ¨NR39R39'C(0)(CR39R39'),-, r is 5, each R39 is H,
and each
R39' is H. In some embodiments, L3 is ¨NR39R39'C(0)(CR39R39'),-, r is 4, each
R39 is H, and
each R39' is H. In some embodiments, L3 is ¨NR39R39'C(0)(CR39R39'),-, r is 3,
each R39 is H,
and each R39' is H.
66
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
In some embodiments, L3 is -(CH2)rNR39-, r is 5 and R39 is H. In some
embodiments, L3
is -(CH2)rNR39-, r is 4 and R39 is H. In some embodiments, L3 is -(CH2)rNR39-,
r is 3 and R39 is
H. In some embodiments, L3 is -(CH2)rNR39-, r is 2 and R39 is H.
In some embodiments, L3 is -(0CR39R39'CR39R39')rC(0)-, r is 5, each R39 is H,
and each
R39' is H. In some embodiments, L3 is -(0CR39R39'CR39R39')rC(0)-, r is 4, each
R39 is H, and
each R39' is H. In some embodiments, L3 is -(0CR39R39'CR39R39')rC(0)-, r is 3,
each R39 is H,
and each R39' is H.
L4 can be present or absent in the conjugates described herein. When L4 is
present, L4
can be any group covalently attaching portions of the linker to one another,
or to D1, or to D2. It
will be understood that the structure of L4 is not particularly limited in any
way. It will be
further understood that L4 can comprise numerous functionalities well known in
the art to
covalently attach portions of the linker to one another, or to D1, or to D2,
including but not
limited to, alkyl groups, ether groups, amide groups, carboxy groups,
sulfonate groups, alkenyl
groups, alkynyl groups, cycloalkyl groups, aryl groups, heterocycloalkyl,
heteroaryl groups, and
the like. In some embodiments, L4 is selected from the group consisting of
-C(0)(cR44R44')õ, NR42cR43R43'cR43-43'
K (OCR44R44'CR44R44')c,
_NR42cR43R43'cR43-43'
K (OCR44R44'CR44R44')c,
_NR42cR43R43'cR43-K43'
(OCR44R44'CR44R44')tC(0)-,
NR42u,-,-x 43 43' 43 43' 44_ 44'
R CR R (CR -CR )t-, and -NR42C6-C10 aryl(Ci-C6 alky1)0C(0)-;
wherein
R42 is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl and C3_C6 cycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6
alkynyl and C3_C6 cycloalkyl is independently optionally substituted by
halogen, C1-C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl,
5- to 7-membered heteroaryl, -0R45, -0C(0)R45, -0C(0)NR45R45', -OS(0)R45,
-0S(0)2R45, -SR45, -S(0)R45, -S(0)2R45, -S(0)NR45R45', -S(0)2NR45R45', -
0S(0)NR45R45',
-OS(0)2NR
45R45', _NR45R45', _NR45c(0)R46, _NR45c
46
(0)0-46, NR 45C(0)NRR 46' ,
_NR455 (0)R46, _NR455 (0)2R46, 4
NK5 S(0)NR46R46', 4
NK5 S(0)2NR46R46', _c("45,
-C(0)0R45 or -C(0)NR45R45',
3043 43' 44 44 i
each R , R , R and R s independently selected from the group consisting of H,
D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each
hydrogen atom in
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is
independently optionally
substituted by halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R47, -
0C(0)R47,
-0C(0)NR47R47', -0S(0)R47, -0S(0)2R47, -5R47, -S(0)R47, -S(0)2R47, -
S(0)NR47R47'
,
67
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-S(0)2NR47R4T, -OS(0)NR47R4T, -OS(0)2NR47R4T, -Nee', -NR47C(0)R48,
-NR47C(0)0R48, -NR47C(0)NR48R48', -NR47S(0)R48, -NR47S(0)2R48, -
NR47S(0)NR48R48',
-NR475(0)2NR48R48', -C(0)R47, -C(0)0R47 or -C(0)NR47R47';
R45, R45-, R46, R46', R47, R47',
R48 and R48' are each independently selected from the
group consisting of H, D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl;
t is in each instance 1, 2, 3, 4, or 5; and
* is a covalent bond.
In some embodiments of the conjugates described herein, L4 is present. In some
embodiments of the conjugates described herein, L4 is absent. In some
embodiments, z5 is 0. In
some embodiments, z5 is 1. In some embodiments, z5 is 2. In some embodiments,
z7 is 0. In
some embodiments, z7 is 1. In some embodiments, z7 is 2. In some embodiments,
z9 is 0. In
some embodiments, z9 is 1. In some embodiments, z9 is 2. In some embodiments,
z7 is 0 and
z9 is 0. In some embodiments, z7 is 0 and z9 is 1. In some embodiments, z7 is
1 and z9 is 1. In
some embodiments, z7 is 1 and z9 is 0.
In some embodiments, L4 is -NR42C6-C10 aryl(Ci-C6 alky1)0C(0)-, wherein R42 is
H. In
some embodiments, z5 is 1, and L4 is -NR42C6-C10 aryl(Ci-C6 alky1)0C(0)-,
wherein R42 is H.
In some embodiments, z7 is 1, and L4 is -NR42C6-C10 aryl(Ci-C6 alky1)0C(0)-,
wherein R42 is
H. In some embodiments, z9 is 1, and L4 is -NR42C6-C10 aryl(Ci-C6 alky1)0C(0)-
, wherein R42
is H. In some embodiments, L4 is -NR42CR43R43'CR43R43'(OCR44R44'cR44R44:)tcu
(--..) _
wherein
each R42, R43, R43', et and R44' is H, and t is 4. In some embodiments, L4 is
-NR42CR43R43'CR43R43'(OCR44R44'CR44R44')tC(0)- or -NR42C6-C10 aryl(Ci-C6
alky1)0C(0)-,
wherein each R42, R43, R43', R44 and R44' is H, z7 is 1, z9 is 1, and t is 4.
In some embodiments, -L3-L4- is -(CH2),NR39C(0)(CR44R44')t-, wherein r is 2, t
is 2,
R39 is H, each R44 is H, and each R44' is H. In some embodiments, -L3-L4-(AA)2
is
-(CR39R39'),C(0)- NR42CR43R43'CR43R43'(OCR44R44'CR44R44')tC(0) -Val-Ala-, -L3-
L4-(AA)2-
L4 is -(CR39R39'),C(0)- NR42CR43R43'CR43R43'(OCR44R44'CR44R44')tC(0)-Val-Ala-
NR42C6-Cio
aryl(Ci-C6 alky1)0C(0)-, wherein each R39, R39', R42, R43, R43',
et and R44' is H, r is 2 and t is
4.
30L5 can be present or absent in the conjugates described herein. When L5 is
present, L5
can be any group covalently attaching D1 to D2. It will be understood that the
structure of L5 is
not particularly limited in any way. It will be further understood that L5 can
comprise numerous
functionalities well known in the art to covalently attach D1 to D2, including
but not limited to,
alkyl groups, ether groups, amide groups, carboxy groups, sulfonate groups,
alkenyl groups,
68
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
alkynyl groups, cycloalkyl groups, aryl groups, heterocycloalkyl, heteroaryl
groups, and the
like. In some embodiments, L5 is selected from the group consisting of C1-C10
alkyl,
-(CR49=CR49').-, -(CR49R49').C(0)-,-CH2CH2(0CR49R49'CR49R49')u-,
- CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)-
and
-CH2CH2(0CR49R49'CR49R49'CR49R49')uC(0)-, wherein
each R49 and R49' is independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl, wherein each
hydrogen atom in C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl and C3_C6 cycloalkyl is independently
optionally substituted
by halogen, C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to
7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R50, -0C(0)R50
,
-0C(0)NR50R50', -0S(0)R50, -0S(0)2R50, -SR50, -S(0)R50, -S(0)2R50, -
S(0)NR50R50',
-S(0)2NR5 R5 ', -0S(0)NR5 R5 ', -0S(0)2NR5 R5 ', -NR50R50', -NR50C(0)R51,
-NR50C(0)0R51, -NR50C(0)NR51 R51 ' , -NR505 (0)R51 , -NR505 (0)2R51 , -NR505
(0)NR51R51 ' ,
-NR505 (0)2NR51 R51 ' , -C(0)R50, -C(0)0R5 or -C(0)NR50R50';
R50, R50', R51 and R51' are each independently selected from the group
consisting of H,
D, C1-C7 alkyl, C2-C7 alkenyl, C2_C7 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl;
u is in each instance 0, 1, 2, 3, 4 or 5; and
* is a covalent bond.
In some embodiments of the conjugates described herein, L5 is present. In some
embodiments of the conjugates described herein, L5 is absent. In some
embodiments, L5 is C1-
C6 alkyl. In some embodiments, L5 is -(CR49R49')õC(0)-, wherein each R49 and
R49' is H, and u
is 3. In some embodiments, L5 is -(CR49R49')õC(0)-, wherein each R49 and R49'
is H, and u is 4.
In some embodiments, L5 is -(CR49R49')õC(0)-, wherein each R49 and R49' is H,
and u is 5.
In some embodiments, the linker is of the formula -(AA)zi-L2-(1- 1 (A A) (I 1
,--3,z2-,----,z3-,--1,z4-
(L4)z5-, wherein AA, L1, L2, L3, L4, zl, z2, z3, z4 and z5 are defined as
described herein. In
I
I
I-AA-L-AA-L-12_
some embodiments, the linker is of the formula _L
(L3)z6-(L4)z7-(AA)z8-
(L4)z9-, wherein AA, L1, L2, L3, L4, z6, z7, z8 and z9 are defined as
described herein. In some
embodiments, the linker is of the formula -(AA)z10-L2-, wherein AA, L2 and z10
are defined as
described herein. In some embodiments, the linker is of the formula -(AA)z11-
L2-, wherein AA,
L2, and zll are defined as described herein. In some embodiments, the linker
is of the formula -
L2-(AA)zi2-, wherein AA, L2, and z12 are defined as described herein. In some
embodiments,
the linker is of the formula -(AA)4-L2-, wherein AA and L2 are defined as
described herein. In
some embodiments, the linker is of the formula -(AA)4-L2-, wherein the
sequence of -(AA)4- is
-Asp-Arg-Asp-Asp-, and L2 is defined as described herein. In some embodiments,
the linker is
69
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
of the formula -(AA)4-L2-L3-AA-L1-L4-, wherein the sequence of -(AA)4- is -Asp-
Arg-Asp-
Asp-, and AA, L1, L2, L3 and L4 are defined as described herein. In some
embodiments, the
linker is of the formula -(AA)4-L2-L3-(AA)2-, wherein AA, L1, L2 and L3 are
defined as
described herein. In some embodiments, the linker is of the formula -(AA)4-L2-
L3-(AA)2-,
wherein the sequence of -(AA)4- is -Asp-Arg-Asp-Asp-, the sequence of -(AA)2-
is Val-Ala,
and L1, L2 and L3 are defined as described herein. In some embodiments, the
linker is of the
formula -(AA)4-L2-L3-(AA)2-, wherein the sequence of -(AA)4- is -Asp-Arg-Asp-
Asp-, the
sequence of -(AA)2- is Val-CIT, and L1, L2 and L3 are defined as described
herein. In some
embodiments, the linker is of the formula -L1-AA-L1-AA-L1-L2-, wherein AA, L1
and L2 are
defined as described herein. In some embodiments, the linker is of the formula
- Ll - AA - Ll - AA-
Ll-L2-L3-(AA)2-L4-, wherein AA, L1, L2, L3 and L4 are defined as described
herein. In some
embodiments, the linker is of the formula -L1-AA-L1-AA L1 L2 L3 L4 (AA)2-L4-,
wherein AA,
L1, L2, L3 and L4 are defined as described herein. In some embodiments, the
linker is of the
formula -L1-AA-L1-AA L1 L2 L3 L4 , AA, L1, L2, L3 and L4 are defined as
described herein. In
some embodiments, the linker is of the formula -L1-AA-L1-AA-L1-L2-L3-(AA)2-,
wherein AA,
L1, L2 and L3 are defined as described herein. -L1-AA-L1-AA-L1-L2-L3-, wherein
AA, L1, L2
and L3 are defined as described herein.
In some embodiments, the linker is of the formula
co2H co2H
yo ) ),Ho zHo co2H O0
*Nõ..11, \I N
_ N N 0
H o H 0
0 H
j
0
0 *
C)N 0 N)criRilic
NH 0 NH NH H
H
õOH He
He' õOH
HO" 1101')
OH HO HO
wherein * is a bond.
In some embodiments, the linker is of the formula
H
Ho2c o2c
co2H 0
H 0 H jrvS
N
Nrc
* Ni N- TIH_1 H
0 NH 0
0 NH
0 NH
0 NH õSOH HN
,OH
.00H \ NH
O fi
='µ0H
HOss% H 0 CZ\
HO'
HO's'
7 *
HO 0
HO
HO OH
OH
OH
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
wherein * is a bond.
In some embodiments, the linker is of the formula
CO2H CO2H
HO) H o H o co2H
JS¨S0)*
N . N
0 0
()\ NH C)-- NH ()\ NH
.00H
.00H õOH
HO'ss'
HO/ HO/ HO/
OH HO HO
wherein * is a bond.
In some embodiments, the linker is of the formula
HNNH2
NH
CO2H
co2H H OH :?LH
*N1\1:).LN N CO2H
H H
0 -CO2H 0 -CO2H 0 zs
*
0 ,
wherein * is a bond.
In some embodiments, the linker is of the formula
HN NH2
NH
CO2H
H 0 H
H CO2H 1110
* N s
CO2H
wherein * is a bond.
In some embodiments, the linker is of the formula
71
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
CO2H CO2H H
1
CO2H 0 H o o CO2H fNI.r*
7 Edj
-1 11NA
*N . N.1 N . N - N 0
1 E H -H = H
H 0 0 0 -1
.\ 0
NH (-)
-:;-'-µNH ¨ NH
OH .,õOH
õ..õOH
OH \OH
HO"' HO' HO'ss 0
s.
HO/ HO
HO/
OH HO HO ,
wherein * is a bond.
In some embodiments, the linker is of the formula
HNyNH2
NH
CO2H
y 9 ,cH 0
H
*N=I\I NN.rN1 CO2H 4
= H = H
-CO2H 0 -CO2H 0 ON----\____\_)._
-S 0
----NH2
........:1 ¨NH
NH HN
0
-------\ 0 0
*,...-0
//
0 ,
wherein * is a bond.
In some embodiments, the linker is of the formula
72
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H Ny N H2
NH
CO2H
* HOHO H
NJ.c NJ.L N N CO_ 24H
= H = H
0 CO2H -CO2H 0 ON
- S
NH FiN__
0
,s---- NH
-----\ 0 0
it
*,.....-0
0 ,
wherein * is a bond.
In some embodiments, the linker is of the formula
0 H
0
CO2H CO2H ----\1/
H 0 -) H 0 H o CO2H ___();----1N)-02C
1 HN
CO2H
. N
N 0
-1-1 0 1-1 0 H
----\
,...,-...\
(:)..5.- L'NNH NH \ NH 0
,,=.õ,0H 0' 00H 0 \OH
HU' HU\ " HOµµ' .'
HOi.
HOl HO/
OH HO HO ,
wherein * is a bond.
In the conjugates described herein, Drug describes one or two drugs selected
D1 and/or
D2, covalently attached to one or more linker portions of the conjugate. In
some embodiments,
both D1 and D2 are present. In some embodiments, D comprises the structure -D1-
L5-D2. In
some embodiments, Drug comprises the structure -D1-L5-D1-.
Certain of the drugs D1 and D2 described herein comprise pyrrolobenzodiazepine
(PBD)
prodrugs. It will be understood that such PBD prodrugs undergo conversion to a
therapeutically
active PBD compound through processes in the body after delivery of a
conjugate as decribed
herein. In some embodiments, at least one of the drugs incorporated into
conjugates decribed
herein is a PBD prodrug as described herein.
73
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
D1 can be described as a PBD prodrug of the formula III
,R2a
µ......fioa 0
" R9a O
R5 0 ¨ R1 a
. N
----
N 0 NR3aR4a
, / 0
Rua 1
R7a
III
wherein
Ria, K- 2a;
R3a and R4a are each independently selected from the group consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
11a la
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R; -C(0)OR,
and -C(0)NR1 laR1 la' ; wherein each hydrogen atom in C1-C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl,
C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-
membered
heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-C6
alkenyl, C2_C6 alkynyl,
C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 7-
membered heteroaryl,
_calla, -0C(0)R11a; _OC(0)NR1 laR1 la' ; _OS(0)R11a; _os(o)2R11a,
_sR1 la; _s (0)R11a; _s (0)2R11a; _
S(0)NR1 laR1 la' , _S (0)2NR1 laR1 la' ; _OS(0)NR1 laR1 la';
-OS (0)2NR1 laR1 la'; _NR1laR1 la'; _NR1lac(0)R12a; _NR1 lac(0)0R12a; _NR1
lac(0)NR12aR12a' ;
_NR1las(0)Ri2a, _NR1las(0)2Ri2a, _NR1las(0)NRi2aRi2a.',
-NR1laS(0)2NRi2aRi2a.', _c(0)R1 la,
-C(0)0R1 la
or -C(0)NR1 laR1 la' ; or Ria is a bond; or R4a is a bond;
R5a, R6a and R7a are each independently selected from the group consisting of
H, D, C 1 -
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R13a, -C(0)0R13a and -
C(0)NR13aR13a', wherein
each hydrogen atom in Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR14a;
_oc(o)R14a,
-0C(0)NR14aR14a'; _
OS(0)R14a; _OS (0)2R14a; _sR14a; _s(0)R14a; _s(0)2R14a; _
S(0)NR14aR14a';
-S(0)2NR14aR14a'; _OS (0)NR14aR14a'; _OS (0)2NR14aR14a' ; _NR14aR14a';
_NR14ac(0)R15a;
-NR 14aC(0)0R15a, -NRi4aC(0)NR15aR15a'; _NR14as(0)R15a; _NR14as(0)2R15a;
-NRi4aS(0)NR15aR15a';
-NR14aS(0)2NR15aR15a'; _c(0)R14a; _
C(0)0R14a or -C(0)NR14aR14a';
wherein R6a and R7a taken together with the atoms to which they are attached
optionally
combine to form a 3- to 7-membered heterocycloalkyl, or R5a and R6a taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
74
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
heterocycloalkyl or 5- to 7-membered heteroaryl, wherein each hydrogen atom in
3- to 7-
membered heterocycloalkyl or 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R16a, -
0C(0)R16a,
-0C(0)NR16aR16a', 0s(0)R16a, 0s(0)2R16a, sR16a, s(0)R16a, s(0)2,,K16a,
S(0)NR16aR16a',
-S(0)2NR16aR16a', OS(0)NR16aR16a', OS(0)2NR16aR16a', NR16aR16a',
NR16ac(0)R17a,
-NR16aC(0)CH2CH2-, -NR16aC(0)0R17a, -NR16aC(0)NR17aRi7a', -NR16aS(0)R17a,
-NR16aS(0)2R17a, -NR16aS(0)NR17aRi7a', -NR16aS(0)2NR17aRi7a', -C(0)R16a, -
C(0)0R16a
or -C(0)NR16aR16a', and wherein one hydrogen atom in 5- to 7-membered
heteroaryl is
optionally a bond, or R5a is a bond;
R8a and R9a are each independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
0R18a,
-0C(0)R18a, -0C(0)NR18aR18a', 0s(0)R18a, 0s(0)2R18a, sR18a, s(0)R18a,
s(0)2R18a,
-S(0)NR18aR18a', S(0)2NR18aR18a', OS(0)NR18aR18a', OS(0)2NR18aR18a',
NR18aR18a',
-NR18aC(0)R19a, -NR18aC(0)0R19a, -NR18aC(0)NR19aRi9a', -NR18aS(0)R19a, -
NR18aS(0)2R19a,
-NR18aS(0)NR19aRi9a', -NR18aS(0)2NR19aRi9a', -C(0)R18a, -C(0)0R18a and -
C(0)NR18aR18a',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -ORma, -
0C(0)R2Oa,
-0C(0)NR20aR20a', 0s(0)R20a, 0s(0)2R20a, sR20a, s(0)R20a, s(0)2,,K20a,
S(0)NR20aR20a',
-S(0)2NR2thR2a', -OS(0)NR20aR20a',
OS(0)2NRmaRma', -NR20aR20a', NR2Oac(0)R21a,
-NR2thC(0)0R21a, -NR2OaC(0)NR2iaR2ia', NR2oas(0)R2ia, NR2oas(0)2R2ia,
-NR2thS(0)NR21aR2la', NR20aS(0)2NR21aR2la', c(0)R20a, C(0)OR2Oa or -
C(0)NR20aR20a';
RMa is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R22a, -0C(0)R22a, -0C(0)NR22aR22a', 0s(0)R22a, 0s(0)2R22a,
sR22a,
-S(0)R22a, -S(0)2R22a, -S(0)NR22aR22a', S(0)2NR22aR22a', OS(0)NR22aR22a',
-OS(0)2NR22aR22a', NR22aR22a', NR22ac(0)R23a, NR22aC(0)0R23a, -
NR22aC(0)NR23aR23a',
-NR22aS(0)R23a, -NR22aS(0)2R23a, -NR22aS(0)NR23aR23a', -NR22aS(0)2NR23aR23a, -
C(0)R22a,
-C(0)0R23a and -C(0)NR22aR22a', wherein each hydrogen atom in C1-C6 alkyl, C2-
C6 alkenyl,
C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10
aryl and 5- to 7-
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2-
C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl,
5- to 7-
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
membered heteroaryl, -OR24a; _0C(0)R24a; _OC(0)NR24aR24a' ; _OS (0)R24a; _OS
(0)2R24a, -
sR24a; _s (0)R24a; _s (0)2R24a;
S (0)NR24aR24a' ;
S (0)2NR24aR24a' ; _OS (0)NR24aR24a' ;
-OS(0)2NR24aR24a' ; _NR24aR24a' ; _NR24ac(0)R25a; _NR24aC(0)0R25a, -
NR24aC(0)NR25aR25a' ;
_NR24as(0)R25a; _NR24as(0)2R25a; _NR24as
(0)NR25aR25a' ; _NR24as(0)2NR25aR25a' ; _c(0)R24a;
-C(0)0R24a
or -C(0)NR24aR24a' ; and
each Ri la, Ri la', Ri2a, Ri3a, Ri4a, ea, Ri6a, Ri7a,
R18a;
a' a a' a a' a a' a a' a a' a a'
R18 ,R19 ,R19 ,R20 ,R20 ,R21 ,R21 ,R22 ,R22 ,R23 ,R23 ,R24 ,R24 ,R25a andR25a'
is
independently selected from the group consisting of H, D, C1-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl,
and 5- to 7-
membered heteroaryl;
provided that at least two of Rla, R4a and R5a are a bond, or when R5a and R6a
taken
together with the atoms to which they are attached optionally combine to form
a 3- to 7-
membered heterocycloalkyl or 5- to 7-membered heteroaryl, one hydrogen atom in
5- to 7-
membered heteroaryl is a bond and one of Rla or R4a is a bond.
In some embodiments, Rla is a bond, and R5a is a bond. In some embodiments,
Rla is a
bond, and R4a is a bond. In some embodiments, Rla is a bond, and R2a is C1-C6
alkyl. In some
embodiments, Rla is a bond, R3a is H, and R4a is H. In some embodiments, Rla
is a bond, and
R2a is C1-C6 alkyl. In some embodiments, Rla is a bond, R2a is C1-C6 alkyl,
R3a is H, and R4a is
H. In some embodiments, Rla is a bond, R5a is a bond, and R6a and R7a taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl. In some embodiments, Rla is a bond, and R5a and R6a taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl or 5- to 7-membered heteroaryl, wherein one hydrogen atom in
5- to 7-
membered heteroaryl is a bond.
In some embodiments, R5a, R6a and R7a are each independently selected from the
group
consisting of H, C1-C6 alkyl, -C(0)R13a, -C(0)0R13a, wherein each hydrogen
atom in C1-C6
alkyl is optionally substituted by -0C(0)R14a; wherein R6a and R7a taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl, or R5a and R6a taken together with the atoms to which they
are attached
optionally combine to form a 3- to 7-membered heterocycloalkyl or 5- to 7-
membered
heteroaryl, provided that at least two of Rla, R4a and R5a are a bond, or when
R5a and R6a taken
together with the atoms to which they are attached optionally combine to form
a 3- to 7-
membered heterocycloalkyl or 5- to 7-membered heteroaryl, one hydrogen atom in
5- to 7-
membered heteroaryl is a bond and one of Rla or R4a is a bond; and each Ri3a
and Ri4a is
independently H or C1-C7 alkyl.
76
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
In some embodiments, D1 is a PBD prodrug of the formula Ma
' R2a
0
R9a 0*
R8a
*N-:\: NR3aR4a
Jo
IIIa
wherein
R2a, R3a and R4a are each independently selected from the group consisting of
H, D, C -
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R, -C(0)OR, and -C(0)NRRi
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl,
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR, -
0C(0)Rila, -0C(0)NR1laRlla', OS (0)R 1 la, -OS (0)2R11a, -Sea, -S(0)R1 la, -
S(0)2R1 la, -S(0)NR1laRlla', S(0)2NR1laR1 la', OS(0)NR1 laR1 la',
-OS (0)2NR 1 laR1 la', NR1laR1 la', NR1lac(0)R12a, NK la-
L(0)0R12a, -NR1laC(0)NR12aR12a',
-NR1laS(0)R12a, -NR1laS(0)2R12a, -NR1laS(0)NRi2aRi2a.',
NR1laS(0)2NR12aR12a', C(0)R1 la,
-C(0)0R1 la or -C(0)NR1 laR1 la' ;
R8a and R9a are each independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
0R18a,
-0C(0)R18a, -0C(0)NR18aR18a', OS(0)R18a, -OS (0)2R18a, -SR18a, -S(0)R18a, -
S(0)2R18a,
-S(0)NR18aR18a'
S(0)2NR18aR18a', OS(0)NR18aR18a', OS (0)2NR18aR18a' NR18aR18a',
-NR18aC(0)R19a, -NR18aC(0)0R19a, -NR18aC(0)NR19aR19a' NR18as(0)R19a,
NR18as(0)2R19a,
-NR18aS(0)NR19aR19a', NR1aS(0)2NR19aR19a' c(0)R18a, C(0)0R18a and -
C(0)NR18aR18a',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl,
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -ORma, -
0C(0)R2a,
-0C(0)NR20aR20a',
OS(0)Rma, -OS (0)2R2a, -SRMa, -S(0)RMa, -S(0)2RMa, -S(0)NR20aR20a',
- S(0 )2NR20aR20a'
OS(0)NR20aR20a',
OS(0)2NR2oaR2oa', NR2oaR2oa', NR2oac (0)R21a,
-NR2OaC(0)0R21a, -NR2OaC(0)NR2laR2la', NR2Oas(0)R2la, NR2Oas(0)2R21a,
77
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-NR2thS(0)NR2laR2la'; _NR2Oas(0)2NR 21aR2la'; _c(o)R20a; _
C(0)ORMa or -C(0)NR20aR20a';
each Ri la, Ri la', Ri2a, Ri2a.', ea, ea', Ri9a, Ri9a.', R2oa, R2oa', R2ia and
R2ia.' is
independently selected from the group consisting of H, D, C1-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl,
and 5- to 7-
membered heteroaryl; and
* is a bond. In some embodiments, R2a, R3a and R`la are each independently H
or C1-C6
alkyl; R8a and R9a are each H, and * is a bond.
In some embodiments, D1 is a PBD prodrug of the formula Mb
....R2a
0
le 0 *
bN R9a
R8a
R5 ::
0 NR3a
*
Mb
wherein
R2a and R3a are each independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
1 _ 1 la
C10 aryl, 5- to 7-membered heteroaryl, -C(0)R1a; C(0)0Rlia, and -C(0)NRR1 la'
; wherein
each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR, -
OC(0)R1 la; _
OC(0)NR 1 laR1 la' ; _
OS(0)Ri 1 a; _
OS (0)2R11a; _sR1 la; _s (0)R11a; _
S(0)2Ri 1 a; _
S(0)NR 1 laR1 la'; _
S(0)2NR1 laR1 la' ; _
OS(0)NR 1 laR1 la';
-OS (0)2NR1 laR1 la'; _NR1laR1 la'; _NR1lac(0)R12a; _NR1 lac(0)0R12a; _NR1
lac(0)NR12aR12a' ;
_NR1 las(0)R12a; _NR1 las(0)2R12a; _NR1 las (0)NR12aR12a' ; _NR1 las
(0)2NR12aR12a'; _c(0)R1 la;
-C(0)0R1 la or -C(0)NR 1 laR1 la' ;
R5a is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -C(0)R13a, -C(0)0R13a and -C(0)NR13aR13a';
wherein each hydrogen atom in C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl and 5- to 7-membered heteroaryl is optionally substituted by C1-C6
alkyl, C2-C6
alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl,
C6-C10 aryl, 5- to
_
7-membered heteroaryl, -OR14a; OC(0)R14a,
-0C(0)NR14aR14a'; _
OS(0)R14a; _
OS (0)2R14a; _sR14a; _s(0)R14a; _s(0)2R14a; _
S(0)NR14aR14a';
78
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
-S(0)2NR14aR14a', OS(0)NR14aR14a', OS(0)2NRi4aRi4a', NRi4aRi4a.', Neac(0)Risa,
-NR14aC(0)0R15a, -NR14aC(0)NRisaRisa', Neas(0)Ri5a, Neas(0)2Risa,
-NR14aS(0)NRi5aRi5a', Neas
(0)2NRisaRisa', c(0)-K 14a,
C(0)0Ri4a or -C(0)NR14aR14a';
R8a and R9a are each independently selected from the group consisting of H, D,
halogen,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
0R18a,
-0C(0)R18a, -0C(0)NR18aR18a', OS(0)R18a, -0S(0)2R18a, sR18a, s(0)R18a,
s(0)2R18a,
-S(0)NR18aR18a', S(0)2NR18aR18a', OS(0)NR18aR18a', OS(0)2NR18aR18a',
NR18aR18a',
NR18ac(0)R19a, N-K18a--4
L(0)0R19a, -NR18aC(0)NRi9aRi9a', Neas(0)Roa, Neas(0)2Roa,
-NR18aS(0)NR19aR19a', NR18as(0)2NR19aR19a', c(0)-K 18a,
C(0)0R18a and -C(0)NR18aR18a',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -ORma, -
0C(0)R2Oa,
-0C(0)NR20aR20a',
OS(0)Rma, -OS (0)2R2, -SRMa, -S(0)RMa, -S(0)2RMa, -S(0)NR20aR20a',
-S(0)2NR20aR20a',
OS(0)NR20aR20a',
OS(0)2NR2oaR2oa', NR2oaR2oa', NR2oac (0)R21a,
-NR2OaC(0)0R21a, NR2OaC(0)NR2laR2la', NR2Oas(0)R2la, NR2Oas(0)2R21a,
-NR2OaS(0)NR2laR2la', NR2Oas(0)2NR 21aR2 Kla', c(0)- 20a, C(0)0R2Oa or -
C(0)NR20aR20a';
each Riia, Ri la', Ri2a, Rl2a, Ri3a, Rl3a, Ri4a, Rl4a, Ra, ea', ea, Rl8a,
Ri9a, Rl9a, R2oa,
R2oa', R2ia 21a'
a R is independently selected from the group consisting of H,
D, C1-C7 alkyl,
C2-C7 alkenyl, C2_C7 alkynyl, C3_C13 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10
aryl, and 5- to 7-membered heteroaryl; and * is a bond. In some embodiments,
R2a and R3a are
each independently H or C1-C6 alkyl; R5a is selected from the group consisting
of H, C1-C6
alkyl, -C(0)R13a, and -C(0)0R13a, wherein each hydrogen atom in C1-C6 alkyl is
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R14a, -
0C(0)R14a, R13a and Ri4a
are each independently selected from the group consisting of H, D, C1-C7
alkyl, C2-C7 alkenyl,
C2_C7 alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10
aryl, and 5- to 7-
membered heteroaryl; R8a and R9a are each H, and * is a bond.
In some embodiments, D1 is a PBD prodrug of the formula IIIc
0'R2a
0*
isN N
0 0 NR3aR4a
147a
79
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
IIIc
wherein
2a
K, R3a and R4a are each independently selected from the group consisting of H,
D, Ci-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R, _C(0)0R1 la, and -C(0)NR1
laR1 la' ,
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR,
_oc(0)R11a,
-0C(0)NR1laRlla',OS(0)R11a, _OS (0)2R1 la, _sR1 la, _s (0)R1 la, _s (0)2R1 la,
S(0)NR1 laR1 la' ,
-S (0)2NR1 laR1 la', _OS (0)NR1 laR1 la',OS (0)2NR1 laR1 la', _NR1laR1 la',
_NR1lac(0)R12a,
-NR1laC(0)0R12a, _NR1 lac
(0)NRi2aRi2a.', _NR1las(0)Ri2a, _NR1las(0)2Ri2a,
-NR1laS(0)NRi2aRi2a.', _NRi las(0)2NR 12aRi2a.', _c(0)R1
C(0)0R1la or -C(0)NR1laRlla';
R7a is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -C(0)R13a, -C(0)0R13a and -C(0)NR13aR13a', wherein each hydrogen
atom in C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl and 5- to 7-membered heteroaryl is optionally substituted by C1-C6
alkyl, C2-C6
alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl,
C6-C10 aryl, 5- to
7-membered heteroaryl, -OR14a, _OC(0)R14a, _OC(0)NR14aR14a' , _OS (0)R14a,
_os(o)2R14a,
_sR14a, _s(0)R14a, _s(0)2R14a,
S(0)NR14aR14a',
S(0)2NR14aR14a' _OS (0)NR14aR14a'
-OS (0)2NR14aR14a' _NR14aR14a', _NR14ac(0)R15a,_NR14a--4
L(0)0R15a, _NR14ac
(0)NRisaRisa',
_Neas(0)Risa, _Neas(0)2Ri5a, _Neas
(0)NRisaRisa', _NR14as (0)2NR15aR15a' _c(0)R14a,
-C(0)OR 14a or -C(0)NR14aR14a'
each Riia, Ri la', Ri2a, Ri3a, Ri4a, Ri9a,
R20a,
R20a', R2la 21a'
a R is independently selected from the group consisting of H,
D, C1-C7 alkyl,
C2-C7 alkenyl, C2_C7alkynyl, C3_C13 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10
aryl, and 5- to 7-membered heteroaryl; and * is a bond. In some embodiments,
R2a, R3a and R4a
are each independently H or C1-C6 alkyl; R7a is H or C1-C6 alkyl; R8a and R9a
are each H, and *
is a bond.
Where, for example, D1 is a PBD prodrug as described herein, D2 can be any
other drug
useful for eliciting a desired biological effect. It will be understood that
the identity of D2 is not
particularly limited, and a variety of drugs known in the art can be used in
connection with the
conjugates described herein as D2. In certain embodiments, D2 can be a DNA
binding agent. In
certain embodiments, D2 can be a DNA alkylating agent. It will be understood
that DNA
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
binding agents and DNA alkylating agents are well known in the art and the
identity of such
DNA binding agents and DNA alkylating agents is not limited. In some
embodiments, D2 can
be a DNA minor groove binding drug.
In some embodiments, D2 is selected from the group consisting of
Ri 1 b ......R2b
R12bR1 Ob
clIN
..,.....4..._ /
R9b 0
0¨R1 b 0-R2C
0 R4C
0 R8b 41/
0 NR3bR O
C21 4
R51 -i R ic
N'\ 4b
R6b/ ? .
R7b ,, -- 5c R3C
/j _4.-
*O ORie
Si kJ
H
I N elei
N
41 \ 140) * N
N N '
N Cl2
( 1 d
R N
0 ______________________________
\ /
HN \
* \ N)/N N 0
N H / i
\
v 0 and
,
CI
0 is N---/--CI
HN
*
wherein
Rib, R2b, R3b and K-.--.4b
are each independently selected from the group consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R13b, -
C(0)0R13b,
and -C(0)NR13bR13b', wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-
membered heteroaryl, -0R13b, -0C(0)R13b, -0C(0)NR13bR13b', _os(0)R13b,
_os(0)2R13b,
81
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
_seb, _s(0)Ri3b, _s(0)2Ri3b, _
S(0)NR13bR13b', _S(0)2NR13bR13b', _OS(0)NR13bR13b',
-0S(0)2NR13bR13W, _NR13bR13b', _NR13bc(0)R14b, _NR13bc(0)0R14b,
_NR13bc(o)NR14bR14b',
_NR13bs(0)R14b, _NR13bs(0)2R14b, _NR13bs(o)NR14bR14b _NR13bs(0)2NR14bR14b
_c(0)R13b,
-C(0)0R13b or -C(0)NR13bR13b'; or any one of Rib, R2b, R3b and R4b is a bond;
R5b, R6b and R7b are each independently selected from the group consisting of
H, D, C1-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R15b, -C(0)0R15b, and -
C(0)NR15bR15b',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -L4H, -
L3H, -0R15b,
-0C(0)R15b, -0C(0)NR157R15W, -OS(0)R, -0S(0)2R15b, -SR', _s(0)R15b, -S(0)2R',
-S(0)NR15bR15b', _S(0)2NR15bR15b', _OS(0)NR15bR15b', _OS(0)2NR15bR15b',
_NR15bR15b',
_NR15bc(0)R161', _NR15bc(0)0R161', _NR15bc(o)NR16bR16b', _NR15bs(0)R161',
_NR15bs(0)2R161'
,
-NR15bS(0)NR16bR16b', _NR15bs(0)2NR16bR16b', _c(0)R15b, _C(0)0R15b or -
C(0)NR15bR15b';
wherein R6b and R7b taken together with the atoms to which they are attached
optionally
combine to form a 3- to 7-membered heterocycloalkyl, or R5b and R6b taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl or 5- to 7-membered heteroaryl, wherein each hydrogen atom in
3- to 7-
membered heterocycloalkyl and 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R171', -
0C(0)R171'
,
-0C(0)NR171'R171", _OS(0)R171', -os(o)2R171', _sR171', _s(0)R171', _s(0)2R171'
,
-S(0)NR171'R171", _S(0)2NR171'R171", _OS(0)NR171'R171", _OS(0)2NR171'R171",
_NR171'R171"
,
_NR171'c(0)R181', _NRimc (0)0Risb, _NRimc (0)NRisbRisw, _NR171's(0)R181',
_NR171's(0)2R181'
,
-NR17bS(0)NR18bR18b', _NR17bs(0)2NR18bR18b', _c(0)R17b, _C(0)0R17b or -
C(0)NR17bR17b; or
any one of R5b, R6b or R7b is a bond;
R8b and R9b are each independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -0R191', -0C(0)R191'
,
-0C(0)NR191'R191", _OS(0)R191', -os(o)2R191', _sR191', _s(0)R191',
_s(0)2R191', _
S(0)NR19bR19b',
-S(0)2NR191'R191", _OS(0)NR191'R191", _OS(0)2NR191'R191", _NR191'R191",
_NR191'c(o)R201'
,
-NR191'C(0)0R201', _NR19bc(0)NR2ObR2Ob', _NR191's(0)R201', _NR191's(0)2R201'
,
-NR19bS(0)NR2ObR2Ob', _NR obs(0)2NR2obR2ow, _c(0)R191', _C(0)0R191' and -
C(0)NR191'R191"
,
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
82
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR21b,
_OC(0)R211'
,
-0C(0)NR21bR2lb', _
OS(0)R21b, _OS(0)2R211'
, _sR21b, _s(0)R21b, _s(0)2R21b, _
S(0)NR21bR2lb',
-S(0)2NR21bR2lb', _OS(0)NR21bR2lb', _
OS(0)2NR21bR2lb', _NR21bR2lb', _NR211c(0)R22b,
-NR21bC(0)0R22b, _NR2lbc
(0)NR22bR22b', _NR211s(0)R22b, _NR2lbs(0)2R22b,
-NR21bS(0)NR22bR22W, _NR21bs
(0)2NR22bR22b', _c(0)R21b, _
C(0)0R2lb or -C(0)NR21bR21b;
R10b, Rllb and R12'
are each independently selected from the group consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R23b, -
0C(0)R23b,
-0C(0)NR23bR23W, _
OS(0)R23b, -0S(0)2R23b, _sR23b, _s(0)R23b, _s(0)2R23b, _
S(0)NR23bR23b',
-S(0)2NR23bR23b', -OS(0)NR23bR23b', -OS(0)2NR23bR23b', _NR23bR23b',
_NR23bc(0)R24b,
-NR23bC(0)0R24b, _NR23bc(0)NR24bR24b', _NR23bs(0)R24b, _NR23bs(0)2R24b,
-NR23bS(0)NR24bR24w, _NR23bs(0)2NR24bR24w, _c(0)R23b, _
C(0)0R23b and -C(0)NR23bR23b',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R2, -
0C(0)R2'
,
-0C(0)NR25bR25b', _
OS(0)R25b, -0S(0)2R25b, _sR25b, -S(0)R2',
-S(0)2R2',
_
S(0)NR25bR25b',
-S(0)2NR25bR25b', -OS(0)NR25bR25b', -OS(0)2NR25bR25b', _NR25bR25b',
_NR25bc(0)R261'
,
-NR25bC(0)0R261'
, _NR25bc(0)NR26bR26b', _NR25bs(0)R261'
, _NR251'
s(0)2R261'
,
-NR25bS(0)NR26bR26w, _NR25bs(0)2NR26bR26w, _c(0)R25b, _
C(0)0R25b or -C(0)NR25bR25b, or
Rim and R1lb taken together with the carbon atoms to which they are attached
optionally
combine to form a C6-C10 aryl, or R1 lb and R12b taken together with the
carbon atom to which
they are attached optionally combine to form an exo-methylene; or R12b is
absent;
each R13b, R13b', R14b, R14b', R15b, R15b', R16b, R16b', R17b, R17b', R18b,
R18b', R19b, R19b',
R2ob, R2ow, R211'
, R2lb', R22b, R22b', R23b, R23b', R24b, R24b', R25b, R25b', R26b and R26b' is
independently selected from the group consisting of H, D, C1-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, C1-
C6 alkyl(C6-C10
aryl) and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C6-C10
aryl, C1-C6
alkyl(C6-C10 aryl) and 5- to 7-membered heteroaryl is independently optionally
substituted by
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
OH, -SH,
-NH2, -503H, -C(0)0H and -C(0)NH2;
provided that one of R11'
, R2b, R3b, R4b, R5b, R6b and K- 7b
is a bond;
83
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Ric, R2c and R5c are each independently selected from the group consisting of
H, D, C1-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R6c, -C(0)0R6c and -
C(0)NR6cR6c, wherein
each hydrogen atom in Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R7c, -
0C(0)R7c,
-0C(0)NR7cR7c, -0S(0)R7c, -0S(0)2R7c, -SR7c, -S(0)R7c, -S(0)2R7c, -S(0)20R7c,
-S(0)NR7cR7c, -S(0)2NR7cR7c, -OS(0)NR7cR7c, -OS(0)2NR7cR7c, -NR7cR7c', -
NR7cC(0)R8c,
-NR7cC(0)0R8c, -NR7cC(0)NR8cR8c, -NR7cS(0)R8c, -NR7cS(0)2R8c, -
NR7cS(0)NR8cR8c,
-NR7cS(0)2NR8cR8c, -C(0)R7c, -C(0)0R7c or -C(0)NR7cR7c; or when J is -CR13c=,
R5c is
absent; provided that one of Ric or R2c is a bond;
R3c and R`ic are each independently selected from the group consisting of H,
D, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -0R9c, -0C(0)R9c, -
0C(0)NR9cR9c,
-0S(0)R9c, -0S(0)2R9c, -SR9c, -S(0)R9c, -S(0)2R9c, -S(0)NR9cR9c, -
S(0)2NR9cR9c,
-OS(0)NR9cR9c , -OS(0)2NR9cR9c , -NR9cR9c , -NR9cC(0)Ri c, -NR9cC(0)0R1 c,
-NR9cC(0)NRiocRioc NR9cs(0)Rioc, NR9cs(0)2R1oc, 9c=-=
NK S(0)NRiocRioc
-NR9cS(0)2NRiocRioc, c(os
)K C(0)0R9c and -C(0)NR9cR9c, wherein each
hydrogen atom
in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-
membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OW lc, -
0C(0)Rlic,
-0C(0)NRiicRi os(0)Ri lc, os(0)2Ri lc, sRi lc, s(0)Ri lc, s (0)2-K11c,
S(0)NRiicRiic,
-S(0)2NR1icRi lc',
OS(0)NR1icRilc,
OS(0)2NR1icRilc, NecRilc,
NR1lcC(0)R12c,
-NR icC(0)0R12c, -NR icC(0)NRi2cRi2c, NR1ics(0)Ri2c, NR1ics(0)2Ri2c,
-NR1 icS(0)NRi2cRi2c
K S(0)2NRi2cRi2c, c(or ilc,
K C(0)0R1ic or -
C(0)NR1icRiic;
J is -C(0)-, -CR13c= or -(CR13cR13c)-
each R6c, R6c, R7c, R7c, R8c, R8c, R9c, R9c Rioc, Rioc RlJc, RlJc, R12c, R12c
R13c and
R13c is independently selected from the group consisting of H, D, C1-C7 alkyl,
C2-C7 alkenyl,
C2_C7alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl
and 5- to 7-
membered heteroaryl;
Rid is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-membered
heteroaryl, -0R2', -SR2d and -NR2dR2d',
84
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R2d and R2d' are each independently selected from the group consisting of H,
D, C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C1-C6
alkyl, C2-C6
alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl,
C6-C10 aryl and 5-
to 7-membered heteroaryl is optionally substituted by ¨0R3d, -SR3d, and
¨NR3dR3d';
R3d and R3d' are each independently selected from the group consisting of H,
D, Ci-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl and 5- to 7-membered heteroaryl;
Rle is selected from the group consisting of H, D, C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2
C6alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5-
to 7-
1 5 membered heteroaryl, -0R2e, -0C(0)R2e, -0C(0)NR2eR2e' ; -Os (0)R2e; -Os
(0)2R2e; _sR2e;
-S (0)R2e, -S (0)2R2e, -S (0)NR2eR2e' , -S (0)2NR2eR2e' , -OS (0)NR2eR2e' , -
OS (0)2NR2eR2e' ,
-NR2eR2e' , -NR2eC(0)R3e, -NR2eC(0)0R3e, -NR2eC(0)NR3eR3e' , -NR2eS(0)R3e, -
NR2eS(0)2R3e,
-NR2eS(0)NR2eR2e' , -NR2eS(0)2NR3eR3e' , -C(0)R2e, -C(0)0R2e or -C(0)NR2eR2e;
each R2e,R 'e ;
2 R3e and R3e' is independently selected from the group
consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl, wherein each
hydrogen atom in
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is optionally
substituted by
¨0R4e, -Sle or ¨NR4eR4e' ;
R`le and We' are independently selected from the group consisting of H, D, C1-
C6 alkyl,
C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl
and 5- to 7-membered heteroaryl;
v is 1, 2 or 3; and
* is a covalent bond.
In some embodiments, Drug can be described by the general formula ¨D1-L5-D2.
In
some embodiments, Drug can be described by the formula
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R71) R6b
,R4b (1) /
0
R5b
Rai)
Rloa 0 "
D2a
RlObR-R12b
R9a
9b
1110 R2b-O R
R1113
R8a
RN O
NR3aRtta
0
Rua/
R7a
wherein, L5, R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a, Rioa, R2b, R3b, R4b, R5b,
R6b, R7b, R8b,
R9b, R10b, Rllb and tc,--.12b
are defined as described herein. In some embodiments, R2a, R3a, R4a,
R8a, R9a, R10a, R2b, R3b, R- 4b,
R8b and R9b are H, L5 is Ci-Cio alkyl, -(CR49=CR49')u-,
-(CR49R49')uC(0)-,-CH2CH2(0CR49R49'CR49R49')u-,
- CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)-
or -
CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and u
is 1, 2, 3, 4
or 5. In some embodiments, R2a, R3a, R4a, R8a, R9a, R10a, R2b, R3b,
K R8b and R9b are H,
and L5
is C1-C10 alkyl. In some embodiments, R2a, R3a, R4a, R8a, R9a, R10a, R2b, R3b,
-4b,
R R8b and R9b are
H, L5 is -(OCR49R49'CR49R49')u-, wherein each R49 and R49' is H, and u is 4.
In some
embodiments, R4a is a bond, R2a, R3a, R8a, R9a, R10a, R2b, R3b, R-4b,
R8b and R9b are H, L5 is
C10 alkyl, -(CR49=CR49')u-, -(CR49R49')uC(0)-,-CH2CH2(OCR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- or -
CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H and u
is 1, 2, 3, 4
or 5. In some embodiments, R4a is a bond, R2a, R3a, R8a, R9a, R10a, R2b, R3b,
R4b,
R8b and R9b are
H, and L5 is C1-C10 alkyl.
In some embodiments, R5a is a bond, R2a, R3a, R4a, R8a, R9a, R10a, R2b, R3b,
K R8b
and
R9b are H, L5 is C1-C10 alkyl, -(CR49=CR49')u-, -(CR49R49')uC(0)-,
-CH2CH2(OCR49R49'CR49R49')u-, - CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-,
-CH2CH2(0CR49R49'CR49R49')uC(0)- or -CH2CH2(0CR49R49'CR49R49'CR49R49')uC(0)-,
wherein each R49 and R49' is H and u is 1, 2, 3, 4 or 5. In some embodiments,
R5a is a bond, R2a,
R3a, R4a, R8a, R9a, R10a, R2b, R3b,
K R8b and R9b
are H, and L5 is C1-C10 alkyl.
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
86
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R5
,
R3c
µ_....JR1 Oa O R2a
R9a 0-L5-0 1100
R
0 R4c
0
R5
N'\ 0 NR3aR4a
/ 0
Rua
R7a
wherein L5, R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a, Rioa, R2c, R3c, R4c, -5c
K and J are as
defined herein. In some embodiments, R2a, R3a, R4a, R8a, R9a, R10a, R2c, R3c,
R4c and Rsc are H,
L5 is C1-C10 alkyl, -(CR49=CR49')õ-, -(CR49R49')õC(0)-,-
CH2CH2(OCR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, J is -C(0)-, R2a, R3a, R4a, R8a, R9a, R10a, R2c,
R3c, R4c and Rsc are
H, and L5 is Cl-Cio alkyl. In some embodiments, J is -CR13c=, R2a, R3a, R4a,
R8a, R9a, R10a, R2c,
R3c, R4c, 5
R c and Ri3c are H, and L5 is Cl-Cio alkyl. In some embodiments, J is -
(CR13cR13e)_,
R2a, R3a, R4a, R8a, R9a, Rioa, R2c, R3c, R4c, R5c, Ri3c and K- 13c'
are H, and L5 is Cl-Cio alkyl.
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
2n. a
Oa 0 rµ
R9a 0_L5_0
R8a
5a
RN"-\ 0 N R3aR4a
R6a/ 0 = \
R7a N
wherein, L5, R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a and K- loa
are as defined herein. In some
embodiments, R2a, R3a, R4a, R8a, R9a and Rioa are H, L5 is Cl-Cio alkyl, -
(CR49=CR49')u-,
-(CR49R49')uC(0)-,-CH2CH2(OCR49R49'CR49R49')u-,
- CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')õC(0)-
or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, R2a, R3a, R4a, R8a, R9a and K- loa
are H, and L5 is Cl-Cio alkyl. In
some embodiments, R2a, R3a, R4a, R8a, R9a and Rioa are H, L5 is -
(CR49R49')uC(0)-, wherein
each R49 and R49' is H, and u is 3. In some embodiments, R2a, R3a, R4a, R8a,
R9a and Rioa are H,
L5 is -(CR49R49')uC(0)-, wherein each R49 and R49' is H, and u is 4. In some
embodiments, R2a,
R3a,
R4a, R8a, R9a and ea are H, L5 is -(CR49R49')uC(0)-, wherein each R49 and R49'
is H, and u
is 5.
87
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
ORle
JR10a 0
R9a o_o_N
C1N
R2a 1O
Rsa
R5
N'\ 0 NR3aR4a CI
R6a/ 0
R7a
wherein, L5, R2a, R3a, R4a, R5a, R6a, R7a, Rsa, R9a, Rioa and K - le
are as defined herein. In
some embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Rie are H-,
L5 is Ci-Cio alkyl,
-(CR49=CR49').-, -(CR49R49')uC(0)-,-CH2CH2(0CR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Rie are H-,
and L5 is Cl-Cio alkyl.
In some embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Rie are H, L5 is -
(CR49R49')õC(0)-
,wherein each R49 and R49' is H, and u is 3. In some embodiments, R2a, R3a,
R4a, Rsa, R9a, Rioa
and Re are H, L5 is -(CR49R49')õC(0)-,wherein each R49 and R49' is H, and u is
4. In some
embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Re are H, L5 is -
(CR49R49')uC(0)-,wherein each
R49 and R49' is H, and u is 5.
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
0
1 d
JR1 Oa 0
R9a0 N N,
N H
Raa
R5
N'\ 0 NR3aR4a
/ 0
Rua
R7a
wherein L5, R2a, R3a, R4a, R5a, R6a, R7a, Rsa, R9a, Rioa, ld
K and v are as defined herein. In
some embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Rie are H-,
L5 is Cl-Cio alkyl,
-(CR49=CR49')u-, -(CR49R49')uC(0)-,-CH2CH2(0CR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')õC(0)- or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Rie are H-,
and L5 is Cl-Cio alkyl.
In some embodiments, R2a, R3a, R4a, Rsa, R9a, Rioa and Rie are H, L5 is -
(CR49R49')uC(0)-,
wherein each R49 and R49' is H, and u is 4. In some embodiments, R2a, R3a,
R4a, Rsa, R9a, Rioa
88
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
and Rie are H, L5 is -(CR49R49')uC(0)-, wherein each R49 and R49' is H, and u
is 5. In some
embodiments, R2a, R3a, R4a, R8a, R9a, Rioa and Rie are H,
L5 is Cl-Cio alkyl, and v is 2. In some
embodiments, R2a, R3a, R4a, R8a, R9a, Rioa and Re are H,
L5 is Cl-Cio alkyl, and v is 3. In some
embodiments, R2a, R3a, R4a, R8a, R9a, Rioa and Re are H,
L5 is -(CR49R49')t,C(0)-, wherein each
R49 and R49' is H, u is 4, and v is 2. In some embodiments, R2a, R3a, R4a,
R8a, R9a, Rioa and Rie
are H, L5 is -(CR49R49')uC(0)-, wherein each R49 and R49' is H, u is 4, and v
is 3. In some
embodiments, R2a, R3a, R4a, R8a, R9a, Rioa and Re are H,
L5 is -(CR49R49')t,C(0)-, wherein each
R49 and R49' is H, u is 5, and v is 2. In some embodiments, R2a, R3a, R4a,
R8a, R9a, Rioa and Rie
are H, L5 is -(CR49R49')uC(0)-, wherein each R49 and R49' is H, u is 5, and v
is 3.
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
2a
JR10a O'R
R9a 401= 0
R8a
R5
N'\ 0 NR3aR4a / 0
/ 0 II..
R6a
R7a 0
wherein L5, R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a and K- loa
are as defined herein. In some
R2a, R3a, Ra
embodiments, R2 3s, R9a and Rma are H, L5 is C1-C10 alkyl, -(CR49=CR49')u-,
-(CR49R49')uC(0)-,-CH2CH2(0CR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, R2a, R3a,
R4a, R8a, R9a and Rma are H, and L5 is C1-C10 alkyl. In
some embodiments, R2a, R3a, R4a, Rs a, R9a and Rith are H, L5 is -
(CR49R49')uC(0)-, wherein
each R49 and R49' is H, and u is 4. In some embodiments, R2a, R3a, R4a, Rs a,
R9a and Rma are H,
L5 is -(CR49R49')uC(0)-, wherein each R49 and R49' is H, and u is 5.
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
Cl
2a N---/"Cl
lOa 0-"R
R5a
R9a
8a
R
NO NR3aR4a
õ / 0
Roa
R7a
89
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
wherein L5, R2a, R3a, R4a, R5a, R6a, R7a, R8a, R9a and K- ioa
are as defined herein. In some
R2a, R3a, K,--.4 s,
R4a, Ra
embodiments, R2 3 R9a and ea are H, L5 is Ci-Cio alkyl, -
(CR49=CR49')u-,
-(CR49R49')uC(0)-,-CH2CH2(OCR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, R2a, R3a, R4a,
R8a, R9a and ea are H, and L5 is C1-C10 alkyl. In
some embodiments, R2a, R3a, tc '-szta, R8a, R9a and Rith are H, L5 is -
(CR49R49')uC(0)-, wherein
each R49 and R49' is H, and u is 4. In some embodiments, R2a, R3a, tc '-szta,
R8a, R9a and ea are H,
L5 is -(CR49R49')uC(0)-, wherein each R49 and R49' is H, and u is 5.
In some embodiments, Drug can be described by the general formula -D1-L5-D2.
In
some embodiments, Drug can be described by the formula
R7b R6b
R3,1_, zwib I
N 0 0\N'
R8b = R5b
.
D 2a
R10a 0
µ..... "
R9a
0 0-L5-0 SI R9b
RlObR'R12b
Uij R2b-0 R1113
R8a
_
R5a ---
1\l'\ N R3a
/ 0 *
R6a I
R7a
wherein L5, R2a, R3a, R5a, R6a, R7a, R8a, R9a, Rioa, R2b, R3b, R4b, Rsb, R6b,
R7b, R8b, R9b,
Riob, Rilb and Ri2b
are defined as described herein. In some embodiments, R2a, R3a, R8a, R9a,
R10a, R2b, R3b, R- 4b,
R8b and R9b are H, L5 is Cl-Cio alkyl, -(CR49=CR49')u-,
-(CR49R49')uC(0)-,-CH2CH2(OCR49R49'CR49R49')u-,
-CH2CH2CH2(0CR49R49'CR49R49'CR49R49')u-, -CH2CH2(0CR49R49'CR49R49')uC(0)- or
-CH2CH2(OCR49R49'CR49R49'CR49R49')uC(0)-, wherein each R49 and R49' is H, and
u is 1, 2, 3,
4 or 5. In some embodiments, R2a, R3a, R4a, R8a, R9a, R10a, R2b, R3b, tc ,--
.4b, Rh
R and R9b are H, and
L5 is Cl-Cio alkyl.
In some embodiments, D1 can be absent. When D1 is absent, D2 is of the formula
R1 1 b 0-R1 b _R2b
R12b R10b
. N
L,
CI R9b O "
(11101 R8b
*N\0 o
L---../ NR3bR4b
wherein
Rib, R2b, R3b and tc,--.4b
are each independently selected from the group consisting of H, D,
Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R13', -
C(0)0R13b,
and -C(0)NR13bR13b', wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl,
C2_C6
alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl and
5- to 7-
membered heteroaryl is independently optionally substituted by C1-C6 alkyl, C2-
C6 alkenyl, C2-
C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl,
5- to 7-
membered heteroaryl, -0R13b, -0C(0)R13b, -0C(0)NR13bR13b'; _OS(0)R13b, -
0S(0)2R13b,
_sR13b; _s(0)R13b; _s(0)2R13b; _
S(0)NR13bR13b', _S(0)2NR13bR13b'; _OS(0)NR13bR13b';
-0S(0)2NR13bR13b'; _NR13bR13b'; _NR13bc(0)R14b; _NR13bc
(0)0R14b, -NR13bC(0)NR14bR14b';
-NR13bS(0)R14b, -NR13bS(0)2R14b, -NR13bS(0)NR14bR14b'; _NR13bs(0)2NR14bR14b';
-C(0)R13b, -C(0)0R13b or -C(0)NR13bR13b'; or any one of R11), R2b, R3b and R4b
is a bond;
R5b, R6b and R7b are each independently selected from the group consisting of
H, D, C1-
C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl,
C6-C10 aryl, 5- to 7-membered heteroaryl, -C(0)R15b, -C(0)0R15b, and -
C(0)NR15bR15b';
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -L4H, -
L3H, -0R15b,
-0C(0)R, -0C(0)NR15bR15b'; -
OS(0)R', -0S(0)2R15b, -SR', -S(0)R', -S(0)2R',
R15b'; _
-S(0)NR15b S(0)2NR15bR15b', _OS(0)NR15bR15b'; _OS(0)2NR15bR15b'; -
NR15bR15b';
-NR15bC(0)R161', -NR15bC(0)0R161', -NR15bC(0)NR16bR16b'; _NR15bs(0)R161'
; _NR15bs(0)2R161'
;
-NR15bS(0)NR16bR16b';
-NR15bS(0)2NRi6bR16b'; _c(0)R15b; _
C(0)0R15b
or -C(0)NR15bR15b';
wherein R6b and R7b taken together with the atoms to which they are attached
optionally
combine to form a 3- to 7-membered heterocycloalkyl, or R5b and R6b taken
together with the
atoms to which they are attached optionally combine to form a 3- to 7-membered
heterocycloalkyl or 5- to 7-membered heteroaryl, wherein each hydrogen atom in
3- to 7-
membered heterocycloalkyl and 5- to 7-membered heteroaryl is independently
optionally
substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3-
to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R171', -
0C(0)R171'
,
-0C(0)NR17bR171"; _
OS(0)R17b, -0S(0)2R171'
; _sR171'
; _s(0)R171'
; _s(0)2R171'
; _
S(0)NR17bR17b';
-S(0)2NR171'R171"; _
OS(0)NR17bR17b'; _
OS(0)2NR17bR17b'; _NR171'
R171"
; _NR171'
c(0)R181'
;
-NR171'C(0)0R181'
; _NR17bc(o)NR1817R18b'; _NR171'
s(0)R181'
; _NR171'
s(0)2R181'
;
-NR17bS(0)NR1817R18b'; _NR17bs(0)2NR1817R18b'; _c(0)R17b; _
C(0)0R17b or -C(0)NR17bR17b; or
any one of R5b, R6b or R7b is a bond;
91
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
R8b and R9b are each independently selected from the group consisting of H, D,
C1-C6
alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-
C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -0R19', -0C(0)R19'
,
-0C(0)NR19bR19W, -OS(0)R19', -OS(0)2R19',
_sR19b, -S(0)R19',
-S(0)2R19',
_
S(0)NR19bR19b',
-S(0)2NR19bR19W, _OS(0)NR19bR19b', _OS(0)2NR19bR19b', _NR19bR19b',
_NR19bc(0)R20b,
-NR19bC(0)0R20b, _NR19bc(0)NR2ObR2Ob', _NR19bs(0)R20b, _NR19bs(0)2R20b,
-NR19bS(0)NR2ObR2Ob', _NRobs(0)2NR2obR2ce, _c(0)R19b, _C(0)0R19' and -
C(0)NR19bR19b',
wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -OR21b,
_OC(0)R211'
,
-0C(0)NR21bR2lb', _OS(0)R211'
, _OS(0)2R211'
, _sR21b, _s(0)R21b, _s(0)2R21b, _
S(0)NR21bR2lb',
-S(0)2NR21bR2lb', _OS(0)NR21bR2lb', _OS(0)2NR21bR2lb', _NR21bR2lb',
_NR211c(0)R22b,
-NR21bC(0)0R22b, _NR2lbc
(0)NR22bR22b _NR2lbs(0)R22b, _NR2lbs(0)2R22b,
-NR21bS(0)NR22bR22w, _NR21bs R _c(0)R
(0)2NR22b22b',
21b,-C(0)0R2lb or -C(0)NR21bR21b;
R10b, Rllb and R12'
are each independently selected from the group consisting of H, D,
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R23b, -
0C(0)R23b,
-0C(0)NR23bR23W, _OS(0)R23b, _OS(0)2R23b, _sR23b, _s(0)R23b, _s(0)2R23b, _
S(0)NR23bR23W,
-S(0)2NR23bR23b', -OS(0)NR23bR23b', -OS(0)2NR23bR23b', _NR23bR23b',
_NR23bc(0)R24b,
-NR23bC(0)0R24b, _NR23bc
(0)NR24bR24b', _NR23bs(0)R24b, _NR23bs(0)2R24b,
-NR23bs(o)NR24bR24w, _NR23bs(0)2NR24b R24b', _c(0)R23b, _
C(0)0R23b and -C(0)NR23bR23b',
wherein each hydrogen atom in Cl-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3-
to 7-membered heterocycloalkyl, C6-C10 aryl and 5- to 7-membered heteroaryl is
independently
optionally substituted by C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6
cycloalkyl, 3- to 7-
membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -0R2, -
0C(0)R2'
,
-0C(0)NR25bR25b', _
OS(0)R25b, -OS(0)2R2',
_sR25b, -S(0)R2',
-S(0)2R2',
_
S(0)NR25bR25b',
-S(0)2NR25bR25b', _OS(0)NR25bR25b', -OS(0)2NR25bR25b', _NR25bR25b',
_NR25bc(0)R261'
,
-NR25bC(0)0R261'
, _NR25bc
(0)NR2bbR26b', _NR25bs(0)R261'
, _NR25bs(0)2R261'
,
-NR25bS(0)NR26bR26w, _NR25bs(0)2NR26b R26b', _c(0)R25b, _
C(0)0R25b or -C(0)NR25bR25b, or
Rim and R1lb taken together with the carbon atoms to which they are attached
optionally
combine to form a C6-C10 aryl, or R1 lb and R12b taken together with the
carbon atom to which
they are attached optionally combine to form an exo-methylene; or R12b is
absent;
each R13b, R13b', R14b, R14b', R15b, R15b', R16b, R16b', R17b, R17b', R18b,
R18b', R19b, R19b',
R2ob, R2ow, R2ib, R2lb', R22b, R22b', R23b, R23b', R24b, R24b', R25b, R25b',
R26b and R26b' is
92
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
independently selected from the group consisting of H, D, C1-C7 alkyl, C2-C7
alkenyl, C2_C7
alkynyl, C3_C13 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, C1-
C6alkyl(C6-Cio
aryl) and 5- to 7-membered heteroaryl, wherein each hydrogen atom in C6-C10
aryl, C1-C6
alkyl(C6-Cio aryl) and 5- to 7-membered heteroaryl is independently optionally
substituted by
C1-C6 alkyl, C2-C6 alkenyl, C2_C6 alkynyl, C3_C6 cycloalkyl, 3- to 7-membered
heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl, -CN, -NO2, -NCO, -
OH, -SH,
-NH2, -S03H, -C(0)0H and -C(0)NH2; and * is a bond.
The conjugates described herein can be used for both human clinical medicine
and
veterinary applications. Thus, the host animal harboring the population of
pathogenic cells and
treated with the conjugates described herein can be human or, in the case of
veterinary
applications, can be a laboratory, agricultural, domestic, or wild animal. The
conjugates
described hereincan be applied to host animals including, but not limited to,
humans, laboratory
animals such rodents (e.g., mice, rats, hamsters, etc.), rabbits, monkeys,
chimpanzees, domestic
animals such as dogs, cats, and rabbits, agricultural animals such as cows,
horses, pigs, sheep,
goats, and wild animals in captivity such as bears, pandas, lions, tigers,
leopards, elephants,
zebras, giraffes, gorillas, dolphins, and whales.
The conjugate, compositions, methods, and uses described herein are useful for
treating
diseases caused at least in part by populations of pathogenic cells, which may
cause a variety of
pathologies in host animals. As used herein, the term "pathogenic cells" or
"population of
pathogenic cells" generally refers to cancer cells, infectious agents such as
bacteria and viruses,
bacteria- or virus-infected cells, inflammatory cells, activated macrophages
capable of causing a
disease state, and any other type of pathogenic cells that uniquely express,
preferentially
express, or overexpress cell surface receptors or cell surface anitgens that
may be bound by or
targeted by the conjugates described herein. Pathogenic cells can also include
any cells causing
a disease state for which treatment with the conjugates described herein
results in reduction of
the symptoms of the disease. For example, the pathogenic cells can be host
cells that are
pathogenic under some circumstances such as cells of the immune system that
are responsible
for graft versus host disease, but not pathogenic under other circumstances.
Thus, the population of pathogenic cells can be a cancer cell population that
is
tumorigenic, including benign tumors and malignant tumors, or it can be non-
tumorigenic. The
cancer cell population can arise spontaneously or by such processes as
mutations present in the
germline of the host animal or somatic mutations, or it can be chemically-,
virally-, or radiation-
induced. The conjugates described herein can be utilized to treat such cancers
as carcinomas,
sarcomas, lymphomas, Hodgekin's disease, melanomas, mesotheliomas, Burkitt's
lymphoma,
nasopharyngeal carcinomas, leukemias, and myelomas. The cancer cell population
can include,
93
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
but is not limited to, oral, thyroid, endocrine, skin, gastric, esophageal,
laryngeal, pancreatic,
colon, bladder, bone, ovarian, cervical, uterine, breast, testicular,
prostate, rectal, kidney, liver,
and lung cancers.
The disclosure includes all pharmaceutically acceptable isotopically-labelled
conjugates,
and their Drug(s) incorporated therein, wherein one or more atoms are replaced
by atoms
having the same atomic number, but an atomic mass or mass number different
from the atomic
mass or mass number which predominates in nature.
Examples of isotopes suitable for inclusion in the conjugates, and their
Drug(s)
incorporated therein, include isotopes of hydrogen, such as 2H and 3H, carbon,
such as 11C, 13c
and 14C, chlorine, such as 36C1, fluorine, such as 18F, iodine, such as 123I
and 125I, nitrogen, such
as 13N and 15N, oxygen, such as 150, 170 and 180, phosphorus, such as 32P, and
sulfur, such as
35s.
Certain isotopically-labelled conjugates, and their Drug(s) incorporated
therein, for
example, those incorporating a radioactive isotope, are useful in drug and/or
substrate tissue
distribution studies. The radioactive isotopes tritium, i.e. 3H, and carbon-
14, i.e. 14C, are
particularly useful for this purpose in view of their ease of incorporation
and ready means of
detection.
Substitution with heavier isotopes such as deuterium, i.e. 2H, may afford
certain
therapeutic advantages resulting from greater metabolic stability, for
example, increased in vivo
half-life or reduced dosage requirements, and hence may be preferred in some
circumstances.
Substitution with positron emitting isotopes, such as 11C, 18F, and 13N, can
be useful in
Positron Emission Topography (PET) studies for examining substrate receptor
occupancy.
Isotopically-labeled conjugates, and their Drug(s) incorporated therein, can
generally be
prepared by conventional techniques known to those skilled in the art or by
processes analogous
to those described in the accompanying Examples using an appropriate
isotopically-labeled
reagents in place of the non-labeled reagent previously employed.
The conjugates and compositions described herein may be administered orally.
Oral
administration may involve swallowing, so that the conjugate or composition
enters the
gastrointestinal tract, or buccal or sublingual administration may be employed
by which the
conjugate or composition enters the blood stream directly from the mouth.
Formulations suitable for oral administration include solid formulations such
as tablets,
capsules containing particulates, liquids, or powders, lozenges (including
liquid-filled), chews,
multi- and nano-particulates, gels, solid solution, liposome, films, ovules,
sprays and liquid
formulations.
94
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Liquid formulations include suspensions, solutions, syrups and elixirs. Such
formulations may be employed as fillers in soft or hard capsules and typically
comprise a
carrier, for example, water, ethanol, polyethylene glycol, propylene glycol,
methylcellulose, or
a suitable oil, and one or more emulsifying agents and/or suspending agents.
Liquid
formulations may also be prepared by the reconstitution of a solid, for
example, from a sachet.
The conjugates and compositions described herein may also be used in fast-
dissolving,
fast-disintegrating dosage forms such as those described in Expert Opinion in
Therapeutic
Patents, 11 (6), 981-986, by Liang and Chen (2001). For tablet dosage forms,
depending on
dose, the conjugate may make up from 1 weight % to 80 weight % of the dosage
form, more
typically from 5 weight % to 60 weight % of the dosage form. In addition to
the conjugates and
compositions described herein, tablets generally contain a disintegrant.
Examples of
disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose,
calcium
carboxymethyl cellulose, croscarmellose sodium, crospovidone,
polyvinylpyrrolidone, methyl
cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl
cellulose, starch,
pregelatinised starch and sodium alginate. Generally, the disintegrant will
comprise from 1
weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the
dosage form.
Binders are generally used to impart cohesive qualities to a tablet
formulation. Suitable
binders include microcrystalline cellulose, gelatin, sugars, polyethylene
glycol, natural and
synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl
cellulose and
hydroxypropyl methylcellulose. Tablets may also contain diluents, such as
lactose
(monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol,
xylitol, dextrose,
sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium
phosphate dihydrate.
Tablets may also optionally comprise surface active agents, such as sodium
lauryl
sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
When present, surface
active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and
glidants may
comprise from 0.2 weight % to 1 weight % of the tablet.
Tablets also generally contain lubricants such as magnesium stearate, calcium
stearate,
zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate
with sodium lauryl
sulphate. Lubricants generally comprise from 0.25 weight % to 10 weight %,
preferably from
0.5 weight % to 3 weight % of the tablet.
Other possible ingredients include anti-oxidants, colorants, flavoring agents,
preservatives and taste-masking agents. Exemplary tablets contain up to about
80% drug, from
about 10 weight % to 25 about 90 weight % binder, from about 0 weight % to
about 85 weight
% diluent, from about 2 weight % to about 10 weight % disintegrant, and from
about 0.25
weight % to about 10 weight % lubricant.
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Tablet blends may be compressed directly or by roller to form tablets. Tablet
blends or
portions of blends may alternatively be wet-, dry-, or melt-granulated, melt
congealed, or
extruded before tableting. The final formulation may comprise one or more
layers and may be
coated or uncoated; it may even be encapsulated. The formulation of tablets is
discussed in
Pharmaceutical Dosage Forms: Tablets, Vol. 1, by H. Lieberman and L. Lachman
(Marcel
Dekker, New York, 1980).
Consumable oral films for human or veterinary use are typically pliable water-
soluble or
water-swellable thin film dosage forms which may be rapidly dissolving or
mucoadhesive and
typically comprise a conjugate as described herein, a film-forming polymer, a
binder, a solvent,
a humectant, a plasticizer, a stabilizer or emulsifier, a viscosity-modifying
agent and a solvent.
Some components of the formulation may perform more than one function.
Solid formulations for oral administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted and programmed release. Suitable modified release
formulations for the
purposes of the disaclosure are described in US Patent No.6,106,864. Details
of other suitable
release technologies such as high energy dispersions and osmotic and coated
particles are to be
found in Pharmaceutical Technology On-line, 25(2), 1-14, by Verma et al
(2001). The use of
chewing gum to achieve controlled release is described in WO 00/35298.
The conjugates described herein can also be administered directly into the
blood stream,
into muscle, or into an internal organ. Suitable means for parenteral
administration include
intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular,
intraurethral, intrasternal,
intracranial, intramuscular and subcutaneous.
Suitable devices for parenteral administration include needle (including micro-
needle)
injectors, needle-free injectors and infusion techniques. Parenteral
formulations are typically
aqueous solutions which may contain excipients such as salts, carbohydrates
and buffering
agents (preferably to a pH of from 3 to 9), but, for some applications, they
may be more
suitably formulated as a sterile non-aqueous solution or as a dried form to be
used in
conjunction with a suitable vehicle such as sterile, pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for
example, by
lyophilisation, may readily be accomplished using standard pharmaceutical
techniques well
known to those skilled in the art. The solubility of conjugates described
herein used in the
preparation of parenteral solutions may be increased by the use of appropriate
formulation
techniques, such as the incorporation of solubility-enhancing agents.
Formulations for parenteral administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
96
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
controlled-, targeted and programmed release. Thus conjugates described herein
can be
formulated as a solid, semi-solid, or thixotropic liquid for administration as
an implanted depot
providing modified release of the active compound. Examples of such
formulations include
drug-coated stents and poly(lactic-coglycolic)acid (PGLA) microspheres. The
conjugates
described herein can also be administered topically to the skin or mucosa,
that is, dermally or
transdermally. Typical formulations for this purpose include gels, hydrogels,
lotions, solutions,
creams, ointments, dusting powders, dressings, foams, films, skin patches,
wafers, implants,
sponges, fibres, bandages and microemulsions. Liposomes may also be used.
Typical carriers
include alcohol, water, mineral oil, liquid petrolatum, white petrolatum,
glycerin, polyethylene
glycol and propylene glycol. Penetration enhancers may be incorporated - see,
for example, J.
Pharm Sci, 88 (10), 955-958 by Finnin and Morgan (October 1999). Other means
of topical
administration include delivery by electroporation, iontophoresis,
phonophoresis, sonophoresis
and microneedle or needle-free (e.g. PowderjectTM, BiojectTM, etc.) injection.
Formulations for topical administration may be formulated to be immediate
and/or
modified release. Modified release formulations include delayed-, sustained-,
pulsed-,
controlled-, targeted and programmed release. The conjugates described herein
can also be
administered intranasally or by inhalation, typically in the form of a dry
powder (either alone,
as a mixture, for example, in a dry blend with lactose, or as a mixed
component particle, for
example, mixed with phospholipids, such as phosphatidylcholine) from a dry
powder inhaler or
as an aerosol spray from a pressurized container, pump, spray, atomizer
(preferably an
atomizer using electrohydrodynamics to produce a fine mist), or nebulizer,
with or without the
use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or
1,1,1,2,3,3,3-
heptafluoropropane. For intranasal use, the powder may comprise a bioadhesive
agent, for
example, chitosan or cyclodextrin. The pressurized container, pump, spray,
atomizer, or
nebulizer contains a solution or suspension of the conjugates(s) of the
present disclosure
comprising, for example, ethanol, aqueous ethanol, or a suitable alternative
agent for
dispersing, solubilizing, or extending release of the active, a propellant(s)
as solvent and an
optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic
acid. Prior to use in a
dry powder or suspension formulation, the conjugate is micronized to a size
suitable for
delivery by inhalation (typically less than 5 microns). This may be achieved
by any appropriate
comminuting method, such as spiral jet milling, fluid bed jet milling,
supercritical fluid
processing to form nanoparticles, high pressure homogenization, or spray
drying. Capsules
(made, for example, from gelatin or hydroxypropylmethylcellulose), blisters
and cartridges for
use in an inhaler or insufflator may be formulated to contain a powder mix of
the conjugate
97
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
described herein, a suitable powder base such as lactose or starch and a
performance modifier
such as Iso-leucine, mannitol, or magnesium stearate.
The lactose may be anhydrous or in the form of the monohydrate, preferably the
latter.
Other suitable excipients include dextran, glucose, maltose, sorbitol,
xylitol, fructose, sucrose
and trehalose. A typical formulation may comprise a conjugate of the present
disclosure,
propylene glycol, sterile water, ethanol and sodium chloride. Alternative
solvents which may be
used instead of propylene glycol include glycerol and polyethylene glycol.
The conjugates described here can be combined with soluble macromolecular
entities,
such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-
containing
polymers, in order to improve their solubility, dissolution rate, taste-
masking, bioavailability
and/or stability for use in any of the aforementioned modes of administration.
Drug-cyclodextrin complexes, for example, are found to be generally useful for
most
dosage forms and administration routes. Both inclusion and non-inclusion
complexes may be
used. As an alternative to direct complexation with the drug, the cyclodextrin
may be used as an
auxiliary additive, i.e. as a carrier, diluent, or solubilizer. Most commonly
used for these
purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be
found in
International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO
98/55148.
Inasmuch as it may desirable to administer a combination of active compounds,
for
example, for the purpose of treating a particular disease or condition, it is
within the scope of
the present disclosure that two or more pharmaceutical compositions, at least
one of which contains a conjugate as described herein, may conveniently be
combined in the
form of a kit suitable for co-administration of the compositions. Thus the kit
of the present
disclosure comprises two or more separate pharmaceutical compositions, at
least one of which
contains a conjugate as described herein, and means for separately retaining
said compositions,
such as a container, divided bottle, or divided foil packet. An example of
such a kit is the
familiar blister pack used for the packaging of tablets, capsules and the
like. The kit of the
present disclosure is particularly suitable for administering different dosage
forms, for example
parenteral, for administering the separate compositions at different dosage
intervals, or for
titrating the separate compositions against one another. To assist compliance,
the kit typically
comprises directions for administration and may be provided with a so-called
memory aid.
EXAMPLES
CHEMICAL EXAMPLES
It is to be understood that the conjuagtes described herein were prepared
according to
the processes described herein and/or conventional processes. Illustratively,
the stereocenters
98
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
of the conjugates described herein may be substantially pure (S), the
substantially pure (R), or
any mixture of (S) and (R) at any asymmetric carbon atom, and each may be used
in the
processes described herein. Similarly, the processes described in these
illustrative examples
may be adapted to prepare other conjuagtes described herein by carrying out
variations of the
processes described herein with routine selection of alternative starting
materials and reagents.
It is also to be understood that radicals of these examples are included in
the PBD prodrugs,
poly-PBD prodrugs, mixed PBDs, conjugates, and conjuagtes described herein.
Example: Process for preparing intermediate Proline derivatives.
0 0
\ A \ A OHCõ
0 ',. Wittig 0 ',. DIBAL ,
BocNfl ¨"'" Boc0¨ Boc0
r3 r)
0 0
r NOS r NOS
\
--J
0 '',.
deprotect
Boc0 HNO-
1. oxazolidine rNFmoc
formation \ --I
deprotect rNFmoc
y 1 \ ..-J
2. N-protection Boc0¨
HO
0 ----,"
)--- 0
rN 0 0 KiN---CNHFmoc
H 0
Boc0¨
/,,, )Ln 0
0
(3)1-0 =N)1.1,N1r-NHFmoc < .; - 0
H 0
Boc0¨ Bockil --
o
)L o o
deprotectC'N 0 0 0 H 7
_. o_i_
N
HNI. H 0 H o
Example: Process for preparing intermediate mono Fmoc-proPBD.
99
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
HO io
0 0,.0 ill
Cu(NO3)2 3H20
DIAD/Ph3P
0 CO2Me Me02C 0 0 CO2Me Ac20
02N 0 0,,.0 401 NO2 NaOH 02N 00= NO2
Pd/C/H 2
/ \
Me02C 0 0 CO2Me THF HO2C 0 0 CO2H NaOH
CyFmoc
0*---j6k
HNI.1
H2N0 0.,..õ...-..,,õõ...-...,..õ.0 so PyBOP
NH2 H2N 40 OC) 0 NH2
_...
HO2C 0 0 CO2H DMF/DCM HO2C 0 0 N
0
NFmoc
Example: Process for preparing proPBD-SN-38.
b
a
HO0 OH .õ........".........0 is
cu(NO3)2= HO....õ.õ,--,--
õ--õ,,,...0 so NO2
1,5-pentandiola
0 CO2Me DIAD/Ph3P 0 CO2Me Ac20 0
CO2Me
HO 01,5-DBP/K2CO3 NO2
acetone Br...,....õ--.õ..õ--..õ...õ.0 is Cu(NO3)2
Br..,...õ....--õõ...-...õ,õ.0
0 CO2Me 0 CO2Me Ac20 0 CO2Me
100
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
c d
HO
NOC) 0 2 Pd/C HC).0 NH2 Mitsunobu
reaction
-.... _______________________________________________________________________
7,
0 CO2Me H2 (:) CO2Me SN-38
* 0
N---N---\,.-0
N
HO \ / 4. NH2 e
___________________________________________________________ II.
0 \O
\ NMe3SnOH
0 CO2Me
0
0
onN
\----\---\,0
N * ONO ..S HO \ / F. H S N
* NH2 + H S
0 \O Ng 0
\ N CO2H
0
0
0 oil/
n
0 NH2 0 oN .r(:)1
f ..F
_,.. / \ N
PyBOP 40) q 0
Y
N 0
DIPEA 0 ()0 S N
0 I ;
10
Example. Process for preparing EC1879.
101
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
NO2 + 'N/Th N * N K2CO3/DMF
µ....../N * \
'C) CO2Me NH N 110
H OH 60 C
02N
CO2Me
1\1/
010 Li0H/RT
P
_..
V..._õN N *
NH N */C)
0 THF/Me0H/H20
H 0
02N
1\l'M CO2H
\ = N411 Pd/C
H2
NH N *
H 0
0
H2N 0
)L
CO2H OS'S,r\IC)
1\1/Th Nµ * 1\µ1 4 + 0,
'O 4N \----"N * NH N * /----/-...-/--
C)
/0
H 0 HI\11-
On'
0 Nr\jf 1
H2N %
N...Th ' 0 S
4 tl
\,...õN . N\ . N
I
NH N 110 N
H /,,,\ZO
0
/
EC1579
________ 1,- EC1 879
10
Example. Process for preparing EC1884.
102
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
H2N 0 0õ0 40 NH2r/ r--1
0, _N_ (:)s-S=0
N ,
HO2C 0 N +
0 HNi...
0 NFmoc 0
0\_. j
¨0. EC1771 ¨0- EC1884
Example. Process for preparing MC-VA-PAB linked proPBD-FmocPBD.
o
H2N NHIt...3
+
HO2C CD' =
= )--. HN NFmoc
HNI- H
0\... j
1
0
2
NH
=
0 s
,
.,.. 0 N =
....,,
*6-12IN di oz io
0 H N:- 0 0
NJ.Li.NiQN)1,1?
H
0 H
FmocN0 0
EC1911
5
Example. Processes for modification of enantiomers of proline derivatives.
It is to be further understood that the processes described herein for
particular
example conjugates are illustrative of the general processes, and each may be
adapted for
preparing other example conjugates described herein. For example, it is to be
understood that
the corresponding preparations using D-proline, L-proline, or proline of
varying optical
mixtures, including racemic proline, is also described herein. For example,
olefination and
reduction of D-proline, L-proline, or proline is described herein as follows:
103
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
O 0
OHC
O Wittig \O A. DIBAL
BocNfl BocNr1 BocNr1
O 0
\O Wittig 0 DIBAL OHC
BocN BocN __________________ Boc)-1a-
O 0
\O Wittig 0 DIBAL OHC
BocN BocNBoc
Example. Synthesis of EC2177.
NHBoc MOMCI,
DIPEA
CH2Cl2 ____________________________ 400 NHBoc NIS
Ts0H*H20 so NHBoc
THF/Me0H (1:1)11'
OH OMOM OMOM
1 EC2173 EC2174
NaH, TBAI
CI \ ra DMF
Cl Cl Cl
I
so
NBoc NBoc Bu3SnH NBoc HCI,
iPrOH, THF so AIBNH ios
toluene
80 oC
OH OMOM OMOM
EC2177 EC2176 EC2175
MOM ether EC2173 was synthesized in 58% yield following the procedure
described in Boger,
D. L.; Hughes, T. V.; Hedrick, H. P. J. Org. Chem. 2001, 66, 2207-2216. 1H NMR
(500 MHz,
CDC13): 6 8.20 - 8.09 (m, 1H), 7.74 - 7.66 (m, 1H), 7.43 (ddd, J = 8.3, 6.8,
1.3 Hz, 1H), 7.35
(ddd, J= 8.2, 6.8, 1.2 Hz, 1H), 7.05 (d, J= 2.0 Hz, 1H), 6.90 - 6.82 (m, 1H),
6.72 (s, 1H), 5.36
(s, 2H), 3.53 (s, 3H), 1.54 (s, 9H). [M+H] = Calculated 304.16, found 304.1
EC2174 was synthesized in 54% yield following the procedure described in
Boger, D. L.;
Hughes, T. V.; Hedrick, H. P. J. Org. Chem. 2001, 66, 2207-2216. 1H NMR (500
MHz,
CDC13): 6 8.21 (dd, J= 8.4, 1.3 Hz, 1H), 8.10 - 7.98 (m, 2H), 7.54 (ddd, J=
8.5, 6.8, 1.4 Hz,
1H), 7.42 (ddd, J= 8.2, 6.8, 1.1 Hz, 1H), 7.32 - 7.16 (m, 1H), 5.46 (s, 2H),
3.58 (s, 3H), 1.59 (s,
9H). [M+H] = Calculated 430.05, found 430.08
104
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Allyl chloride EC2175 was synthesized in 48% yield following the procedure
described in
Boger, D. L.; Hughes, T. V.; Hedrick, H. P. J. Org. Chem. 2001, 66, 2207-
2216.1H NMR (500
MHz, CDC13): 6 8.30 - 8.14 (m, 2H), 7.64 - 7.45 (m, 2H), 6.99 (s, 1H), 6.18 -
6.03 (m, 2H),
5.37 (s, 2H), 4.68 - 4.55 (m, 1H), 4.31 (dd, J = 15.8, 6.8 Hz, 1H), 3.53 (s,
3H), 1.35 (s, 9H).
[M+H] = Calculated 504.05, found 504.06
EC2176 was synthesized in 78% yield following the procedure described in
Boger, D. L.;
Hughes, T. V.; Hedrick, H. P. J. Org. Chem. 2001, 66, 2207-2216. 1H NMR (500
MHz,
CDC13): 6 8.29 - 8.20 (m, 1H), 7.92 (s, 1H), 7.67 (dd, J = 24.1, 8.3 Hz, 1H),
7.49 (dddd, J =
16.4, 8.3, 6.8, 1.3 Hz, 1H), 7.35 (tdd, J= 8.2, 7.5, 1.2 Hz, 1H), 5.42 (s,
2H), 4.15 (ddd, J= 22.0,
15.5, 10.1 Hz, 1H), 4.00 - 3.88 (m, 1H), 3.75 - 3.66 (m, 1H), 3.56 (d, J= 1.5
Hz, 3H), 1.63 (s,
9H). [M+H] = Calculated 378.15, found 378.15
EC2177 was synthesized in 64% yield following the procedure described in
Boger, D. L.;
Hughes, T. V.; Hedrick, H. P. J. Org. Chem. 2001, 66, 2207-2216. 1H NMR (500
MHz,
CDC13): 6 8.20 (t, J= 8.2 Hz, 1H), 7.81 (s, 1H), 7.65 (dd, J= 24.5, 8.4 Hz,
1H), 7.53 - 7.41 (m,
1H), 7.37 - 7.28 (m, 1H), 4.22 - 4.05 (m, 1H), 4.00 - 3.87 (m, 1H), 3.83 -
3.64 (m, 1H), 1.61 (d,
J= 6.3 Hz, 9H).
Cl Cl Cl
p-Nitrophenyl /
chloroformate, N-Methyl Piperazine
DIPEA
NBoc DIPEA NBoc NBoc
4040 THF 0 oC SO DMF ______ SOri\l
O
OH ONj
TO 0
8
NO2
EC2177 EC2178 EC2179
EC2178 was synthesized following the procedure described Wang, Y.; Li, L.;
Tian, Z.; Jiang,
W.; Larrick, J. W. Bioorg. Med. Chem. 2006, 14, 7854-7861. 1H NMR (500 MHz,
CDC13): 6
8.24 - 8.17 (m, 2H), 8.15 (dd, J = 9.2, 2.5 Hz, 2H), 7.49 - 7.42 (m, 2H), 7.42
- 7.34 (m, 1H),
7.28 - 7.20 (m, 1H), 4.34 - 4.18 (m, 1H), 4.15 - 4.03 (m, 1H), 3.97 (td, J =
9.2, 3.8 Hz, 1H),
3.91 - 3.82 (m, 1H), 3.53 - 3.41 (m, 1H), 3.36 - 3.23 (m, 1H), 1.56 (s, 9H).
[M+H] =
Calculated 499.12, found 499.02
EC2179 was synthesized following the procedure described in Wang, Y.; Li, L.;
Tian, Z.;
Jiang, W.; Larrick, J. W. Bioorg. Med. Chem. 2006, 14, 7854-7861. 1H NMR (500
MHz,
CDC13): 6 7.88 (s, 1H), 7.75 (d, J = 8.4 Hz, 1H), 7.57 (d, J = 8.3 Hz, 1H),
7.37 (ddd, J = 8.2,
6.7, 1.2 Hz, 1H), 7.30 - 7.22 (m, 1H), 4.23 - 4.08 (m, 1H), 4.01 (dd, J= 11.8,
8.7 Hz, 1H), 3.95
- 3.84 (m, 1H), 3.81 (dd, J= 11.1, 3.3 Hz, 1H), 3.74 (s, 2H), 3.54 (s, 2H),
3.37 (t, J= 10.7 Hz,
1H), 2.47 - 2.33 (m, 4H), 2.27 (s, 3H), 1.50 (s, 9H). [M+H] = Calculated
460.98, found 460.20
105
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
o
o/
1) 30% TFA, CH2Cl2
Cl 2) 0 Cl alk
Wr NH2
NBoc O EC2180
0 NH2 HATU, DIPEA 0
DMF rN
YN YN
0 0
EC2179 EC2189
EC2189 was prepared as described herein. 1H NMR (500 MHz, CDC13): 6 8.37 (s,
1H), 7.87 (d,
J = 8.4 Hz, 1H), 7.71 (d, J = 8.4 Hz, 1H), 7.52 (ddd, J = 8.1, 6.7, 1.2 Hz,
1H), 7.41 (ddd, J =
8.0, 6.8, 1.1 Hz, 1H), 7.06 (d, J = 1.9 Hz, 1H), 7.01 (d, J = 1.9 Hz, 1H),
4.37 - 4.18 (m, 2H),
4.06 (t, J= 6.5 Hz, 3H), 3.95 (dd, J= 11.2, 3.3 Hz, 1H), 3.86 (s, 3H), 3.85
(s, 3H), 3.69 - 3.62
(m, 2H), 3.45 (t, J= 10.9 Hz, 1H), 2.56 (dt, J= 24.1, 17.9 Hz, 6H), 2.40 (s,
3H), 1.84 (p, J= 6.9
Hz, 5H), 1.67 - 1.56 (m, 2H). [M+H] = Calculated 653.28, found 653.29
O 0 a,s
ai
-- D
0-- OH N S 0 12,E) s NH2 THF Me0H
H20= 44LIF *12 H
0 r-\ N-- 0 r---"\N___
0
NBoc
EC2189 EC2190 EC1693
1)50% TFA
2) PyBop
DIPEA
DMF
Cl Onlõ
-0 R 0 -0
NH2
0
EC2191
To ester EC2189 (72 mg, 0.11 mmol) in a THF/Me0H/H20 (3:1:1, 1m1) was added
LiOH (1.1
ml, 1.1 mmol). The reaction was allowed to stir at room temperature and
monitored by LCMS.
Upon completion the reaction mixture was acidified to pH 2 with 1M HC1 and the
volatile
solvents were removed via reduced pressure. The product was purified by low
pressure
chromatography using C18 stationary phase and eluting with H20 and
acetonitrile, followed by
lyophilization to yield the desired acid EC2190 (42 mg, 60%) as a colorless
oil. 1H NMR (500
MHz, CDC13) Pivotal signals: 6 8.31 - 8.20 (m, 1H), 7.81 - 7.72 (m, 1H), 7.66
(d, J = 8.4 Hz,
1H), 7.52 - 7.41 (m, 1H), 7.40 - 7.30 (m, 1H), 7.11 - 7.01 (m, 1H), 7.01 -
6.92 (m, 1H), 4.22
(dd, J = 23.9, 10.0 Hz, 3H), 4.07 - 3.91 (m, 4H), 3.90 - 3.81 (m, 2H), 3.78
(s, 3H). [M+Hr =
Calculated 639.26, found 639.30
106
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Boc amine EC1693 (21 mg, 44.1 [tmol) was dissolved in a 50:50 TFA:CH2C12
solution and
stirred for 30 mins. The solvent was removed in vacuo and the residue was
taken in saturated
NaHCO3 and extracted with ethyl acetate three times. The organic extracts were
combined,
dried over Na2SO4, filtered and the solvent was removed to yield the amine.
The crude amine
was dissolved in DMF (2 ml) and transferred onto acid EC2190 (18.8 mg, 29.4
[tmol) under
Argon atmosphere. To the solution were added PyBOP (33.6 mg, 64.7 [tmol),
DIPEA (31.5 jul,
0.177 mmol) and left to stir for 5 hours. Upon completion, the reaction was
diluted with water
(10m1), saturated NH4C1 (10m1) and extracted with ethyl acetate three times.
The organic
extracts were combined, dried over Na2SO4, filtered and the solvent was
removed via reduced
pressure. The product was purified using silica gel chromatography with
dichloromethane and
methanol as the eluent to yield the desired amide EC2191 (23 mg, 79%). 1H NMR
(500 MHz,
CDC13) Pivotal signals: 6 8.36 (s, 1H), 8.26 (s, 1H), 7.77 (d, J = 8.4 Hz,
1H), 7.67 - 7.50 (m,
3H), 7.43 (t, J = 7.6 Hz, 1H), 7.33 (t, J = 7.6 Hz, 1H), 7.29 - 7.20 (m, 2H),
7.07 - 6.94 (m, 1H),
6.42 (t, J= 15.6 Hz, 1H), 5.14 - 4.77 (m, 3H), 4.34 - 4.14 (m, 3H), 3.73 (s,
3H), 2.42 (s, 3H),
2.30 - 2.10 (m, 1H). [M+H] = Calculated 988.35, found 988.45
ci ci ci
NBoc NBoc NBoc
Chiral Separation se so
omom omom omom
EC2176 (R) - EC2176 (S) - EC2176
EC2176 was separated into (R)- EC2176 and (S)- EC217 using Normal phase HPLC
on Chiral
Stationary Phase was used for chiral separation of racemic EC 2176. Conditions
as follows:
Column Name: (S,S)-Whelk-01, Column Size: 250 mm x 4.6 mm, Mobile Phase:
Hexane/IPA
(70/30).
1) 30%z_TFA CH2Cl2
CI
2)
OOH CI
0 ,CI 0
NBoc õ.0 1101 EC2180o O2H
0 NI-IFyBOP DIPEA Ofik N LION
WI' NH 2 ____ = N
0 NH
OMOM DMF THF H20 Me0H
MOMO MOMO EC2257
(S)-EC2176 EC2256
1) 50% TFA
N
, I
EC16k----c)-
NBoc
PyBOP DMF
DI PEA
On
0 0 N
N
NH
momo EC2258
107
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Boc amine, (S)-EC2176 (49 mg, 0.13 mmol) was dissolved in a 30% TFA in CH2C12
solution
(5m1) at 0 C and let stir for 3 hr. LCMS was used to monitor the reaction
until complete
deprotection. The reaction mixture was quenched with saturated NaHCO3 and
extracted three
times with ethyl acetate. The organic extracts were combined, dried over
Na2SO4, filtered and
the solvent was removed under vacuum to yield the crude amine. The amine and
EC2180 (40
mg, 0.13 mmol) were dissolved in DMF (1m1) under Agron atmosphere. To the
reaction
mixture, PyBOP (134 mg, 0.26 mmol) was added followed by DIPEA (0.114 ml, 0.65
mmol)
and the reaction mixture was stirred for 5 hours. The reaction mixture was
quenched with
saturated NH4C1 and extracted three times with ethyl acetate. The organic
extracts were
combined, dried over Na2SO4, filtered, the solvent was removed under vacuum
and EC2256
was purified using silica gel chromatography to yield the desired amide (20
mg, 28%). [M+H]
= Calculated 571.21, found 571.30
Ester EC2256 (19 mg, 0.033mmol) was dissolved in a 3:1:1 mixture of
THF:H20:Me0H (1m1)
and LiOH (0.33 ml, 0.33mmol) was added. The reaction was monitored until full
conversion
was complete. The organic solvents were removed under vacuum and the crude
product was
purified by low pressure chromatography using C18 stationary phase and eluted
with H20 and
ACN. Fractions of the desired product were combined, CAN was removed, the
aqueous layer
was extracted with ethyl acetate, dried over Na2504 and concentrated to yield
acid EC2257
(17.5 mg, 94%). [M+H] = Calculated 558.03, found 557.31
Boc amine, EC1693 (19 mg, 0.04 mmol) was dissolved in a 50% TFA in CH2C12
solution (5m1)
at 0 C and stirred for 3 hr. LCMS was used to monitor the reaction until
deprotection was
complete. The reaction mixture was quneched with saturated NaHCO3 and
extracted three times
with ethyl acetate. The organic extracts were combined, dried over Na2504,
filtered and the
solvent was removed under vacuum to yield the crude amine. The amine and
EC2257 (17.5 mg,
0.03 mmol) were dissolved in DMF (1m1) under Argon atmosphere. To the reaction
mixture,
PyBOP (36 mg, 0.07 mmol) was added followed by DIPEA (0.033 ml, 0.19 mmol),
and the
reaction mixture was stirred for 5 hours. The reaction mixture was quenched
with saturated
NH4C1 and extracted three times with ethyl acetate. The organic extracts were
combined, dried
over Na2504, filtered, the solvent was removed under vacuum and the crude
product was
purified using silica gel chromatography to yield the desired amide EC2258 (22
mg, 77%).
[M+H]+ = Calculated 906.29, found 906.47
108
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
)
002H 002H
)
0 c02H li,
i = ,1 _ cc _ hi-,1 _ hi
H H),'," IND-11
2N N )'NH 0 NH 0
NH MOMO
0 04
EC1579
Cl' 0 CI
HO HO HO DIPEA
OH HO HO
1N0/
DMSHO 002H r2F1
0 cO2H N 0 / H 0 / N 0 CO2H 0 z
0 r.,.....PAirN,,AryNsõ,11. ry- N,,LL,1,1,...S,_0)\11 713
0
riN H1j.IIVI NrN 0 riN 0 NH ),
(G1 0 NH
Or'3'''S'S HN tµ 2
fiks, Nr----0
momo HO HO HO
OH HO HO
EC2258
EC2259
EC2259: Disulfide EC2258 (15mg, 0.017 mmol) and the folate spacer EC1579 (36.6
mg,
0.022 mmol) were dissolved in anhydrous DMSO under argon. DIPEA (18 [1.1, 0.1
mmol) was
added to the reaction mixture and stirred for 2 hours. The crude product was
purified by low
pressure chromatography using C18 stationary phase and eluted with Ph7 buffer
and
acetonitrile, followed by lyophilization to produce conjugate EC2259 (12.4 mg,
30%). [M+H]
= Calculated 2473.89, 1237.94, found 1238.19
momo
O..
Cl
H2N Illp
T21-I ?02H 0 'CN
0 CO2H H 0 ---..H 0 '-"HOCO2H 0
0N,A NN)L N,.)L S
I. 10( 1 1111 . INror . H s-7-. \¨/
HN)tfrN
I , H
H2N N N 0 NH 0 NH 0 NH
1...,12,0:1 [L;H) LI õ:),H1
EC2259
HO"
OH He õOH
HO HO HO
OH HO HO
HO
Conc. HCI H20
0 00100
0 CI
0
TO2H CO2
H 1,...:1\1
0 (:)2H H 0 õ--,H0rH 0 ,02H 0 0
0 N.,...), N.,J.L. .....,,s >Le-0
40 or rI
HN)LXN-r.'N
H2N N N 0 NH ) )
NH - NH
LIN)....1 EC2288
,,OH .õOH .,,OH
OH Floss, õOH
HO HO HO
OH HO HO
109
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
EC2259 (7 mg, 2.83 [tmol) was dissolved in DI H2O (3m1) with the addition of
conc. HC1 (6
drops). The reaction was monitored until deprotection was complete and the
product purified by
low pressure chromatography using C18 stationary phase and eluted with H20 and
acetonitrile,
followed by lyophilization to yield the desired conjugate EC2288 (5.5 mg,
80%). [M+H] =
Calculated 2429.86, 1215.93, found 1215.88
HO Ail DIAD/Ph3P a C'/.\/\.ip r& 02N 0,õ,-.............-
^,,õõ0 is No2
_ _
0 w CO2Me Me02C Ill'illIF 0 0 IW CO2Me Me02C "IP
0 0 CO2Me
EC1624 EC1686
02N0.,............-...,.,,0 Ali NO2 H2N An 0,...............-..õ.0
NH2
0
-.. -*.
HO2C 0 0 IW CO2H HO2C "1111 0 0 IW CO2H
EC1687 EC1709
Methyl vanillate (2.18g, 11.98 mmol) and Ph3P (4.71 g, 17.97 mmol) in THF (20
mL) was
cooled to 0 C and to which was added DIAD (2.59 mL, 13.18 mmol) dropwise. The
reaction
was stirred at 0 C for 1 hr. 1,5-petanediol (0.6 mL, 5.75 mmol) in THF (20 mL)
was added
over 30 min. The reaction was stirred overnight and prESIpitate formed and was
collected with
filtration. The filtrate was concentrated to form more solid. The solid was
combined and
triturated with Me0H (5 mL) to give qite clean product EC1624 1.74 g in yield
of 70%. 1H
NMR (CDC13, 6 in ppm): 7.66(m 2H), 7.62(m, 2H), 6.87(m, 2H), 4.10(m, 4H),
3.89(m, 12H),
1.95(m, 4H), 1.69(m, 2H). 13C NMR: 166.88, 152.50, 148.86, 132.12, 132.04,
131.88, 128.52,
128.42, 123.50, 122.55, 112.35, 111.46, 68.67, 56.03, 51.93, 28.73, 22.52,
21.92.
EC1624 (201.2 mg, 0.465 mmol) in Ac20 (1.2 mL) was cooled to 0 C and then
Cu(NO3)2.3H20 (280.3 mg, 1.16 mmol) was added slowly and after 1 hr, the ice-
bath was
removed. The reaction was stirred at r.t. for 4 hrs. The reaction was poured
into ice water and
stirred for 1 h till yellow precipitate formed and was collected with
filtration. The solid was
washed with more cold water (2 mL, 3 x) and air-dried. 198.4 mg of EC1686 was
obtained in
yield of 82%. LCMS: [M+NH4]+ m/z =540.
EC1686 (198.4 mg) was dissolved in THF (2 mL) and treated with aq. NaOH (2 mL,
1 M) and
heated to 40 C for 3 hrs. The solvent was removed in vacuo. The aqueous phase
was acidified
to pH 1 with concentrated HC1 to form precipitate, which was collected by
filtration and was
washed with H20 (1 mL, 3 x). The solid was air-dried to give the acid 187.7 mg
of EC1687 in
quantitative yield. LCMS: [M+NH4]+ m/z =512.
Acid EC1687 was dissolved in 0.5 M aq. NaOH (6 mL) and hydrogenation was
carried out
with Pd/C (10%, 4.82 mg) under H2 (45 PSI) in the hydrogenation parr. The
reaction was
110
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
shook for 5 hrs and the filtered through a pad of celite and the filtrate was
adjusted to pH 2-3
with concentrated HC1 while stirring. The formed precipitate was isolated by
filtration and
washed with H2O (1 mL, 3 x). The solid was dried in a desiccator with the
presence of P2O5
under high vacuum overnight. EC1709 was obtained 34.2 mg as a brown solid in
the yield of
81%. LCMS: [M-H] m/z =433.
Crmoc
Me02C,,. Me02Cõ.
Bocr\fl BocN BocN
Boc0¨
EC1692 EC1768
(S)-1-tert-butyl 2-methyl 4-oxopyrrolidine-1,2-dicarboxylate was converted to
EC1692 by
Wittig reaction: Ph3PCH3Br (917.8 mg, 2.57 mmol) in THF (30 mL) was treated
with KO'Bu (1
M in THF, 2.57 [IL, 2.57 mmol) at 0 C by dropwise addition. The reaction was
kept at room
temperature for 2 hrs. Into the stirred solution was added the ketone (250 mg,
1.028 mmol) in
THF 20 mL) at 0-10 C. The reaction was then stirred at room temperature for
onvernight. The
reaction was quenched with H20/Et0Ac (1:1, 40 mL) after most of the THF was
removed in
vacuo. The aq. phase was extracted with Et0Ac (20 mL, 3 x) and the organic
phase was washed
with H20, followed by brine, and dried over anhydrous Na2SO4 and concentrated.
The residue
was purified with CombiFlash in 0-50% Et0Ac/p-ether to afford the EC1692 77.2
mg, in yield
of 31%. LCMS: [M-Boc+F1]+ m/z =142.
(S)-1-tert-butyl 2-methyl 4-methylenepyrrolidine-1,2-dicarboxylate (353.2 mg,
1.46 mmol) in
DCM/toluene (1:3, 9.8 mL) was treated with Dibal (1 M in toluene, 2 eq, 2.92
mmol) dropwise
at -78 C under argon. The reaction was stirred at -78 C for ca. 4hrs. Then the
reaction was
quenched with addition of 60 [IL of Me0H at -78 C followed by 5% HC1 (.5 mL)
and Et0Ac
(18 mL). The cold bath was removed and the reaction was stirred for 30 min.
The Et0Ac layer
was separated and washed with brine, dried over anhydrous Na2504 and
concentrated to give
the crude aldehyde intermediate.
The crude aldehyde was redissolved in dry DCM (10 mL) and treated with
ethanolamine (106
[IL, 1.75 mmol) in the presence of anhydrous Mg504 (5 mmol, mg) at r.t. (room
temperature)
under Ar. The reaction was stirred for 1 hr. Then into this reaction mixture
was added FmocC1
(755.4 mg, 2.92 mmol) and TEA (611 [IL, 4.38 mmol) and the reaction was
stirred for
overnight at r.t. under Ar. The reaction was purified with CombiFlash in 0-50%
Et0Ac/petroleum ether to provide EC1768 334.2 mg, 46% for 3 steps. LCMS: [M+H]
m/z
=477. 1H NMR (CD30D, 6 in ppm):7.81(d, J=7.5Hz, 2H), 7.60(d, J=7Hz, 2H),
7.40(m, 2H),
111
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
7.32(m, 2H), 4.96(br, 2H), 4.60(br,1H), 4.23(t, J=5.5 Hz, 1H), 3.97(br, 2H),
3.73(br, m, 3H),
2.50(br, 2H), 1.47(s, 1H), 1.39(s, 9H).
croc (roc
EC1768 EC1769
EC1768 was deprotected in TFA/DCM (1:1) at r.t. for 30 min, the solvent was
removed in
vacuo. The product (EC1769) was used for the coupling reaction with EC1709
without further
purification. LCMS: [M+H] m/z =377.
o-
-
oNH2
40 401
NH2
¨0
HO2C N .õC()--)
¨
H02C 0 CO2H NH2
NH2 Pmoc
EC1709 EC1770
C) OH
40 N¨._s,
H020 w 0 iw
O2C
H 0 IW
NH2 0 NH2 0
EC2170
EC1709 (42.0 mg, 0.097 mmol), EC1769 (0.053 mmol), and PyBOP (29.0 mg, 0.056
mmol)
were dissolved in DMF/DCM (0.5 mL/0.5 mL) and treated with DIPEA (74 [IL, 0.43
mmol) at
r.t. under Ar. The reaction was completed within lhr, then loaded onto
CombiFlash column in
0-20% Me0H/DCM to afford the pure product EC1770 (25.5 mg, 60%). LCMS: [M+H]
m/z
=793. 1H NMR (CD30D, 6 in ppm):
EC1770 (25.5 mg, 0.032 mmol) was dissolved in DCM (1 mL) was treated with
diethylamine
(DEA, 83.5 [IL, 0.80 mmol) at r.t. under Ar. The reaction was stirred for
2hrs, and then the
solvent was removed in vacuo. This immine was redissolved in DCM (0.3 mL) and
absolute
ethanol (0.6 mL) and cooled to 0 C. To this cooled solution was added NaBH4
(1.33 mg,
0.0352 mmol) and the reaction was stirred for 5 min at 0 C then the ice bath
was removed. The
reaction was stirred at r.t. for 2 hrs. After Et0H was removed, the reaction
mixture was purified
with CombiFlash in 0-15% Me0H/DCM to afford 9.9 mg of EC2170 (yield 60% for 2
steps).
LCMS: [M-H] m/z =510. 1H NMR (CD30D, 6 in ppm): 7..41 (s, 1H), 7.31 (s, 1H),
6.32(s, 1H),
6.26(s, 1H), 5.07(m, 2H), 4.27(m, 2H), 4.00(q, J=7Hz, 4H), 3.75(s, 3H),
3.73(s, 3H), 3.57(dd,
J=1.5, 13 Hz, 1H), 2.98(m, 1H), 2.49(m, 1H), 1.88(m, 4H), 1.68(m, 2H).
112
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0o
Me02Cõ,
BocNT1- N Bock.j- c 0
EC1692 BocNr1
EC1693 EC2186
EC1693 was synthesized by the same methods as EC1768. LCMS: [M+H] m/z =468. 1H
NMR
(CDC13, 6 in ppm): 8.47(d, J= 5Hz, 1H), 7.66(m, 2H), 7.09(m, 1H), 5.16(br,
1H), 4.97(br, 2H),
4.38(br, 3H), 4.05(br, 2H), 3.85(br, 3H), 3.20(m, 1H), 3.06(br, 2H), 2.85(br,
1H), 2.52(m, 1H),
1.55(s, 3H), 1.43(s, 9H).
EC2186 was synthesized by the same methods as EC1769. LCMS: [M+H] m/z =368.
0 H00
NrKo, PY,s,S10 io
HO glir
0 NH2 0HNI 0 N--"\ 0 NH2
0
L..")
EC2170 EC2186 EC2181
EC2181: Acid EC2170 (4.95 mg, 0.0097 mmol) was dissolved in dry DMF (0.5 mL)
and was
treated with PyBOP (10.1 mg, 0.0194 mmol). To the reaction mixture was added
the solution of
EC2186 (0.01 mmol, from 4.76 mg of EC1693) and DIPEA (30 [IL, 0.17 mmol) in
DCM (0.5
mL). The reaction was stirred for 5 hrs and was purified with prep-HPLC in 10-
100%
MeCN/pH7 buffer to give pure EC2181 2.3 mg (30% in yield). LCMS: [M+H] m/z
=861. 1H
NMR (CD30D, 6 in ppm):8.37(s, 1H), 7.77(m, 2H), 7.40(s, 1H), 7.19(s, 1H),
6.42(s, 1H),
6.26(s, 1H), 5.07(m, 4H), 5.01(s, 1H), 4.56(d, J=1Hz, 1H), 4.20(m, 6H),
4.01(m, 7H), 3.75(s,
3H), 3.73(s, 3H), 3.67(d, J=11Hz, 2H), 3.44(m, 4H), 3.13(br, 2H), 3.05(m, 1H),
2.50(,3H),
2.48(m, 2H), 1.85(m, 3H)1.26(m, 4H).
CO2H CO2H
) )
0 g021-1 0, r r ri CO2H
Hy,) =
H2N N N 0 NH 0 NH 0 NH
0 NH2SOH OH SOH OH CO
EC1579OH ' EC2181
HO HO HO
OH HO HO
CO2H CO2H
) )
0 CO2H H O ,O i02Hs_s
0
4110H
b
H2N N 0 NH 0 NH 0 NH (DIN --'k 0
NH2 0
ssOH .,OH õOH Li
EC2182
HO HO HO
OH HO HO
113
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
EC1579 (8.7 mg, 0.0052 mmol) in DMSO (0.5 mL) under Ar was stirred to a clear
solution the
solution of EC2181 (3.7 mg, 0.0043 mmol) in DMSO (0.5 mL) was added and
followed by
addition of TEA (3.6 [t.L, 0.026 mmol). The reaction was stirred for 1 hr at
r.t. under Ar. The
product was isolated with prep-HPLC in 10-100% MeCN/pH 7 buffer to give EC2182
6.5 mg
(62% in yield) as a solid after lyophilized. LCMS: [M+31-1]3+ m/z =810. 1H NMR
(9:1 DMSO-
d6:D20, 6 in ppm): 8.53 (s, 1H), 7.55 (d, J=8Hz, 2H), 7.21 (s, 1H), 6.60 (d, J
= 7.5Hz, 3H),
6.29 (s, 1H), 6.22 (s, 1H), 4.97 (s, 2H), 4.91 (s, 1H), 4.45 (s, 3H).
0
OH 0
OH
H3C0 io H3C0 40 0 WI
Cu(NO3)2 3H20
WI
CH3S020H H3co 410 Pd/C, H2
= H3C0
Ac20
CH, CI, Et0H
0 0 NO, 0 NO2 0 NH2
EC2093 EC1882
EC2038
Methyl-4-Benzyloxy-3-methoxy Benzoate (5.00 g, 18.4 mmol) was dissolved in
Ac20 (23.5
mL) and cooled to 0 C. Cu(NO3)2 (5.05g, 27.0 mmol) was added in small portions
over 10
minutes. After 90 min, LCMS indicated product formation. The mixture was
poured into ice-
water and stirred for 45 minutes. Crude product was recovered by
centrifugation, rinsed with
water, and dried. The crude product was purified via silica-gel chromatography
on a
Combiflash system using a petroleum ether/ethyl acetate gradient. 5.80g (99%),
off-white
solid. 1H NMR (CD30D, 6 in ppm): 7.62 (s, 1H), 7.45 (d, 2H), 7.40 (t, 2H),
7.35 (m, 1H), 7.25
(s, 1H), 5.20 (s, 2H), 3.95 (s, 3H), 3.90 (s, 3H). MS (ESI-QMS): m/z = 318.03
(M+H).
EC2093 (5.80 g, 18.2 mmol) was dissolved in CH2C12 (10 mL). A mixture of 2.5
mL CH2C12
and 2.5 mL of CH3S020H was added and the mixture stirred. After 3 hours, LCMS
indicated
product formation. The solvent was removed and the product was purified via
silica-gel
chromatography on a Combiflash system using a CH2C12 / CH3OH gradient to
provide EC1882
3.46g (84%), as off-white solid. 1H NMR (CD30D, 6 in ppm): 7.35 (s, 1H), 7.2
(s, 1H), 3.95 (s,
3H), 3.90 (s, 3H). MS (ESI-QMS): m/z = 225.78 (M-H).
EC1882 (1.0331 g, 4.55 mmol) was dissolved in ethanol (200 proof, 70 mL). Pd/C
(10%, 200
mg) was added. The reaction flask was evacuated and backfilled with H2 three
times. H2 was
applied by balloon for 3 hours, at which point the flask was evacuated and
backfilled with air
three times. Celite was added and the product filtered through with ethanol
and concentrated.
Typical yield 781.0 mg, 90% recovery, brown solid. 1H NMR (CD30D, 6 in ppm):
7.25 (s,
1H), 6.20 (s, 1H), 3.85 (s, 3H), 3.80 (s, 3H). MS (ESI): m/z = 196.23 (M-H).
114
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
N
L/N,c-JH
HO ip
1 5-DBP/K2CO, BrO Cu(N00)2 BrO
NO2 OH
CO2Me Ae20 4111" CO2Me K2CO2/DMF
EC1852 60 C
EC1851
02N
,N N LiON/RT N N CO2H
* Pd/C
Ns. H \ THF/Me0H/H20- IS H .22/2-
'0 H2
/0
EC1859 major product EC1863
H2N 002H OFA--1{2-
S'S
NI, = N * H2N:ILq
0
/0
/0 --- /-, NNI õEN
H /110 /0
EC1870
EC1869
The phenol compound (2.2044g, 12.1 mmol) was dissolved in acetone (dried
through a pad of
Na2SO4, 48.4 mL) and to this solution was added 1,5-dibromopentane (49.4 mL,
36.3 mmol)
and K2CO3 (6.69 g, 48.4 mmol). The reaction was heated to reflux under Ar for
6 hrs. The
reaction was cooled to RT and the solid was filtered out. The filtrate was
concentrated and
purified with CombiFlash in 0-30% Et0Ac/p-ether to obtained EC1851 (3.3893 g,
yield
84.5%) as a solid. LCMS: [M+H] m/z =331. 1H NMR (CDC13, 6 in ppm): 7.65 (dd, J
= 8.5, 2.0
Hz, 1H), 7.54 (d, J = 2.0 Hz, 1H), 6.86 (d, J = 8.50 Hz, 1H), 4.08 (t, J =
6.50 Hz, 2H), 3.91 (s,
3H), 3.89 (s, 3H), 3.44 (t, J = 6.5 Hz, 2H), 1.95 (m, 4H), 1.65 (m, 2H).
EC1851 (3.3893 g, 10.23 mmol) in Ac20 (52 mL) was cooled to 0 C and treated
with
Cu(NO3)3H20 (2.967 g, 12.28 mmol) by slow addition. The reaction was stirred
at 0 C for 1 hr
then at RT for 2 hrs. After the reaction was completed, the reaction mixture
was poured into ice
water and stirred for 1 hr. The resultant precipitate was collected by
filtration. The product was
washed with water (3 x) and air-dried as EC1852 (3.7097 g, yield 96%). LCMS:
[M+H] m/z
=376. 1H NMR (CDC13, 6 in ppm): 7.41 (s, 1H), 7.05 (s, 1H), 4.08 (t, J = 6.50
Hz, 2H), 3.94 (s,
3H), 3.89 (s, 3H), 3.42 (t, J = 7.0 Hz, 2H), 1.93 (m, 4H), 1.63 (m, 2H).
The solution of EC1852 (37.6 mg, 0.1 mmol) and Hochest dye (53.3 mg, 0.1 mmol)
in DMF
(1.5 mL) under Ar was treated with K2CO3 at rt. The reaction was heated to 60
C and kept for
overnight. Then the reaction was cooled to rt and the solid was filtered out.
The residue was
purified with Prep-HPLC (Mobile phase A: 50 mM NH4HCO3 buffer, pH 7.0; B =
ACN.
Method: 10-100 B% in 30 min.) to afford EC1859 (13.1 mg, yield 18%). LCMS:
[M+H] m/z
=720.71.
EC1859 (13.1 mg, 0.0182 mmol) was dissolved in THF/Me0H/H20 (3/1/1, 0.2 mL)
and
treated with aq. LiOH solution (1 M, 36 [1.L) for 4 hrs at rt under Ar. Most
of the solvent was
removed in vacuo and the aqueous phase was acidified with concentrated HC1 to
pH 2-3, the
115
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
precipitate was collected as solid (EC1863, 12.8 mg, without purification) by
filtration. The
filtrate was washed with water (3 x) and air dried for the next step. LCMS:
[M+H] m/z = 706.
EC1863 (15.7 mg, 0.022 mmol) in Me0H (10 mL) was subjected to hydrogenation in
a Parr
shaker (10% wet Pd/C, 5% wt, 7.85 mg, H2 41 PSI) for 2 hrs. The product was
isolated by
filtration through a pad of celite. The solvent was removed in vacuo to give
crude EC1870,
LCMS: [M+H] m/z = 676.79. The crude product in DMF (0.5 mL) was mixed with the
solution of EC2186 (8.81 mg, 0.024 mmol) in DCM (2.0 mL). The reaction mixture
was treated
with PyBOP (20.8 mg, 0.04 mmol) and DIPEA (13.9 uL, 0.08 mmol) under Ar at rt.
The
reaction was stirred for overnight and then purified with Prep-HPLC (Mobile
phase A: 50 mM
NH4HCO3 buffer, pH 7.0; B = ACN. Method: 10-100 B% in 30 min.) to afford 17.4
mg
EC1869 in the yield of 85% for the two steps. LCMS: [M+H] m/z =1025.9. 1H NMR
(CD30D, 6 in ppm, selected data): 8.36 (s, 1H), 8.25 (d, J = 1.0 Hz, 1H), 8.03
(m, 2H), 7.96 (m,
1H), 7.77 (m, 3H), 7.69 (d, J = 8.5 Hz, 1H), 7.52 (d, J = 9.0 Hz, 1H), 7.16
(m, 2H), 7.06 (m,
4H), 6.43 (m, 1H).
CO2H
702H
0/ 0 CO2H H 0 "..... H 0 r'' 0
CO2H
C) 4 HN illit 0 di rr--------for-N-Arry,k.N---yrt,sH
0,-s-s b e . , mi... N,õ + HN-kiNrN,
N N--- H261).'N N 0.... NH 0 H 1NH 0 ),
NH
ciI,N....fs, 0 NH2 \----"
Li0
EC1869 1.,t;1
L
HO 1 HO1
I:i
HO')
1OH I,,cill
HO
OH HO
HO
i
702H TO21-1 0"0....//---/O ti HN
0 go2e HO ---..%0 '' OC.20H
N * 'NI
0 40 oo t\N 110
H2611.-i N tlINNrN C)
NH s*NH ::)).'NH 1 ....k, 0 NH2
c?--NL2
L..1...
õOH õOH õOH
EC1879
HO' 'C)1-1 µ HO" µµC)H
HO)) HO HO
OH HO HO
EC1579 (10.24 mg, 0.006 mmol) was dissolved in DMSO (0.3 mL) and water (0.2
mL) and
bubbled with Ar at rt in an amber vial. To this solution was added a solution
of EC1869 (5.0
mg, 0.0049 mmol) in DMSO (0.2 mL) and followed by addition of DIPEA (5.1 [IL,
0.029
mmol). The reaction was stirred at rt under Ar for 30 min. The reaction was
purified with prep-
HPLC (10 to 100% ACN in 50 mM NH4HCO3, pH 7.4) to give the conjugate EC1879
(3.9 mg,
30% yield). LCMS: [M+2I-1]2+ m/z = 1297, [M+3I-1]3+ m/z = 865.
is H OH 0 moc
Frnoc-CI Na2CO3 N (I) N 0
OH
H N
H2:10H ______ FmocHN'IrEN1j'OH _____ 2 FiNH'":"")4'
Dioxane-water 0 H
0 E 0 E EEDQ
DCM Me0H EC1930
116
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
To a solution of Val-Ala-OH (1 g, 5.31 mM) in water (40 ml) was added Na2CO3
(1.42 g,
13.28 mM) and cooled to 0 C before dioxane (40 mL) was added. A solution of
Fmoc-Cl (1.44
g, 5.58 mM) in dioxane (40 mL) was added dropwise over 10 min at 0 C. The
reaction mixture
was stirred at 0 C for 2h. Then the reaction mixture was allowed to stir at RT
for 16 h. Dioxane
was removed under vacuum, the reaction mixture diluted with water (450 mL), pH
was adjusted
to 2 using 1N HC1 and extracted with Et0Ac (3 x 250 mL). The combined organic
layers were
washed with brine, dried over MgSO4, filtered, concentrated under reduced
pressure and dried
to yield Fmoc-Val-Ala-OH. This product was suspended in dry DCM (25 ml), PABA
(0.785 g,
6.38 mM) and EEDQ (1.971 g, 7.97mM) were added. The resulting mixture was
treated under
Argon with methanol until a clear solution was obtained. The reaction was
stirred overnight and
filtered. The filtrate was washed with diethyl ether (4x) and dried under high
vacum to yield
EC1930 (1.85 g, 68%). 1H NMR (500 MHz, CD30D): 5 7.79 (d, Ji= 8.0 Hz, 2H),
7.65 (t, Ji=
7.0 Hz, .12= 7.5 Hz, 2H), 7.54 (d, Ji= 8.0 Hz, 2H), 7.38 (t, Ji= 7.5 Hz, .12=
7.5 Hz, 2H), 7.33-
7.24 (m, 4H), 4.54 (s, 2H), 4.48 (q, J1= 14.0 Hz, .12= 7.0 Hz, 1H), 4.42-4.32
(m, 2H), 4.22 (t,
J1= 7.0 Hz, .12= 6.5 Hz, 1H), 3.94 (d, J1= 7.0 Hz, 1H), 2.07 (m, 1H), 1.43 (d,
Ji= 7.5 Hz, 3H),
0.97 (d, J1= 7.0 Hz, 3H), 0.95 (d, J1= 7.0 Hz, 3H); LCMS (ESI): (M + H) =
Calculated for
C30H33N305, 516.24; found 516.24
ome LIBH4 Doss-Martin
OH H N'Boc
THF N Py , DCM
Boo 0
Boo Boc HN
EC2404 EC2405
To a mixture of 1-(tert-butyl) 2-methyl (S)-4-methylenepyrrolidine-1,2-
dicarboxylate (0.5 g,
2.07 mmol) in THF (10 mL) was added LiBH4 (67.7 mg, 3.11 mmol) in portions at
0 C under
argon. The mixture was allowed to warm to room temperature over 2.5 hours. It
was cooled to
0 C and quenched with H20. The mixture was extracted with Et0Ac (3x30 mL) and
the organic
phase was washed with H20, brine sequentially and dried over anhydrous Mg504.
It was
filtered and concentrated in vacuo. The crude product EC2404 was used in next
step without
further purification.
To a mixture of EC2404 and pyridine (0.84 ml, 10.35 mmol) in dichloromethane
(8 ml) was
added Dess-Martin periodinane (1.2 g, 2.90 mmol) at 0 C. It was stirred at
room temperature
for 2 hours. The crude product was purified with CombiFlash in 0-40% Et0Ac/p-
ether to afford
0.26 g of EC2405 in 59.3 % yield. 1H NMR (500 MHz, CDC13) (rotamers): 6 9.56
and 9.49 (s,
1H), 5.03 (m, 2H), 4.35-4.20 (m, 1H), 4.13-4.02 (m, 2H), 2.86-2.71 (m, 1H),
2.67-2.64 (m, 1H),
1.49 and 1.44 (s, 9H).
117
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
A mixture of EC2405 (42.7 mg, 0.20 mmol), 2-aminoethan-1-ol (12.8 01, 0.21
mmol) and
molecular sieves in toluene (1 ml) was stirred at room temperature for 1.5
hours to generate the
tert-butyl (2S)-4-methylene-2-(oxazolidin-2-yl)pyrrolidine-1-carboxylate in
situ.
0 ¨
411 Hphosgene, THF, py, -78 C 0)LCI
FmocHIN
0 H H
0 -
EC1930
___________________________________________________________ FmocHNT'Fick =
ethanolamine
0 H
EC2076 01
\.õ..NBoc MgSO4, DCM NBoc
The proline derived aldehyde (550 mg, 2.6 mmol) was dissolved in DCM (10 mL),
MgSO4 (3
g) was added followed by dropwise addition of ethanolamine (0.16 mL, 2.6 mmol)
in DCM (10
mL) and was added to the EC2405 mixture. The reaction was stirred at rt for 1
hr. Filtration and
concentration under vacuum gave the oxazoline intermediate. In another flask,
EC1930 (516
mg, 1.0 mmol) was dissolved in THF (40 mL) and pyridine was added (0.8 mL, 10
mmol). The
solution was cooled to -78 C, and diphosgene (0.16 mL, 1.5 mmol) was added.
The reaction
was stirred at -78 C for lh, DCM (20 mL) and a solution of oxazolidine
intermediate was
added dropwise. The reaction mixture was allowed to warm to -20 C over
several hours. LC-
MS and TLC showed product formation. The reaction mixture was concentrated
with silica gel
and purified by flash chromatography (120 gold Redisep column, 0-100% Et0Ac in
petroleum
ether) to give EC2076 (0.59 g, 74%). LCMS (ESI): (M + H) = Calculated for
C44H53N509,
796.38; found 796.74.
FmocH1:1)LN CµA FmociN'fireC-.1LN = -.N1.1):::
0 H TFA 0 H
NBoc
EC2076
0/
HN
HO IP =Hunig's base
HATU, DMF
0 NH 2 EC1870
V
03L-N/
0 Al
- H
O
=\ 40
FmocHN 0 0 NH2
N
EC2078 Chemical Formula:
C7,H24N,20,
Exact Mass: 1352.64
Molecular Weight: 1353.56
EC2076 (101.0 mg, 0.127 mmol) was stirred in TFA/DCM (0.5 mL each) at rt for
30min. LC-
MS showed complete removal of Boc group. The reaction mixture was concentrated
under high
vacuum to remove TFA and DCM, re-dissolved in DMF (1.0 mL), and adjusted pH to
8-9 by
adding Hunig's base (0.3 mL). EC1870 (86.0 mg, 0.127 mmol) was added, followed
by PyBoP
(84 mg, 0.16 mmol) and the reaction was stirred at rt for 2h. LC-MS at 90min
showed that the
118
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
major peak had the desired product. The reaction mixture was loaded onto a
silica gel cartridge
and purified by flash chromatography (12g gold, 0-30% Me0H/DCM) to give
desired product,
EC2078 (140 mg, 81%). LCMS (ESI): (M + H) = Calculated for C77H84N12011,
1353.64;
found 1354.18.
e
a Ai
li,)LN ww
9
FmocH -, 0 0, 40
H 0 0
0 N
N
l 1 H FIV
_..,:c=---..}...N.--,...,0,----Ø2-...,02.,.-2.00,?
0
0 - I
0 NH2 \ H
EC2078 N.1--111111. N.."21 0
MP-tetra-EG-0Su
DEA, DCM
O NI
0
_.ICIFNio,..).LEUN 0 ,___-) 0-
,
H 0i H
--1 1110 (\-----X----"\--0
0
H2N *
1 H
EC2079 Chemical Formula:
C801-100N14017
Exact Mass: 1528.74 N = \ N
Molecular Weight: 1529.73 N
,,,,,
cN
\--
EC2078 (140 mg, 0.10 mmol) was dissolved in DEA/DCM (12/18 mL) and stirred at
rt for
30min. LC-MS showed complete removal of Fmoc group. The reaction mixture was
concentrated under high vacuum to remove excess diethylamine and re-dissolved
in DCM (5
mL). MP-tetra-EG-Osu (62 mg, 0.12 mmol) was added and the reaction was stirred
at rt for 1
hr. The reaction mixture was concentrated, redissolved in DMSO and loaded
directly to HPLC
column and purified by preparative HPLC (C18 column, 5-80% ACN/pH7 buffer)
giving
desired product EC2079 (55.8 mg, 36%). LCMS: [M+2I-1]2+ m/z = Calculated for
C80H1001\114017, 765.37; found 765.74.
H027 HC::,C, 02H 0
)1-
N-615o,
HN)LiNfN EC2079
bN'k''N N
EC1579
011 I DMSO, DIPEA
-,1q4-" =--' \ -- 0
roo 2c H02,c, 2H
r.....A.A,,.....õ......,0õAxiAJ--016 . scY
o
d-HA2'rcef ' ' H 0 H N.0- 0
H2N1,',5c:NrN .= H N. "
;OH .1 H EC2080 NTh
Exam Mem 920719
MolecJer Weight 9209.90
H H
EC1579 (9.85 mg, 0.006 mmol) was stirred in DMSO (2 mL) until dissolved. DIPEA
(50 uL)
was added, followed by EC2079 (6.24 mg, 0.004 mmol) in DMSO (2 mL). The
reaction was
stirred at RT for 50min. LC-MS analysis at 10 min showed complete conversion.
The reaction
mixture was directly loaded on a prep-HPLC column and purified (10-100%
MeCN/Ammonium bicarbonate, pH 7 buffer) to give desired product EC2080 (5.5
mg,
119
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
42%).1H NMR (500 MHz, DMSO-D6 + D20) (selected data): 5 8.60 (s, 1H), 8.44-
8.08 (m*,
1H), 8.07 (d, J=8.5 Hz, 2H), 8.06-7.84 (m*, 2H), 7.80-7.57 (m*, 2H), 7.57 (d,
J=8 Hz, 2H),
7.51 (d, J=6.5 Hz, 2H), 7.44 (m*, 1H), 7.22 (m*, 2H), 7.08 (d, J=8 Hz, 2H),
6.93 (d, J=8.5 Hz,
1H), 6.60 (d, J=8.5 Hz, 2H), 6.33 (s, 1H), 4.95 (m*, 4H), 4.45 (m*, 3H); LCMS:
[M+41-1]4+ m/z
= Calculated for C145H198N30051S, 803.34; found 803.80.
* Due to diasteromeric and/or rotameric nature of the compound
OH 51, OH OTBDPS OTBDPS OTBDPS OTBDPS
CI TBDPSCI L BHq Dees Et0H CH(OEt), TBAF
o DI3N OoO Alloc D.,THF AllocDCM P-
EC2234 EC2235 EC2236 EC2237 EC2238
OH 0
0. Ph PCH Brlyl chloride N, S 3 SCCI2 NH NeH
Ns¨s- N
Alloc CMS Alloc t-BuOK Alloc CH3COCI . Alloc
2DMSO m6
o2c.....õ_),,,Nsi 'Alio
0¨ \ 0-- \ 0-- \Cl
EC2239 EC2242 EC2246 EC2247
Pd(PPP) qoo 0,0
Pyrroidere N\ . NH110 H H
HO PyBoo DIPEA N H
0 NH: I N N N
N DMF 0 NH: N
N \
N N"-) --C)=/ N
Me0
EC2248 EC1870 0 EC2224
OO
0 0'
1401
LOH
N H
THF Me0H
0 NH 2 sNIN N.õõ1
0
EC2250
EC2234 was synthesized in 91% yield following the procedure described in
Murray et al.
W02008098368 1H NMR (500 MHz, CDC13) (rotamers): 6 6-5.8 (m, 1H), 5.4-5.1 (m,
2H), 4.6-
4.4 (m, 4H), 3.8-3.5 (m, 2H), 2.4-2 (m, 2H).
To a mixture of EC2234 (1 g, 4.36 mmol) and imidazole (0.59 g, 8.72 mmol) in
DMF was
added tert-Butyldiphenylchlorosilane (1.36 ml, 5.23 mmol) dropwise at room
temperature. The
mixture was stirred at room temperature overnight. The reaction was quenched
with water,
extracted with Et0Ac (3x30 ml) and the organic phase was washed with H20,
brine
sequentially and dried over anhydrous Mg504 and concentrated. The residue was
purified with
CombiFlash in 0-80% Et0Ac/p-ether to afford the EC2235 1.84 g, in yield of 90
%. 1H NMR
(500 MHz, CDC13): 6 7.68-7.60 (m, 4H), 7.48-7.36 (m, 6H), 5.91 (m, 1H), 5.25
(m, 2H), 4.59
(m, 2H), 4.43 (m, 1H), 4.24-3.60 (m, 4H), 3.53 (m, 2H), 1.05 (m, 9H). LCMS:
[M+H] m/z =
468.41.
To a mixture of EC2235 (0.94 g, 2.01 mmol) in THF (15 ml) was added LiBH4
(65.7 mg,
3.02mmol) in portions at 0 C under argon. The mixture was allowed to warm to
room
temperature over 2.5 hours. It was cooled to 0 C and quenched with H20. The
mixture was
extracted with Et0Ac (3x30 ml) and the organic phase was washed with H20,
brine
sequentially and dried over anhydrous Mg504. It was filtered and concentrated
in vacuo. The
120
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
crude product was used in next step without further purification. 0.88 g of
EC2236 was
obtained in 99 % yield. 1H NMR (500 MHz, CDC13): 6 7.68-7.60 (m, 4H), 7.48-
7.36 (m, 6H),
5.91 (m, 1H), 5.25 (m, 2H), 4.59 (m, 2H), 4.43 (m, 1H), 4.24-3.60 (m, 4H),
3.53 (m, 2H), 1.05
(m, 9H). LCMS: [M+Hr m/z = 440.41.
To a mixture of EC2236 (0.88 g, 2.0 mmol) in DCM (6 ml) was added Dess-Martin
reagent
(1.02 g, 2.4 mmol) at room temperature. The mixture was stirred at room
temperature for 4
hours. The crude product was purified with CombiFlash in 0-40% Et0Ac/p-ether
to afford 0.69
g of EC2237 in 80 % yield. 1H NMR (500 MHz, CDC13): 6 9.46 (d, J = 48 Hz, 1H),
7.64-7.59
(m, 4H), 7.46-7.26 (m, 6H), 5.90 (m, 1H), 5.30 (d, J= 11 Hz, 1H), 5.22 (m,
1H), 4.62 (m, 2H),
4.38 (m, 2H), 3.62 (dd, Ji = 11 Hz, J2 = 62.5 Hz, 1H), 3.44 (m, 2H), 2.10 (M,
1H), 1.82 (M,
2H), 1.05 (s, 9H). LCMS: [M+Hr m/z = 438.35.
To a mixture of EC2237 (0.395 g, 0.9 mmol) in ethanol (5 ml) and Triethyl
orthoformate (0.6
ml, 3.6 mmol) was added p-Ts0H (catalytic amount) at room temperature. The
mixture was
stirred at room temperature for 3 hours. The crude product was purified with
CombiFlash in 0-
40% Et0Ac/p-ether to afford 0.45 g of EC2238 in 97 % yield. 1H NMR (500 MHz,
CDC13): 6
7.63 (m, 4H), 7.37 (m, 6H), 5.93 (m, 1H), 5.30-5.19 (m, 2H), 4.77-4.49 (m,
4H), 4.11 (m, 1H),
3.67 (m, 2H), 3.54-3.42 (m, 2H), 3.37-3.23 (m, 2H), 2.22 (m, 1H), 1.98 (m,
1H), 1.19 (m, 3H),
1.04 (s, 9H), 0.98 (m, 3H). LCMS: [M+Hr m/z = 512.58.
To a mixture of EC2238 (0.446 g, 0.87 mmol) in THF (6 ml) was added TBAF
solution (1.05
ml g, 1.05 mmol) at room temperature under argon. The mixture was stirred at
room
temperature overnight. The crude product was purified with CombiFlash in 0-40%
Et0Ac/p-
ether to afford 0.23 g of EC2239 in 95 % yield. 1H NMR (500 MHz, CDC13): 6
5.95 (m, 1H),
5.31 (d, J= 17.5 Hz, 1H), 5.21 (d, J= 10.5 Hz, 1H), 4.87 (s, 1H), 4.60 (m,
3H), 4.13 (m, 1H),
3.74 (m, 2H), 3.53 (m, 5H), 2.41 (m, 1H), 1.89 (m, 1H), 1.21 (t, Ji = J2 = 7.5
Hz, 3H) 1.16 (t, Ji
= J2 = 7.5 Hz, 3H).
To a mixture of DMSO (0.32 g, 4.51 mmol) in DCM (10 ml) was added oxalyl
chloride (1.13
ml, 2 M in methylene chloride, 2.25 mmol) at -78 C under argon. After stirring
for 30 minutes,
EC2239 (0.56 g, 2.05 mmol) was added at -78 C. The mixture was stirred at -78
C for 2 hours,
then it was treated with Et3N (1.42 ml, 10.25 mmol). It was allowed to warm to
room
temperature. The reaction mixture was diluted with DCM and quenched with
brine. It was
washed with brine and dried over anhydrous Mg504. The crude product was
purified with
CombiFlash in 0-40% Et0Ac/p-ether to afford 0.43 g of EC2242 in 77 % yield. 1H
NMR (500
MHz, CDC13): 6 5.95 (m, 1H), 5.35-5.22 (m, 2H), 4.70-4.58 (m, 3H), 4.40 (dd,
Ji = 9.5 Hz, J2 =
31.5 Hz, 1H), 3.89 (m, 1H), 3.77 (m, 3H), 3.54 (m, 1H), 3.46 (m, 1H), 2.72 (d,
J = 18.5 Hz,
1H), 2.48 (m, 1H), 1.23 (t, J1= J2 = 7.5 Hz, 3H) 1.13 (t, J1= J2 = 7.5 Hz,
3H).
121
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Potassium tert-butoxide (2.54 ml, 1M in THF, 2.54 mmol) was added dropwise to
a suspension
of methyltriphenylphosphonium bromide (0.91 g, 2.54 mmol) in THF (10 ml) at 0
C under
argon. After being stirred for 2 hours at 0 C, a solution of EC2242 (0.345 g,
1.27 mmol) g in
THF (8 ml) was added dropwise, and the reaction was allowed to warm to room
temperature.
After being stirred overnight the reaction mixture was diluted with Et0Ac and
washed with
H20, brine sequentially and dried over anhydrous MgSO4. It was filtered and
concentrated in
vacuo. The crude product was purified with CombiFlash in 0-20% Et0Ac/p-ether
to afford
0.306 g of EC2246 in 89.5 % yield. 1H NMR (500 MHz, CDC13): 6 5.94 (5.94, m,
1H), 5.31 (d,
J= 17.5 Hz, 1H), 5.20 (d, J= 11Hz, 1H), 4.91 (m, 2H), 4.71 (m, 3H), 4.14(m,
2H), 3.94 (d, J=
15 Hz, 1H), 3.72 (M, 2H), 3.48 (m, 2H), 2.79 (d, J=16.5 Hz, 1H), 2.60 (m, 1H),
1.20 (t, J1 = J2
= 7.5 Hz, 3H), 1.14 (t, Ji = .12 = 7.5 Hz, 3H).
A mixture of EC2246 (43.3 mg, 0.16 mmol), thionyl chloride (2.34 ml, 0.032
mmol) and acetyl
chloride (18.4 ml, 0.26 mmol) was stirred at 70 C for 2h. It was cooled to
room temperature
and concentrated under reduced pressure. The crude chloro hemi-acetal was used
for next step
without further purification.
A mixture of methyl 3-(1H-imidazol-4-yl)propanoate (29.6 mg, 0.19 mmol) and
sodium
hydride (7.04 mg, 60 % dispersion in mineral oil, 0.18 mmol) in DMSO was
stirred at room
temperature for 30 minutes. It was transferred in to a flask containing the
chloro hemi-acetal
and the mixture was stirred at room temperature overnight. The crude product
was purified with
CombiFlash in 0-100% Et0Ac/p-ether to afford 23.1 mg of EC2247 in 38.3 %
yield. 1H NMR
(500 MHz, CDC13) (Diastereomers): 6 7.55 (m, 1H), 7.36 (s, 1H), 6.77 (s, 1H),
6.64 (s, 1H),
5.92, (m, 2H), 5.34-5.19 (m, 2H), 5.03 (m, 2H), 4.90-4.75 (m, 2H), 4.63-4.52
(m, 4H), 4.40 (m,
2H), 4.22 (m, 2H), 3.932 (m, 2H), 3.67 (s, 6H), 3.56-3.41 (m, 6H), 3.39-2.85
(m, 4H), 2.76 (m,
2H), 2.72-2.63 (m, 6H), 1.21-1.14 (m, 6H). LCMS: [M+Hr m/z = 378.68.
A mixture of EC2247 (42 mg, 0.11 mmol), Pyrrolindine (10.2 [IL, 0.12 mmol) and
Pd(PPh3)4
(6.4 mg, 0.0055 mmol)in DCM (0.6 ml) was stirred at room temperature for 3
hours. It was
diluted with DCM, washed with H20, brine sequentially and dried over anhydrous
Mg504. It
was filtered and concentrated in vacuo. The crude product was used for next
step without
further purification. LCMS: [M+H1+ m/z = 294.60.
A mixture of EC2248 (10.72 mg, 0.037 mmol), EC1870 (24.7 mg, 0.037 mmol),
PyBop (28.9
mg, 0.056 mmol) and DIEA (19.4 pi, 0.11 mmol) in DMSO (1 ml) was stirred at
room
temperature overnight. The crude product was purified with prep-HPLC (10 to
100%
acetonitrile in 20 mM NH4HCO3, pH 7.4) to yield pure EC2224 (14.4 mg, 41 %).
LCMS:
[M+Hr m/z = 952.15.
122
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
To a mixture of EC2224 (16 mg, 0.017 mmol) in THF (1.5 ml), Me0H (0.5 ml) and
H20 (0.5
ml) was added LiOH (85 pi, 1.0 M solution, 0.085 mmol) at room temperature.
The mixture
was stirred at room temperature for 4 hours. The solvent was removed under
reduced pressure
and the crude product was used for next step without further purification.
LCMS: [M+H] + n-ilz
=938.58.
6i? 0 - .,0 H 0 J.NH2TFA
N
HC))(/" 0 NH, 4/, N PyBop
0
N N'Th 0 DIEA DMSO
EC2250
702H TD2F1
O O go2H H o H o H 0 CO,H
clt,N
0 =N
N
0 J-N'Tr.'").1 0 NH, * 40 Hzyrr, N-Th
00
H2N 0 NH )'NH 0
NH
0
EC2253 EC1579 HO HO HO
OH HO
HO
OO
=
cy0H,H 0 )0H2H 0 co2H 0
\ \¨N1 Ur IV
N
N b 0 NH,
sNN
0 go2H H 0
0 00 N
=
H2NHIJNIINNr'l 0
0 NN 0 NH 0 NH
HO HO HO
OH HO HO
EC2290
A mixture of EC2250 (12.5 mg, 0.013 mmol), 1-(2-aminoethyl)-1H-pyrrole-2,5-
dione TFA salt
(3.4 mg, 0.013 mmol), PyBop (10.4 mg, 0.02 mmol) and DIEA (6.8 pi, 0.04 mmol)
in DMSO
(1 ml) was stirred at room temperature for 1 hour. Then an aqueous solution of
EC1579 was
added at room temperature. To the mixture was added EC1579 (32.8 mg, 0.02
mmol) in H20
(0.5 ml) The mixture was stirred at room temperature for 30 minutes and the
crude product was
purified with prep-HPLC (10 to 100% acetonitrile in 20 mM NH4HCO3, pH 7.4) to
yield pure
EC2290 (2 mg, 5.6 %). LCMS: [M+2I-1]2+ m/z = 1370.76.
123
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
=
o
ECOSIO
Bo e
EC2606 EC2605 0)'NH.
=KG
,m0Nlikt, j1 . rrANy,,
4-04:101,
N
õNY
Cd'NH. ECM,
0,Y,YA,C(.131
4--04D01, 0
N tok, tteo
õNr
CAIN
EC2372
0 CH
0 glyli a 9 0
(17,,com
1 '002¶
'811
CIN/12 .2065
0
0 002.
CLYI
;6
õ2.11¶Nrn .0211
õNY
eLN112
EC2376
011 Cr'
N
0 90.11 õ 9(J (C002I
0 c02.0 0 11
4111 111¶ õ1"-
co 070
-0---v..kb Li-
¶_00
-1C(1
EC2375
To a mixture of 1-(tert-butyl) 2-methyl (S)-4-methylenepyrrolidine-1,2-
dicarboxylate (0.5 g,
2.07 mmol) in THF (10 mL) was added LiBH4 (67.7 mg, 3.11 mmol) in portions at
0 C under
argon. The mixture was allowed to warm to room temperature over 2.5 hours. It
was cooled to
0 C and quenched with H20. The mixture was extracted with Et0Ac (3x30 mL) and
the organic
phase was washed with H20, brine sequentially and dried over anhydrous MgSO4.
It was
filtered and concentrated in vacuo. The crude product EC2404 was used in next
step without
further purification.
To a mixture of EC2404 and pyridine (0.84 ml, 10.35 mmol) in dichloromethane
(8 ml) was
added Dess-Martin periodinane (1.2 g, 2.90 mmol) at 0 C. It was stirred at
room temperature
for 2 hours. The crude product was purified with CombiFlash in 0-40% Et0Ac/p-
ether to afford
0.26 g of EC2405 in 59.3 % yield. 1H NMR (500 MHz, CDC13) (rotamers): 6 9.56
and 9.49 (s,
1H), 5.03 (m, 2H), 4.35-4.20 (m, 1H), 4.13-4.02 (m, 2H), 2.86-2.71 (m, 1H),
2.67-2.64 (m, 1H),
1.49 and 1.44 (s, 9H).
A mixture of EC2405 (42.7 mg, 0.20 mmol), 2-aminoethan- 1-ol (12.8 pi, 0.21
mmol) and
molecular sieves in toluene (1 ml) was stirred at room temperature for 1.5
hours to generate the
tert-butyl (2S)-4-methylene-2-(oxazolidin-2-yl)pyrrolidine- 1-carboxylate in
situ. A mixture of
124
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
Fmoc-Val-Cit-OH (0.11 g, 0.22 mmol) and HATU (0.12 g, 0.30 mmol) in DMF (2 ml)
was
stirred at room temperature for 1 hour, then DIEA (0.11 ml, 0.61 mmol) was
added. The tert-
butyl (2S)-4-methylene-2-(oxazolidin-2-yl)pyrrolidine-1-carboxylate reaction
mixture was
transferred into this reaction mixture and stirred at room temperature
overnight. The crude
product was purified with CombiFlash in 0-20% Me0H/DCM to afford 40 mg of
EC2369 in
24.8 % yield. LCMS: [M+H] m/z = 733.73.
A mixture of EC2369 (40 mg, 0.055 mmol) in 50 % TFA/DCM (1 ml) solution was
stirred at
room temperature for 3 hours. It was concentrated in vacuo to give the EC2370
as pale yellow
solid. It was used in next step without further purification. LCMS: [M+H]+ m/z
= 633.62.
A mixture of EC2370 (20 mg, 0.032 mmol) EC1870 (21.4 mg, 0.032 mmol), PyBop
(24.7 mg,
0.047 mmol) and DIEA (16.6 pi, 0.095 mmol) in DMSO (1 ml) was stirred at room
temperature
for 5 hours. The crude product was purified with Combiflash in 0-20 % Me0H/DCM
to afford
10 mg of EC2371 in 24.5 % yield. LCMS: [M+H] m/z = 1291.92.
To a mixture of EC2371 (10 mg, 0.008 mmol) in acetonitrile (1 ml) was added
Et2NH (12 pi,
0.116 mmol) at room temperature. The mixture was stirred at room temperature
for 4 hours. It
was concentrated under reduced pressure. The crude product of EC2372 was used
in next step
without further purification. [M+H]+ m/z = 1069.29.
A mixture of EC2372 (0.008 mmol), Mal-PEG4-NHS (4.1 mg, 0.008 mmol) and DIEA
(4.2 pi,
0.024 mmol) in acetonitrile (1 ml) was stirred at room temperature overnight.
The reaction
mixture was concentrated under reduced pressure and the crude product was
purified by prep-
HPLC (10 to 100% acetonitrile in 20 mM NH4HCO3, pH 7.4) to yield pure EC2373.
LCMS:
[M+H] m/z = 1467.99.
A mixture of EC2373 (46.4 mg, 0.032 mmol) and EC2045 (34.5 mg, 0.032 mmol) in
Me0H
(0.5 ml) and DMSO (0.5 ml) was stirred at room temperature overnight. The
crude product was
purified by prep-HPLC (10 to 100% acetonitrile in 20 mM NH4HCO3, pH 7.4) to
yield pure
EC2374. LCMS: [M+2H]2+ m/z = 1280.63.
A mixture of EC2374 (41 mg, 0.016 mmol) and EMCH (5.4 mg, 0.016 mmol) in Me0H
(0.5
ml) and DMSO (0.5 ml) was stirred at room temperature overnight. The crude
product was
purified by prep-HPLC (10 to 100% acetonitrile in 20 mM NH4HCO3, pH 7.4) to
yield pure
EC2375. LCMS: [M+2H]2+ m/z = 1384.71. 1H NMR (500 MHz, DMSO): 6 8.59 (m, 1H),
8.12
(m, 2H), 7.96 (M, 1H), 7.67-7.50 (m, 5H), 7.45 (m, 1H), 7.41-7.18 (m, 3H),
7.17-7.06 (m, 3H),
6.98-6.84 (m, 4H), 6.76-6.58 (m, 3H), 6.40-6.30 (m, 1H), 5.0-4.8 (m, 2H), 4.20-
3.98 (m, 4H),
3.96-3.72 (m, 4H), 3.70-3.60 (m, 6H), 3.2-3.0 (m, 7H), 2.91(m, 1H), 2.85 (m,
1H), 2.61-2.65
(m, 4H), 2.43 (m, 3H), 2.34-2.18(m, 12H), 2.18-2.0 (m, 3H), 1.98-1.84 (m, 5H),
1.79 (m, 6H),
1.72 (m, 10H), 1.64-1.36 (m, 15H), 1.3-1.02 (m, 18H), 0.88-0.62 (m, 12H).
125
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
/ /
Boc-Py-OH .....-N Boc-Py-OH n _.-
N
HCI=H-Py-OMe
PyBop, DIPEA 0 1 PyBop DIPEA
\ N H \ N H
\ 0 \
______________________________ EC2155 R - CO2tBu EC2157 R = CO2tBu
HCI L HCI
Et20 Et20 __
EC2156 R = H ' EC2158 R = H
Boc-Py-OH N/
PyBop DIPEA
\ N H \ N H
\ 0 \
EC2159
/
....-N
).....1¨0O2Me PyBop, DIPEA
/
EC2157/EC2159 NaOH ____________________________________
BocHN H2NNMe2
' ,, N_-il'N
H20/Dioxane \ C N H DMF
0 \
n
EC2161 n = 1
EC2164 n = 2
/ N H Nre _.
BocHN N H I -C11-13N N H
1 CI
\ N H Et20 \ N H
0 \
n 0 \
n
EC2162 n = 1 EC2163 n = 1
EC2165 n = 2 EC2166 n = 2
Boc-Py-Py-OMe (EC2155): To a solution of 500 mg HC141-Py-OMe (2.63 mmol., 1.1
equiv),
573 mg Boc-Py-OH (2.38 mmol., 1.0 equiv), and 850 [IL DIPEA (4.77 mmol., 2.0
equiv) in 5.4
mL DMF (0.44M) was added 1.24 g PyBOP (2.38 mmol., 1.0 equiv). The reaction
mixture was
stirred for 4 h at room temperature, and then diluted (15x) with deionized
water. The
precipitate that was isolated by centrifugation (4000 rpm for 10 min) and the
supernatant was
decanted yielding a pellet. The pellet was resuspended in deionized water and
sonicated for 5
min, before the precipitate was recollected by centrifugation (repeated
twice). Residual water
was removed by freezing and lyophilizing from the sample to dryness. 853 mg
(86.4%) of
product was collected as a light brown solid. 1H NMR (CDC13): 6 7.45 (s, 1H),
7.39 (s, 1H),
6.83 (s, 1H), 6.72 (s, 1H), 6.56 (s, 1H), 6.22 (s, 1H), 3.90 (s, 6H), 3.81(s,
3H), 1.50 (s, 9H).
LC/MS (ESI): m/z = 377.13 (M+H).
HC1*H-Py-Py-OMe (EC2156): 38 jai (0.03M) of 2N anhydrous hydrochloric acid
(HC1) in
diethyl ether was added to 424 mg of EC2155 (1.13 mmol.) and stirred for 5 h
at room
temperature. The reaction mixture was then diluted with one volume of diethyl
ether and
126
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
filtered by a fritted glass funnel. The filter cake was rinsed with excess
diethyl ether (5x
reaction volume), and dried in vacuo to yield 343 mg (97.5%) of the product as
a tan solid. 1H
NMR (d6-DMS0): 6 10.07 (s, 1H), 9.97 (br s, 3H), 7.46 (d, J = 2.0 Hz, 1H),
7.10 (d, J = 2.0
Hz, 1H), 6.98 (d, J = 2.0 Hz, 1H), 6.89 (d, J = 2.0 Hz, 1H), 3.87 (s, 3H),
3.83 (s, 3H), 3.72 (s,
3H). LC/MS (ESI): m/z = 277.07 (M+H).
Boc-Py-Py-Py-OMe (EC2157): EC2157 was synthesized accord to the same produced
as
EC2155. 832 mg of EC2156 yielded 1.19 g of EC2157 as a light brown solid in
89.7 % yield.
1H NMR (d6-DMS0): 6 9.89 (s, 1H), 9.84 (s, 1H), 9.07 (s, 1H), 7.45 (d, J = 2.0
Hz, 1H), 7.20
(d, J = 1.7 Hz, 1H), 7.04 (d, J = 1.5 Hz, 1H), 6.89 (m, 2H), 6.82 (s, 1H),
3.82 (s, 6H), 3.79 (s,
3H), 3.72 (s, 3H), 1.44 (s, 9H). LC/MS (ESI): m/z = 499.46 (M+H)
HC1*H-Py-Py-Py-OMe (EC2158): EC2158 was synthesized accord to the same
produced as
EC2156. 541 mg of EC2157 yielded 343 mg of EC2158 as a tan solid in 92.1 %
yield. 1H
NMR (d6-DMS0): 6 10.08 (s, 1H), 10.03 (br s, 3H), 9.93 (s, 1H), 7.44 (d, J =
1.9 Hz, 1H), 7.23
(d, J = 1.9 Hz, 1H), 7.09 (d, J=2.0 Hz, 1H), 7.05 (d, J = 1.5 Hz, 1H), 6.99
(d, J = 1.9 Hz, 1H),
6.89 (d, J = 1.9 Hz, 1H), 3.88 (s, 3H), 3.83 (s, 3H), 3.82 (s, 3H), 3.72 (s,
3H). LC/MS (ESI): m/z
= 402.44 (M+H).
Boc-Py-Py-Py-Py-OMe (EC2159): EC2159 was synthesized accord to the same
produced as
EC2155. 200 mg of EC2158 yielded 267 mg of EC2159 as a light brown solid in
93.6 % yield.
1H-NMR (d6-DMS0): 6 9.92 (s, 2H), 9.85 (s, 1H), 9.07 (s, 1H), 7.46 (d, J = 2.0
Hz, 1H), 7.22
(d, J=2.0 Hz, 1H), 7.21 (d, J = 1.4 Hz, 1H), 7.06 (d, J = 1.9 Hz, 1H), 7.04
(d, J = 1.5 Hz, 1H),
6.90 (d, J = 1.9 Hz, 1H), 6.88 (s, 1H), 6.83 (s, 1H), 3.85 (s, 6H), 3.84 (s,
3H), 3.83 (s, 3H), 3.83
(s, 3H), 3.80 (s, 3H), 3.73 (s, 3H), 1.45 (s, 9H). LC/MS (ESI): m/z = 621.78
(M+H).
Boc-Py-Py-Py-OH (EC2161): 316 mg (0.643 mmol.) of EC2157 was added to a
solution of
12.5 mL 1,4-dioxane and 12.5 mL 1 N aqueous sodium hydroxide (0.025M). The
reaction
mixture was stirred for 4 h at room temperature before evaporating to dryness.
The solid was
dissolved in water, acidified to pH 3 with aqueous HC1, and extracted with
ethyl acetate (3 X).
The combined organic layers were dried with sodium sulfate and concentrated to
yield 290 mg
of a brown/orange solid (93.1%). 1H NMR (CDC13) 6 7.41 (s, 1H), 7.21 (2, 2H),
6.82 (d, J =
2.0 Hz, 2H), 6.74 (s, 1H), 3.89 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H), 1.48 (s,
9H). LC/MS (ESI):
m/z = 485.49 (M+H).
Boc-Py-Py-Py-NH(CH2)3N(CH3)2 (EC2162): To a solution of 170 mg of EC2161
(0.351
mmol., 1.0 equiv), 53.0 [1.1 of 3-(dimethylamino)-1-propylamine (0.421 mmol.,
1.2 equiv), and
125 01 of DIPEA (0.702 mmol., 2.0 equiv) in 3.5 ml of DMF (0.1M) was added 201
mg of
PyBOP (0.386 mmol., 1.1 equiv). The reaction mixture was stirred for 4 h at
room temperature,
before it was concentrated in vacuo to yield a dark brown oil. The crude
product was further
127
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
purified via silica chromatography (0-10% methanol in DCM) to yield 147 mg the
product as a
white solid (73.6%). 1H NMR (d6-DMS0): 6 9.87 (s, 1H), 9.83 (s, 1H), 9.06 (s,
1H), 8.13 (t, J
= 1.2 Hz, 1H), 7.18 (d, J = 0.3 Hz, 1H), 7.15 (d, J = 1.9 Hz, 1H), 7.04 (d, J
= 1.5 Hz, 1H), 6.92
(d, J = 1.5 Hz, 1H), 6.87 (s, 1H), 6.82 (s, 1H), 3.82 (s, 3H), 3.80 (s, 3H),
3.79 (s, 3H), 3.22 (t, J
= 6.1 Hz, 2H), 3.15 (d, J = 2.4 Hz, 2H), 2.77 (s, 6H), 1.82 (m, 2H), 1.44 (s,
9H). LC/MS (ESI):
m/z = 569.67 (M+H).
2HC1*H-Py-Py-Py-NH(CH2)3N(CH3)2 (EC2163): EC2163 was synthesized accord to the
same
produced as EC2156. 110 mg of EC2162 yield 99 mg of EC2163 as a pale brown
solid in 98 %
yield. 1H NMR (d6-DMS0): 6 10.05 (s, 1H), 9.91 (m, 4H), 9.89 (br s, 1H), 8.16
(t, J = 1.2 Hz,
1H), 7.22 (d, J = 1.4 Hz, 1H), 7.15 (d, J = 1.9 Hz, 1H), 7.10 (d, J = 1.9 Hz,
1H), 7.05 (d, J = 1.5
Hz, 1H), 6.97 (d, J = 1.9 Hz, 1H), 6.92 (d, J = 1.5 Hz, 1H), 3.88 (s, 3H),
3.83 (s, 3H), 3.79 (s,
3H), 3.23 (m, 2H), 3.04 (m, 2H), 2.75 (s, 3H), 2.74 (s, 3H), 1.82 (m, 2H).
LC/MS (ESI): m/z =
469.43 (M+H).
Boc-Py-Py-Py-Py-OH (EC2164): EC2164 was synthesized accord to the same
produced as
EC2161. 359 mg of EC2159 yielded 340 mg of EC2164 as a brown/orange solid in
97.0 %
yield. 1H NMR (d6-DMS0): 6 9.98 (s, 1H), 9.84 (s, 1H), 9.74 (s, 1H), 9.07 (s,
1H), 7.21 (s,
2H), 7.17 (s, 1H), 7.03 (d, J = 1.5 Hz, 1H), 7.00 (s, 1H), 6.87 (s, 1H), 6.82
(s, 1H), 3.83 (s, 3H),
3.82 (s, 3H), 3.81 (s, 3H), 3.79 (s, 3H), 1.44 (s, 9H). LC/MS (ESI): m/z =
607.72 (M+H).
Boc-Py-Py-Py-Py-NH(CH2)3N(CH3)2 (EC2165): EC2165 was synthesized accord to the
same
produced as EC2162. 335 mg of EC2164 yielded 240 mg of EC2165 as a white solid
in 62.9 %
yield. 1H NMR (d6-DMS0): 6 9.90 (s, 1H), 9.86 (s, 1H), 9.84 (s, 1H), 9.07 (s,
1H), 8.05 (t, J =
5.7 Hz, 1H), 7.22 (d, J = 2.5 Hz, 1H), 7.20 (d, J = 1.4 Hz), 7.17 (d, J = 2.0
Hz, 1H), 7.04 (d, J =
1.5 Hz, 1H), 7.03 (d, J = 1.9 Hz), 6.87 (s, 1H), 6.82 (s, 1H), 6.81 (s, 1H),
3.83 (s, 6H), 3.79 (s,
3H), 3.78 (s, 3H), 3.22 (m, 2H), 2.22 (t, J = 7.2 Hz, 2H), 2.12 (s, 6H), 1.60
(m, 2H), 1.44 (s,
9H). LC/MS (ESI): m/z = 691.56 (M+H).
2HC1*H-Py-Py-Py-Py-NH(CH2)3N(CH3)2 (EC2166): EC2166 was synthesized accord to
the
same produced as EC2156. 115 mg of EC2165 yielded 92 mg of EC2166 as a pale
brown solid
in 92 % yield. 1H NMR (d6-DMS0): 6 9.89 (s, 1H), 9.85 (m, 4H), 9.58 (s, 1H),
8.03 (t, J = 1.2
Hz, 1H), 7.21 (d, J = 2.0 Hz, 1H), 7.18 (d, J = 1.9 Hz), 7.15 (d, J = 2.0 Hz,
1H), 7.01 (d, J = 1.9
Hz, 1H), 7.00 (d, J = 1.9 Hz, 1H), 6.80 (d, J = 1.5 Hz, 1H), 6.35 (d, J = 1.4
Hz, 1H), 6.24 (d, J =
2.0 Hz, 1H), 3.82 (s, 6H), 3.77 (s, 3H), 3.71 (s, 3H), 3.23 (q, J = 6.8, 23.3
Hz, 2H), 2.21 (t, J =
7.1 Hz, 2H), 2.11 (s, 6H), 1.58 (m, 2H). LC/MS (ESI): m/z = 597.67 (M+H).
128
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0 NH2
-0 Ni HN-_Cy*"
N "µ
H, H,N N H 0
L-NrA =
E
EC2169 C2166
H2N Lõ. H2N
,0 I, 0, 0 N\ ry HO
0
0 0
EC2192 EC2194
s
N S' bwi
010,
EC2186 N s bH N 40
0
0;--)-N 0
EC2193
EC2192. EC2169 (28.3 mg, 0.1 mmol) and EC2166 (56.1 mg, 0.1 mmol) were
dissolved in
DMF (1.2 mL). The solution was treated with PyBOP (104.1 mg, 0.2 mmol) and
DIPEA (69.7
[IL, 0.4 mmol) at ambient temperature under Ar. The reaction was stirred for
2h and purified
with CombiFlash in 0-20% Me0H/DCM+0.1% TEA. 30.3 mg of EC2192 is obtained
(35%).
LCMS: [M+H] m/z = 856.
EC2193. EC2192 (30.3 mg, 0.035 mmol) was converted to EC2194 in THF/Me0H/H20
(0.9/0.3/0.3 mL) by LiOH (1M solution, 0.3 mL) at ambient temperature. EC2194
was isolated
under reduced pressure. LCMS: [M+H] m/z = 842. EC 2186 (0.044 mmol, 25.4 mg)
and
EC2194 (0.035 mmol) were mixed in THF/DMF (1 mL/0.5 mL) and treated with PyBOP
(36.4
mg, 0.07 mmol) and DIPEA (12.2 pL/0.07 mmol) at ambient temperature under Ar.
The
reaction was stirred for 2-3h then separated with CombiFlash in 0-20%
Me0H/DCM+0.1%
TEA to obtain EC2193 (14.7 mg, 35%). LCMS: [M+H] m/z = 1192.
=OH 0 0
0 K2CO3 DMF 75 C Alb. 0""\l".
0
EC2153 0 EC2314
A mixture of methyl vanillate (402.2 mg, 2.21 mmol), EC2153 (502.9 mg, 2.43
mmol), and
K2CO3 (0.6 g, 4.42 mmol) in anhydrous acetone (8.84 mL) was heated with
stirring at 60 C for
1.5 hr. The reaction was cooled to ambient temperature, the solid was filtered
out, and
concentrated under reduced pressure to give a residue, which was purified by
CombiFlash in 0-
25% Et0Ac/p-ether to give 678.8 mg of EC2314 (yield 99%). LCMS: [M+H] m/z
=309. 1H
NMR (500 MHz, CDC13) 5 7.64 (dd,J = 8.80, 1.96 Hz, 1H), 7.53 (d, J = 1.96 Hz,
1H), 5.90 (m,
1H), 5.32 (dd, J = 17.60, 1.95 Hz, 1H), 5.23 (dd, J = 10.27, 0.98 Hz, 1H),
4.59 (dd, J = 5.87,
129
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
1.47 Hz, 2H), 4.13 (t, J = 6.35 Hz, 2H), 3.90 (s, 3H), 3.89 (s, 3H), 2.58 (t,
J = 7.09 Hz, 2H),
2.19 (m, 2H).
`c)0
io 3
0,-,)(OH
0 0 IW
0 0 NO, 0 NO,
EC2314 EC2315 EC2316
A mixture of EC2314 (598.9 mg, 1.94mmol) in acetic anhydride (9.7 mL) was
cooled to 0 C
and treated with Cu(NO3)2.3H20 by slow addition. The reaction was kept at 0 C
for lh. The
reaction was stirred at rt for 2hrs. The reaction was poured into a stirred
ice water and stirred
for lhr. The reaction mixture in water was extracted with Et0Ac (3x). The
combined organic
phase was washed with water and dried over anhydrous Na2SO4 and concentrated
under
reduced pressure. The residue was loaded onto a CombiFlash system for
purification (silica gel,
gradient elution: 0-25% Et0Ac in p-ether) to produce 559.7 mg EC2315 in a
yield of 82%.
LCMS: [M+H] m/z = 354.1H NMR (500 MHz, CDC13) 6: 7.43 (s, 1H), 7.05 (s, 1H),
5.89 (m,
1H), 5.30 (d, J = 17.1 Hz, 1H, 5.22 (d, J = 10.27 Hz, 1H), 4.58 (d, J = 6.84
Hz, 2H), 4.57 (t, J =
6.36 Hz, 2H), 4.11 (s, 3H), 3.92 (s, 3H), 2.57 (t, J = 7.34 Hz, 2H), 2.19 (m,
2H). 13C NMR (500
MHz, CDC13) (5: 172.39, 166.27, 152.78, 149.64, 141.12, 132.04, 121.62,
118.42, 110.96,
108.13, 68.41, 65.27, 56.52, 53.19, 30.38, 24.14.
The mixture of EC2315 (559.7 mg, 1.58 mmol) and Pd(PPh3)4 was dissolved in pre-
mixed
piperidine (1.1 mL, 11.06 mmol) and formic acid (417.3 [IL, 11.06 mmol) in DCM
(40 mL). To
that solution was added water (1.0 mL) and the reaction was stirred at rt for
30 min. When the
reaction was completed, the solvent was removed in vacuo, the residue was
loaded to
CombiFalsh in 0-20%Me0H/DCM to give the correspondent acid EC2316 as a solid
(264.6
mg, yield 53%). LCMS: [M+H] m/z =314.52. 1H NMR (500 MHz, Me0H-d4) 6: 7.55 (s,
1H),
7.23 (s, 1H), 4.15 (t, J = 5.86 Hz, 2H), 3.95 (s, 3H), 3.87 (s, 3H), 2.51 (t,
J = 7.34 Hz, 2H), 2.11
(m, 2H).
PyBOPIDI PEA 02N
NO, 0
EC2166 'C) EC2365
EC2316
The solution of EC2166 (107.1 mg, 0.18 mmol) and EC2316 (56.8 mg, 0.18 mmol)
in
anhydrous DMF (1 mL) was treated with PyBOP (187.3 mg, 0.36 mmol) and DIPEA
(125.4
[IL, 0.72 mmol) at rt for 2hr under Ar. The reaction was purified with
CombiFalsh (silica, 0-
130
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
20% Me0H/DCM) to give EC2365 (79.3 mg, yield 50%). LCMS: [M+H] m/z = 886.97.
13C
NMR (500 MHz, Me0H-d4) 6: 162.82, 152.88, 123.26, 121.89, 121.10, 119.40,
118.99,
110.81, 107.97, 105.14, 104.51, 68.59, 56.91, 55.63, 52.12, 43.94, 37.13,
35.36, 35.30, 32.21,
26.82, 24.87. 1H NMR (500 MHz, Me0H-d4) 6:7.54 (s, 1H), 7.20 (s, 1H), 7.16 (m,
3H), 7.11
(d, J = 1.95 Hz, 1H), 6.92 (m, 2H), 6.82 (d, J = 1.96 Hz, 1H), 6.78 (d, J =
1.96 Hz, 1H), 4.17 (t,
J = 5.87 Hz, 2H), 3.88 (m, 12H), 3.86 (s, 6H), 3.33 (m, 2H), 2.53 (t, J = 7.34
Hz, 2H), 2.43 (m,
2H), 2.28 (s, 6H), 2.21 (m, 2H), 1.78 (m, 2H).
*
:02N #
0 0 -
0
0
EC2365 EC2194
EC2363 (68.9 mg, 0.078 mmol) was dissolved in THF/Me0H/water (3:1:1, 1.6 mL)
and treated
with LiOH (0.33 mmol) at rt for 3hrs. Then the reaction was diluted with Me0H
(2.0 mL) and
treated with Pd/C (10% wt, 10 mg) under H2 balloon at rt for overnight. The
reaction was
filtered through a pad of celite and concentrated in vacuo. The obtained amino
acid (EC2194)
was used for the next step without further purification. LCMS: [M+H] m/z =
842.85.
L.?
EC2186 01 I's' _ 511_?A-
0.,1)/(FNi" N/ I
Slo UH2N * H 0 QIN-
A
EC2193
00,- d* --0c oN
, 0 \___(___CI_N/
H
0
EC2194
The solution of EC2194 (33.0 mg, 0.039 mmol) and EC2186 (17.3 mg, 0.047 mmol)
in DMF
(0.5 mL) was treated with PyBOP (40.6 mg, 0.078 mmol) and DIPEA (27.2 [IL,
0.156 mmol) at
rt for overnight. The reaction was purified with prep-HPLC (10 to 100% ACN in
50 mM
NH4HCO3, pH 7.4) to give the product (8.4 mg, EC2193, low yield due to the
instrument issue
during the purification). LCMS: [M+I-1] m/z = 1192.
131
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
. N =
CO EC2193 CO2H CO2H
)
0 CO2H H 0 ) H 0 H 0
002H
0 0
H2NINH
NLINr
0 NH 0 NH 0 NH
OH OH OH
EC1579
V
HO HO HO
OH HO HO
TO2H TD 2H
0 cop N ? _'' N ,i, ,"" N (,) iops
oN * rrn -------
mr-g- --:,-11----is .:--,,r...., \sAi1(H 0 /
H2NHXINLINrN 'NH '
bH2N aim
NH 0 NH 0 NH ...`0 N 4111
=
).,1 0
HO, ,OH HO, .,OH He ,OH c)N&
OH OH OH
HO HO HO'2ì EC2201
OH HO HO
EC1579 (14.4 mg, 0.0086 mmol) was dissolved in DMS0 (0.5 mL) at rt under Ar,
and to
which was added the solution of EC2193 (8.4 mg, 0.0071 mmol) in DMS0 (0.5 mL).
The
reaction mixture was treated with TEA (5.9 [t.L, 0.043 mmoL) and stirred at rt
for 30 min under
Ar. The reaction was purified with prep-HPLC (10 to 100% ACN in 50 mM NH4HCO3,
pH
7.4) to give the conjugate EC2201 (8.0 mg, 41% yield). LCMS: [M+2I-1]2+ m/z =
1380.56;
[M+3I-1]3+ m/z = 921.89. 1H NMR (500 MHz, DMSO-d6, D20 drops, selected data)
6: 8.57 (s,
1H), 7.54 (d, J = 8.80 Hz, 2H), 7.20 (m, 4H), 6.87 (m, 2H), 6.77 (m, 2H), 6.58
(d, J = 8.80 Hz,
3H), 6.31 (d, J = 13.69 Hz, 1H), 4.95 (d, br, 2H).
/ 0
,EI\I-4 ,
BocHN N OH N \ H
EC2163
BocHN H 0 N H
\ 0
EC2313
Imidazole carboxylic acid (35.03 mg, 0.145 mmol) and EC2163 (56.7 mg, 0.121
mmol) were
dissolved in DMF (2 mL) and treated with PyBOP (126.0 mg, 0.242 mmol) and
DIPEA (84.3
[t.L, 0.484 mmol) at rt under Ar. The reaction was stirred for 1 hr and then
loaded to
CombiFlash ((silica gel, gradient elution: 0-20% Me0H in DCM and 0.1% TEA) to
give 90.1
mg of EC2313 in a yield of 93%. LCMS: [M+H] m/z = 692.9. Prior to the next
step, the Boc
group in EC2313 was deprotected with 50% TFA in DCM at rt for 0.5 hr to the
amine TFA
salt product which was used directly after the solvent and TFA were removed in
vacuo.
132
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0 NO2 0
-0
quirooH2N _05( fõA0N N \ H
=EN\v_ N
0, 0
NnO
EC2316
0 NI/ H 0 0
02N H2N akh
i_N_C),...11
0 II H 0 N
HO IV 0 N H
0 0
0 0
E
EC2364 C2367
N s,Slo eINH
/ 0 /
rN 0 N/
or,ArLN
EC2186
NCO EC2366
EC2313 (90.1 mg, 0.13 mmol) was treated with 50% TFA/DCM at rt for 0.5 hr. the
solvent was
then removed in vacuo and redissolved in DMF (0.5 mL). To the solution was
added EC2316
(40.8 mg, 0.13 mmol), PyBOP (134.3 mg, 0.26 mmol) and DIPEA (90.6 [t.L, 0.52
mmol). The
reaction was stirred overnight at rt. The reaction was purified with prep-HPLC
(10 to 100%
ACN in 50 mM NH4HCO3, pH 7.4). 78.1 mg of the desired product EC2364 was
obtained
(68% yield). LCMS: [M+H] m/z = 887.8. 1H NMR (500 MHz, Me0H-d4, selected data)
6:
7.56 (s, 1H), 7.38 (s, 1H), 7.26 (d, J = 1.96 Hz, 1H) 7.21 (s, 1H), 7.19 (d, J
= 1.46 Hz, 1H) 7.17
(d, J = 1.95 Hz, 1H), 6.95 (m, 2H), 6.85 (d, J = 1.96 Hz, 1H) 4.20 (t, J =
5.87 Hz, 2H), 4.03 (s,
3H), 3.93(s, 3H), 3.91 (s, 3H) 3.89 (s, 3H), 3.88 (s, 3H), 3.87 (s, 3H) 3.85
(s, 3H).
EC2364 (78.1 mg, 0.088 mmol) was converted to an acid in THF/Me0H (0.9/0.3 mL)
by LiOH
(1M solution, 0.3 mL) at rt. LCMS: [M+H] m/z = 873.8. To the reaction mixture
was added
Pd/C (10%, wet) after flushed with H2. The reaction was stirred under hydrogen
balloon
overnight at rt. The mixture was filtered through a pad of celite and
concentrated to give the
amino acid EC2367 which was used for the next step without further
purification. 59.7 mg
(81% yield). LCMS: [M+H] m/z = 843.8.
Amino acid EC2367 (59.7 mg, 0.071 mmol) in DMF (0.5 mL) was coupled with
EC2186 (29.4
mg, 0.08 mmol) in the presence of PyBOP (73.9 mg, 0.142 mmol) and DIPEA (49.5
[t.L, 0.284
mmol) overnight at rt. The product was purified with prep-HPLC (10 to 100% ACN
in 50 mM
NH4HCO3, pH 7.4) to provide EC2366 (8.1 mg, 10% for 3 steps). LCMS: [M+2I-1]2+
m/z =
597.2.
133
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
a
Ç55 n, es1H,N 0
N, H
0
C)-
; 0
'NICIO
EC2366
CO,H CO,H
) )
0 g 0 2 H EN, 9 EN, 9
_ H 9 F2HsH
o
,y,... 40 H-nr";-"'- Hor----.'-
H2NHI:jNIIN"
N
0 NH 0 NH NH
I . 1)0, I, ,i-1
1., i :OH OH
HO HO' ;:: 1- 1 I, . . . . OH s0 11
EC1579
T HO HO HO
OH HO HO
CO2H CO2H
0 CO2H 0 ) )
0 N.....õ.õ,ir w____it,H . 0 ri,:yLThry_ EN,...),,z o Hio.:\
,,A / N/ ,, 0 N/
cyr 0 ),NH ),NH
),NH 1 bH2N 0 o::,,_,INi. H ....- 0 ki...erriv,$) EN,,,,,...A.,
H2N N N
He ,,OHOH Hoe ,soHoH Ho ,s0H H 0.;:'-') Co 0
ss, .
HO]HO HO
,õ -----A.s
OH HO HO EC2368
EC2366 (8.1 mg, 0.0068 mmol) in Me0H (0.5 mL) was added to the solution of
EC1579 (15.0
mg, 0.0089 mmol) in DMSO (1 mL) at rt under Ar. The reaction was stirred for
0.5-1hr. The
reaction was purified with prep-HPLC (10 to 100% ACN in 50 mM NH4HCO3, pH 7.4)
to give
3.0 mg of the product EC2368 (16% yield). LCMS: [M+3I-1]3+ m/z = 921, [M+2I-
1]2+ m/z =
1382. 1H NMR (500 MHz, DMSO-d6, D20 drops, selected data) 6: 8.57 (s, br.,
1H), 7.57 (s,
br., 2H), 7.38 (s, 1H), 7.24 (s, 1H), 7.19 (s, 1H), 7.14 (s, 1H), 7.05 (s,
1H), 6.98 (s, 1H), 6.77 (s,
1H), 6.61 (s, br, 3H), 6.33 (s, 1H).
'o o
'o o
Pd(PPh3)4, Piperidine/HCO2H/DCM/H20 IS
0......_õ,-...........i.
OH
_________________________________________________________ "' 20
0
0 NH2
0 NH2
EC2168 EC2169
EC2169. A mixture of EC2168 (982 mg, 3.04 mmol) and Pd(PPh3)4 (422 mg, 0.365
mmol) was
dissolved in a pre-mixed solution of piperdine (2.10 mL)/formic acid (0.802
mL)/DCM (98.0
mL), followed by addition of water (2.0 mL). The reaction mixture was stirred
at ambient
temperature for 30 min, the volume was reduced to about half of the original
under reduced
pressure, and loaded onto a CombiFlash system for purification (Column: silica
gel. Gradient
elution: 0-2% Me0H in DCM) to produce 725 mg EC2169 as a light ivory solid. MS
(ESI m/z)
calculated for C13H18N06 (M + H) : 284.11; found 284.14.
134
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
/
/ N/ ,4_yCL ,L1¨ PyBop,
DIPEA
N N ________
OH + H2N " õ.... ki ---- N H I DM F
,0 10 \ N H
\
0 NH2 o
EC2163
EC2169
/
0 0 ,-N 0
io
/ ____cyll rt.) ci ...--..õ......
0 NH2 --, N .--
0,..õ)...,N____cim,N /
0 H \ N H H I
O \
EC2184
EC2184. To a solution of EC2169 (20 mg, 0.070 mM) and EC2163 (34.4 mg, 0.060
mM) in
DMF (1 mL) was added PyBop (54.6 mg, 0.105 mM) and DIPEA (0.122 mL, 0.70 mM).
The
reaction was allowed to stir for 30 min. LCMS analysis (20 mM NH4HCO3, pH 7.4)
indicated
that the reaction was complete. The reaction mixture was loaded onto a
CombiFlash (Si02)
column and eluted with 0-30% Me0H in CH2C12 to yield pure EC2184 (22 mg, 50%).
LCMS
(ESI): (M + H) = Calculated for C36H48N908, 734.35; found 734.39
/
_.....N 0
0 ON____OlcH 7.,)1N,L1
N.,-...........-..,N,--- LIOH H20
__________________________________________________________________ p-
0 HH
--- H 1
---U THF/Me0H/H20
\
0 NH2 0
EC2184
/
N...-..,..........--..,N,--
HO H \ N H H I
\
0 NH2 0
EC2185
EC2185. To a solution of EC2184 (19 mg, 0.026 mM) in THF/Me0H (1 mL/0.33 mL)
was
added Li0H4120 (6.5 mg, 0.155 mM) in 0.33 mL of water. The reaction was
allowed to stir for
18 h. LCMS analysis (20 mM NH4HCO3, pH 7.4) indicated that the reaction was
complete. The
reaction mixture was concentrated to remove organic solvents and acidified
with 2M HC1 to pH
2 and freeze dried for 2 days. The isolated product was used without further
purification. LCMS
(ESI): (M + H) = Calculated for C35H46N908, 720.34; found 720.46
/
`o 0
0,,AOHPyBop, DIPEA
NN
0 lel + N2N /...-N --y.-ILN ,..-
\ N H H I DMF __ i.
0 NO2 0 \
EC2316 EC2163
/
o N 0
0 0
\
0 NO2 0
EC2415
135
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
To a solution of EC2316 (33.4 mg, 0.107 mM) and EC2163 (50 mg, 0.107 mM) in
DMF (1 ml)
was added PyBop (83.5 mg, 0.161 mM) and DIPEA (0.075 ml, 0.70 mM)
respectively. The
reaction was allowed to stir for 3h. LCMS analysis (20 mM NH4HCO3, pH 7.4)
indicated that
the reaction was complete. The reaction mixture was loaded onto a combiflsh
(Si02) column
and eluted with 0-30% Me0H in CH2C12 (0.2% TEA) to yield pure EC2415 (30 mg,
37%). 1H
NMR (500 MHz, CD30D): 5 7.51 (s, 1H), 7.17 (s, 1H), 7.14 (m, 2H), 7.10 (d, J=2
Hz, 1H),
6.89 (d, J=2 Hz, 1H), 6.80 (d, J=1.5 Hz, 1H), 6.76 (d, J=2 Hz, 1H), 4.14 (t,
Ji= 6.0 Hz, .12= 6.5
Hz, 2H), 3.87 (s, 6H), 3.86 (s, 3H), 3.85 (s, 3H), 3.84 (s, 3H), 3.31 (t, J1,
7.0 Hz, J2= 7.5 Hz,
2H), 2.52 (t, J1= 7.5 Hz, .12= 7.5 Hz, 2H), 2.39 (t, J1= 8.5 Hz, .12= 7.0 Hz,
2H), 2.25 (s, 6H),
2.17 (m, 2H), 1.75 (m, 2H); LCMS (ESI): (M + H) = Calculated for C36H45N9010,
764.33;
found 764.38
LION H20
0 r¨ hN 0
H2,10% Pd/C
OHN
,0THFe0H 0 H N¨C4 I
H N \ H I /M/H2 HO 1110
0 N \ 0 NH2 0 \
0 NO2
EC2415 EC2185
To a solution of EC2415 (30 mg, 0.039 mM) in THF/Me0H (0.6 mL/0.2 mL) was
added
Li0H.H20 (4.9 mg, 0.118 mM) in 0.2 mL of water. The reaction was allowed to
stir for 24 h.
LCMS analysis (20 mM NH4HCO3, pH 7.4) indicated that the reaction was
complete. The
reaction mixture was diluted with methanol (1.0 mL), 10% Pd/C (6 mg) was
added. Reaction
mixture was stirred under H2 atmosphere (balloon) for 24h. LCMS analysis (20
mM NH4HCO3,
pH 7.4) indicated that the reaction was complete (same retention time as
starting material but
mass is different). Reaction mixture was filtered over celite pad and
concentrated. Crude
product (EC2185) was dried and directly used for next reaction. LCMS (ESI): (M
+ H) =
Calculated for C35H45N908, 720.34; found 720.40
'0 j N, H iN()
0
s ,),z Ho N N
TFA/DCM N s' 0 NH2 0 s EC2185
0 __________________________________________________________________________
3.
EC1693 NBoc <JH PyBop, DIPEA, DMF, DCM
EC2186
,s, N 0
N S 0
Jul 0
N N N
N H
0 NH2 0
EC1693 (21 mg, 0.045 mM) was treated with the mixture of TFA/
dichloromethane/TIPS (1
mL/1 mL/ 0.05 mL) and stirred for 30 min. LCMS analysis (20 mM NH4HCO3, pH
7.4)
indicated that the reaction was complete. The reaction mixture was
concentrated to dryness, co-
evaporated with DCM (3 times) and dried under high vacuum for lh to yield
EC2186. In
136
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
another flask, EC2185 (28 mg, 0.039 mM, from previous reaction) was dissolved
in dry DMF
(1mL). PyBop (40.6 mg, 0.078 mM) and DIPEA (0.136 mL, 0.78 mM) were added
respectively. After the reaction mixture stirred for 5 min, EC2186 (prepared
earlier) in DCM (1
mL) was added, and stirred for lh. LCMS analysis (20 mM NH4HCO3, pH 7.4)
indicated that
the reaction was complete. The reaction mixture was purified with prep-HPLC
(10 to 100%
acetonitrile in 20 mM NH4HCO3, pH 7.4) to yield pure EC2187 (22 mg, 53%, over
3 steps). 1H
NMR (500 MHz, CD30D): 6 8.40 (m*, 1H), 8.37 (m*, 1H), 8.16 (m*, 1H), 7.84-7.70
(m*, 2H),
7.26-7.20 (m*, 1H), 7.17 (m*, 1H), 7.13 (d, J= 1.5 Hz, 1H), 6.92 (d, J= 1.5
Hz, 1H), 6.82 (dd,
J 1= 6 Hz, J2 = 1.5 Hz, 2H), 6.42 (s, 1H), 5.14 (d, J= 5 Hz, 1H) 5.10-4.94
(m*, 3H), 4.50-4.06
(m*, 5H), 4.04 (t, Ji= 6 Hz, J2 = 6.5 Hz, 2H), 3.90 (s, 3H), 3.88 (s, 3H),
3.87 (s, 3H), 3.85 (m*,
1H), 3.73 (s, 3H), 3.36 (t, J 1= 6 Hz, J2 = 7 Hz, 2H), 3.33 (m*, 1H), 3.20-
3.00 (m*, 5H), 2.72
(m*, 2H), 2.55 (m*, 2H), 2.53 (s, 6H), 2.20-2.12 (m*, 2H), 1.85 (m, 2H); LCMS
(ESI): (M +
H) = Calculated for C51H65N1201052, 1069.43; found 1069.60
* Due to diasteromeric and/or rotameric nature of the compound
CO,H CO,H
0 gO2H H 0 /H 0 /H 0 CO2H
0 0 rr.....M.s N ...,,11` ()or N .,,,II,
NI. N .õ....U.Thil,,SH n 0 ,
H2NHIjNIINN:r rli ), ), L NAVS'''....0)LN --.'0 0 ,
0 q-N/\_fr
0 NH 0 NH NH
e 1401 L11-"Chl--OAN"Lrn'
,OH ,OH ,OH
o \ N\ H
EC1579 HO' 's(DH HO; 'µCM HO: 's H 0 NH2
EC2187
HO1 HO HO DIPEA, DMSO
OH HO HO
CO2H CO2H
0 gO2H L"...' 0), 0 CO2Hs s 0
0
101 Irs..Thcr)-.0r , rior o , o ri-"fi_
_(e)
HAIF1N2:11N;.'",),
e 01 A11--ari "1-ONAN'Lj 'N''r
0 NH 0 NH NH
.,OH .,OH .,OH 0 NH2
0 \
HO' 's(DH HOs' 'µCM HO''' 's()H
Chemical Formula: Cm H157N27044S2
EC2188
HO OH HO HO HO HO Exact Mass: 2636.03
Molecular Weight 2637.72
EC1579 (13.3 mg, 0.0079 mmol) in DMS0 (0.5 mL) under Argon was stirred to a
clear
solution and to which was added the solution of EC2187 (7 mg, 0.0066 mmol) in
DMS0 (0.5
mL) followed by addition of DIPEA (0.023 mL, 0.131 mmol). The reaction was
stirred for 1 hr
at r.t. under Argon. The product was isolated with prep-HPLC in 10-100%
MeCN/pH 7 buffer
to give EC2188, 10.4 mg (60% in yield) as a solid after lyophilized. 1H NMR
(500 MHz,
DMSO-D6 + D20) (selected data): ä 8.59 (s, 1H), 7.57 (d, J=8.5 Hz, 2H), 7.20
(d, J=2 Hz, 1H),
7.16 (d, J=2 Hz, 1H), 7.13 (d, J=1.5 Hz, 1H), 6.94 (d, J=2 Hz, 1H), 6.82 (d,
J=1.5 Hz, 1H), 6.77
(d, J=2 Hz, 1H), 6.60 (d, J=9 Hz, 2H), 6.58 (m, 1H), 6.33 (s, 1H), 4.97 (s,
2H), 4.93 (s, 1H),
4.45 (s, 2H); LCMS: [M+21-1]2 m/z = Calculated for C111H157N2704.4S2, 1319.02;
found 1319.51
137
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0- - '
Ho NH2 \:& Ho 0 N
INFmoc DENDCM
0 0
_õ.. 0 Ck----"--'-'":, 0 N'i__
Ho 0
, NaNS03 H20/DCM _ oõ,,,,,,...,,0
0 NH2 0 ri-I
0 0
S031,1a
0
EC1770 0 NH2 0 '' 0 NH2 0
EC2322
A solution of EC1770 (111 mg) and diethylamine (2.0 mL) in anhydrous DCM (5.0
mL) was
stirred at ambient temperature under argon for 90 min, concentrated, co-
evaporated with DCM
(3 mL x 3), dried under vacuum for 60 min, re-dissolved in DCM (20 mL), and
mixed with a
solution of NaHS03 (14.6 mg) in water (20 mL). The reaction mixture was
stirred at ambient
temperature for 60 min and separated. The organic layer was extracted with
water (15 mL) and
the combined aqueous layers were freeze-dried to yield 86.5 mg (101%) EC2322
as a beige
solid. 1H NMR (500 MHz, 298 K, DMSO-d6) 6 7.301(s, 1H), 6.968 (s, 1H),6.478
(s, 1H),
6.220 (s, 1H), 5.078 (s, 1H), 5.026 (s, 1H), 4.215 (d, J= 17.0 Hz, 1H), 3.953
(m, 4H), 3.884 (m,
2H), 3.714 (d, J= 22.5 Hz, 1H), 3.669 (s, 3H), 3.596 (s, 3H), 3.151 (d, J=
14.0 Hz, 1H), 2.830
(m, 1H), 1.757 (m, 4H), 1.525 (m, 2H). MS- (ESI m/z) calculated for
C27H32N30105: 590.18;
found 590.27.
a5.5,_, ....I
IF{ NBoc
õN
EC1693
ITFV2N/l
) E PyBOP TEA DMF
111) EC1579 buffer
CO2H CO2H CO' kl
02 H H ? ? ( ) i x - ' .j FN{ ? CO 0 2
H 0 ---,S031-1
s _ s (A,
0 41 oornir'''''..
0.."Ni 0 NH2 0
H2NHIJNNN'r :INN :::INH :DINH 1...,10
EC2323
HO HO HO
OH HO HO
EC1693 (19.8 mg) was dissolved in a solution of TFA (0.15 mL) and DCM (0.85
mL), stirred
at ambient temperature for 30 min, concentrated, co-evaporated with DCM (1 mL
x 3), and
dried under vacuum for 60 min. The residue was dissolved in anhydrous DMF (2.5
mL) and
transferred into a small vial containing EC2322 (18.3 mg) and PyBOP (19.4 mg).
To the
resulting solution was added TEA (32.0 p.L). The reaction mixture was stirred
at ambient
temperature under argon for 15 min and a solution of EC1579 (76.1 mg) in
buffer (50 mM
NH4HCO3, pH 7.0, 7.0 mL) was added. The resulting homogeneous solution was
stirred at
ambient temperature under argon for 15 min and loaded directly onto a
preparative HPLC
(Mobile phase A: 50 mM NH4HCO3 buffer, pH 7.0; B = ACN. Method: 10-80 B% in 20
min.)
for purification to produce 7.9 mg (10.6%) EC2323 as a pale yellow solid.
Selective 1H NMR
138
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
(500 MHz, 298 K, D20) 5 8.671 (s, 1H), 7.711 (b, 2H), 7.146 (s, 1H), 6.824 (b,
3H), 6.728 (s,
1H), 6.419 (b, 2H). MS- (ESI m/2z) calculated for C103H144N21046S3: 1253.44;
found 1253.89.
111 0 H
0 H C',/\/\)11¨NCc
NH
tip C)0HTFAH2NNH PyBOP TEA DMF
* r
0,
EC2160 NH EC2361
EC2361 0
O
TEA (80.0 [tL) was added to a solution of EC2351 (25.3 mg), EC2160 (57.1 mg),
and PyBOP
(42.9 mg) in anhydrous DMF (3.5 mL). The reaction mixture was stirred at
ambient
temperature under argon for 15 min and passed through a flash column eluting
with 0-10%
Me0H in DCM) to yield 62.4 mg (99.1%) crude EC2361 as a beige solid, which was
used in
the next step without further purification. MS + (ESI m/z) calculated for
C42H50N9010: 840.37;
found 840.47.
H 0 H
Pd(PPh2)4
;¨"N=NcrNH ppendine/HCO2C '0
C'%5N-1AINCc-
,
H milr NH
O
0 NH2
0 0' 0 NH2
0
EC2361 EC2362
0'
A mixture of EC2361 (62.4 mg), Pd(PPh3)4 (14.7 mg), piperidine (51.4 [tL),
formic acid (19.6
p.L), and water (30.0 [tL) in DCM (3.0 mL) was stirred at ambient temperature
for 25 min, then
loaded directly onto a CombiFlash system (silica gel column. Gradient: 0-10%
Me0H in
DCM) for purification to yield 20.7 mg (34.8%) EC2362 as a beige solid. 1H NMR
(500 MHz,
298 K, CD30D) ä 7.360 (s, 1H), 7.319 (s, 1H), 7.217 (s, 1H), 7.189 (s, 1H),
7.135 (s, 1H),
6.937 (s, 1H), 6.931 (s, 2H), 6.833 (s, 1H), 6.334 (s, 1H), 4.013 (t, J = 6.5
Hz, 2H), 3.919 (s,
6H), 3.908 (s, 3H), 3.895 (s, 3H), 3.803 (s, 3H), 3.723 (s, 3H), 2.368 (t, J=
7.0 Hz, 2H), 1.872
(m, 2H), 1.793 (m, 2H), 1.585 (m, 2H). MS + (ESI m/z) calculated for
C39H46N9010: 800.34;
found 840.63.
139
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
as-s----OjsNFiNBoc
t..../0
EC1693
I1 -rF3)2rM
) E PyBOP
TEA DMF
111) EC1579 buffer
ri NH
0 i_ =Ni H
a
CO2H CO2H
'0 0
is 0 C_ 02H 0ijo NH,.....li..f iiii ...)0 NH,A H (:)..'N 0 NH2
_Fi__N 0
NV H
H2NHININN2rill ), 0 NH 0 NH 0 ), NH Li0
CD.O'..
EC2363
HO HO HO
OH HO HO
EC1693 (15.1 mg) was dissolved in a solution of TFA (0.20 mL) and DCM (1.5
mL), stirred at
ambient temperature for 15 min, concentrated, co-evaporated with DCM (1.5 mL x
3), and
dried under vacuum for 60 min. The residue was dissolved in anhydrous DMF (1.5
mL) and
transferred into a small vial containing EC2362 (20.7 mg) and PyBOP (14.8 mg).
To the
resulting solution was added TEA (30.0 p.L). The reaction mixture was stirred
at ambient
temperature under argon for 10 min, diluted with DMSO (3.0 mL), and a solution
of EC1579
(56.6 mg) in buffer (50 mM NH4HCO3, pH 7.0, 5.0 mL) was added. The reaction
mixture was
stirred at ambient temperature under argon for 10 min, at 40 C for an
additional 10 min, and
loaded directly onto a preparative HPLC (Mobile phase A: 50 mM NH4HCO3 buffer,
pH 7.0; B
= ACN. Method: 10-80 B% in 20 min.) for purification to give 35.6 mg (50.6%)
EC2363 as a
pale yellow solid. Selective 1H NMR (500 MHz, 298 K, D20) 6 8.438 (s, 1H),
7.476 (d, J = 8.0
Hz, 2H), 7.113 (s, 1H), 7.031 (s, 2H), 6.984 (s, 1H), 6.734 (s, 1H), 6.686 (s,
2H), 6.643 (s, 1H),
6.531 (d, J = 9.0 Hz, 2H), 6.262 (b, 1H). MS- (ESI in/2z) calculated for
C115H156N2704652:
1357.51; found 1357.89.
0
1 0
i_.,cc;
H ¨
NH DIPEA Br...........-
.,.......LL, N 0
NH
Bk.,............õ,,,,,,Aci . TFA H2N H
0 ¨1. 0 5
DMF
,...,.
N. N...._
EC2160 0 e EC2270
0 0
DIPEA (0.20 mL) was added dropwise to a solution of EC2160 (115.0 mg) and 6-
bromohexanoyl chloride (55.0 [t.L) in anhydrous DMF (3.2 mL). The reaction
mixture was
stirred at ambient temperature under argon for 5 min, diluted with DMSO (10
mL), and loaded
onto a preparative HPLC (Mobile phase A: 50 mM NH4HCO3 buffer, pH 7.0; B =
ACN.
Method: 10-100 B% in 20 min) for purification to give 66.5 mg EC2270 as a
white solid. MS
(ESI m/z) calculated for C31H38BrN806 (M + H) : 697.21; found 697.53.
140
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
N---V-IN-Q-
401 OH K2CO3 0N H 0
+ EC2270 -I, )7-NH
0 DMF 0 IW H 6'
0 NH2 80 C
0 NH2 EC2292
EC2267 6%-
o'
A mixture of EC2267 (15.0 mg), EC2270 (18.7 mg), and K2CO3 (26.1 mg) in
anhydrous DMF
(2.0 mL) was heated with stirring at 80 C in a sealed vessel for 8 min, cooled
in an ice-bath,
diluted with DMSO (7.5 mL), filtered, and the filtrate was loaded onto a
preparative HPLC
(Mobile phase A: 50 mM NH4HCO3 buffer, pH 7.0; B = ACN. Method: 10-100 B% in
20 min)
for purification to produce 11.5 mg EC2292 as a white solid. MS (ESI m/z)
calculated for
C42H50N9010 (M + H) : 840.37; found 840.81.
I 0 N/ H
Pd(PPh3)4 0
H
Piperidine/HCO2H 0.õ..õ......----õ,),Ni 0 )i-NH
EC2292 _____________________ p.-
HO ir H 0 __
DCM/H20 N
N--
0 NH2
EC2299 0
o'
A pre-mixed solution of piperidine (2.60 [IL) and formic acid (0.994 [IL) in
DCM (980 [IL) and
water (20 [IL) was added to a mixture of EC2292 (3.2 mg) and Pd(PPh3)4 (0.70
mg) in tandem.
The reaction mixture was stirred at ambient temperature under argon for lh and
loaded directly
onto a CombiFlash system (Column: silica gel. Mobile phase A: DCM; B: Me0H.
Gradient: 0-
10% B) for purification to give 1.2 mg EC2299 as a white solid. MS (ESI m/z)
calculated for
C39H46N9010 (M + H) : 800.34; found 800.59.
NBoc TFA/DCM EC2299
NH TFA ,
PyBOP
0 N--"'S 0 N--;\-
L,... JO L.,./0 TEA
DMF
EC1963
-
0 \ i\l/ric---01.---e--Cci
0
a40 0,..11..1), H 0 0 NH -
s-s,0 el _
.. , ,,. EC1579
0 N- \ 0 NH2 Buffer
1...... JO
0 0"--
r\O
ZOõ,
CO2H CO2H 0 ,, , N 0 NH2
0 CO2H H 0 ? H 0 µ-j H 0 CO2H
H2N N N N 1
0 An r,Thor..,,,),N.Thor
N
H N AIN7----N IF .., H 0"--ThrN r
Nl---Cy0 H(
_e
N O'''NH 0 NH 0 NH
HOS
1 0 \
. H How, AOH Hoe .0H
HO1 HO HO EC2307
OH OH OH
EC1963 (1.4 mg) was dissolved in a solution of TFA (50 [IL) and DCM (150 [tL),
stirred at
141
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
ambient temperature for 10 min, concentrated, co-evaporated with DCM (0.5 mL x
3), and
dried under vacuum for lh. The residue was dissolved in anhydrous DMF (350
[t.L) and
transferred into a small vial containing EC2299 (0.50 mg) and PyBOP (1.2 mg).
To the
resulting solution was added TEA (1.8 p.L). The reaction mixture was stirred
at ambient
temperature under argon for 15 min, diluted with DMSO (500 p.L), and a
solution of EC1579
(3.2 mg) in buffer (50 mM NH4HCO3, pH 7.0, 1.3 mL) was added. The resulting
homogeneous
solution was stirred at ambient temperature under argon for 20 min and loaded
directly onto a
preparative HPLC (Mobile phase A: 50 mM NH4HCO3 buffer, pH 7.0; B = ACN.
Method: 10-
100 B% in 20 min) for purification to produce 0.35 mg EC2299 as a white solid.
MS (ESI
m/2z) calculated for C115H159N2704652 [(M + 2H)/21+: 1359.02; found 1360.15.
>L O
01.
2-Ethanolamine MgSO4 DCM
0
0
0
HATU DIPEA DMF
u
CO2H N N
c.õ0 Boc
EC2407
O
2-Ethano!amine MgSO4, DCM
0
0
0
FmocHN)Lu HATU DIPEA, DMF = u
v
\
CO2H C), N N
Boc
EC2407
A suspension of I (376 mg), 2-ethanolamine (80.6 p.L), and Mg504 (960 mg) in
DCM (20 mL)
was stirred at ambient temperature under argon for 2 hr. The solid was
filtered off and the
filtrate was transferred into a solution of Fmoc-Glu-Oall (656 mg) and HATU
(609 mg) in
anhydrous DMF (6.0 mL), followed by addition of DIPEA (0.62 mL). After
stirring at ambient
temperature under argon for 1 hr, the reaction mixture was loaded directly
onto a CombiFlash
system (silica gel column. Gradient: 0-50% Et0Ac in petroleum ether) for
purification to
produce 365 mg (42.5%) EC2407 as a white solid. 1H NMR (500 MHz, 298 K, CDC13)
5 7.764
(b, 2H), 7.605 (b, 2H), 7.392 (b, 2H), 7.312 (b, 2H), 5.905 (m, 1H), 5.495-
4.979 (m, 3H),
5.004-4.928 (m, 2H), 4.655-3.409 (m, 13H), 2.730-2.172 (m, 6H), 1.433 (m, 9H).
MS + (ESI
142
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
m/z) calculated for C39H46N9010: 800.34; found 840.63. MS + (ESI m/z)
calculated for
C36H44N308: 646.31; found 646.50.
o o
FmocHN.õ,e1_,u,,,,i,
H2N-.1.L0 Fmoc-Glu-OtBu ay0
H 0
z
\ H. DEA, DCM
.....r)= 3 HATU, DIPEA, DCM FmocHN)'"rLO''''''',
N N C\ Nj N 0 "...I
h...11.
c,0 Boc c...0 Boc CAN. N
c.._0 Boc
EC2407
EC2438
A solution of EC2407 (365 mg) and diethylamine (4.0 mL) in anhydrous DCM (4.0
mL) was
stirred at ambient temperature under argon for 3.5 hr, concentrated, co-
evaporated with DCM (5
mL x 3), dried under vacuum for 60 min, re-dissolved in DCM (45 mL) and DMF
(1.0 mL),
and added to a mixture of Fmoc-Glu-013u (229 mg) and HATU (204 mg). The
reaction
mixture was stirred at ambient temperature under argon for 35 min,
concentrated to a small
volume, and loaded directly onto a CombiFlash system (silica gel column.
Gradient: 0-70%
Et0Ac in petroleum ether) for purification to yield 300 mg (67.2%) EC2438 as a
white solid.
1H NMR (500 MHz, 298 K, CDC13) 6 7.768 (d, J = 7.5 Hz, 2H), 7.620 (d, J = 7.5
Hz, 2H),
7.398 (t, J=7.5 Hz, 2H), 7.317 (t, J=7.5 Hz, 2H), 5.901 (m, 1H), 5.338 (d, J=
19.5 Hz, 2H),
5.244 (m, 1H), 4.959 (m, 2H), 4.617 (m, 3H), 4.375 (m, 2H), 4.220 (m, 2H),
4.116-3.813 (m,
4H), 3.611 (b, 1H), 3.388 (m, 1H), 2.755-1.913 (m, 10H), 1.430 (m, 18H). MS +
(ESI m/z)
calculated for C45H59N4011: 831.42; found 831.65.
*
oyo .õ,0 0
Li 0 0 0 o 0
H 0 NHS ester y t, o
DEA DCM _ H2N.I.,õ ,
0,---,,- DIPEA DCM
....1r)Lr"',riskr0
0
8Slc 0
_F-
0 N N
N N N N
EC2438 Co Boc Co Boc EC2439
Co Boc
A solution of EC2408 (300 mg) and diethylamine (10.0 mL) in anhydrous DCM (5.0
mL) was
stirred at ambient temperature under argon for 1.5 hr, concentrated, co-
evaporated with DCM
(10 mL x 3), dried under vacuum for 1 hr, and re-dissolved in DCM (10 mL). To
this solution
were added 3-(Maleimido)propionic acid N-succinimidyl ester (115 mg) and DIPEA
(0.15 mL)
in tandem. The reaction mixture was stirred at ambient temperature under argon
for 50 min,
concentrated to about half of the original volume, and passed through a flash
column eluting
with 0-100% Et0Ac in petroleum ether to give 138 mg (50.3%) crude EC2439 as a
white
solid, which was used in the next step without further purification. MS + (ESI
m/z) calculated
for C37H54N5012: 760.38; found 760.56.
143
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
0 jOa:OH
DL
õ 0 0 Pd(PPh3)4 0 0 0,,,0 0
Piperid2r02H 1U,N)k.0F, TFA/DCM ....14
HN 4'.*Thor i H
CA, 0
0 0 ==0õ)\ s.c ..--k0
(:)\ ...H.r., EC2446
N N
c- "
EC2439 oCI 0 11\31 c
Boc
N N
c._.0
A mixture of EC2439 (192 mg), Pd(PPh3)4 (76.1 mg), piperidine (25.0 p.L), and
formic acid
(9.53 [t.L) in DCM (5.0 mL) was stirred at ambient temperature under argon for
1 hr. To the
mixture was added TFA (2.5 mL). The reaction mixture was stirred at ambient
temperature
under argon for 1.5 hr, concentrated, re-dissolved in DMSO (9.5 mL) and loaded
directly onto a
preparative HPLC (Mobile phase A: 0.1% TFA buffer; B = ACN. Method: 0-30 B% in
20
min.) for purification to afford 65.0 mg (45.6%) EC2446 as a white solid. 1H
NMR (500 MHz,
298 K, DMSO-d6) 6 12.605 (b, 2H), 8.270 (d, J= 8.0 Hz, 1H), 8.111 (d, J= 8.5
Hz, 1H), 7.002
(s, 2H), 5.415 (s, 1H), 5.104 (s, 2H), 4.284 (m, 1H), 4.151 (m, 2H), 4.003 (m,
2H), 3.867 (d, J=
15.0 Hz, 1H), 3.789 (m, 2H), 3.600 (m, 2H), 3.546 (m, 1H), 2.607 (m, 1H),
2.522 (m, 1H),
2.448 (m, 1H), 2.428 (m, 2H), 2.339 (m, 1H), 2.195 (m, 2H), 2.047 (m, 2H),
1.741 (m, 2H).
MS- (ESI m/z) calculated for C25H32N5010: 562.22; found 562.53.
OOH
0 0 T. ri o
...zi..-----)1=11 '"---( =-!----0H
0
:D.SINCI
EC2446
ck 0 H
I0 EC2322, PyBOP, DMF, TEA
ii) EC1579, buffer
O co2H H
02H CH
0 6*--' 0 CO 2H 0 HN__C- 102C N
1111 \---"\--%-0 H
00 rN,,ThsNN...yN....,...i,N,..u,N,ILsyN_r_4.0 CO2H c/o
H2N
\O iii N,,,,,,, SO3H
I-I,NLO Nr N =-=õ1 H i H 0 , H
LO
0 N,
H2N 'NI N' H 0'"NiF1 0 NH 0, NH
EC2451
HO HO HO
OH HO HO
TEA (19.0 [t.L) was added to a solution of EC2322 (8.4 mg), EC2446 (8.4 mg),
and PyBOP
(7.5 mg) in anhydrous DMF (3.0 mL) and the solution was stirred at ambient
temperature under
argon for 60 min. To the solution was added a solution of EC1579 (25.3 mg) in
buffer (50 mM
NH4HCO3, pH 7.0, 6.0 mL) and the reaction mixture was stirred at ambient
temperature under
argon for 20 min, then loaded directly onto a preparative HPLC (Mobile phase
A: 50 mM
NH4HCO3 buffer, pH 7.0; B = ACN. Method: 10-80 B% in 20 min.) for purification
to produce
144
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
2.3 mg (5.8%) EC2451 as a pale yellow solid. Selective 1H NMR (500 MHz, 298 K,
D20) 6
8.688 (s, 1H), 7.699 (d, J= 8.0 Hz, 2H), 7.144 (s, 1H), 6.841 (b, 3H), 6.746
(s, 1H), 6.497 (s,
1H). MS- (ESI m/2z) calculated for C117H161N24053S2: 1407.01; found 1407.69.
0 HIµb_FNI
N¨r-µ0 04;11Boc
0
EC2461
1)-rEF23D2MPyBOP DMF TEA
H) EC1579 buffer
CO2H CO2H
0 CO2H F
O ) ) n CO2H ,_ , ,õ,..._H
H2H N-' 0---
0 Ni ji, ,...,y. UN,T= s u AN0 0 N
46
H-L)NLIN "I 0
S03H
0 N
EC2464
HO HO HO
OH HO HO
EC2461 (10.4 mg) was dissolved in a solution of TFA (0.30 mL) and DCM (1.1
mL), stirred at
ambient temperature for 30 min, concentrated, co-evaporated with DCM (2 mL x
3), and dried
under vacuum for 60 min. The residue was dissolved in anhydrous DMF (3.0 mL)
and to
which are added EC2322 (9.3 mg) and PyBOP (8.1 mg), followed by TEA (21.0
p.L). The
reaction mixture was stirred at ambient temperature under argon for 25 min,
diluted with DMF
(1.5 mL), and a solution of EC1579 (32.1 mg) in buffer (50 mM NH4HCO3, pH 7.0,
5.0 mL)
was added. The resulting homogeneous solution was stirred at ambient
temperature under
argon for 10 min and loaded directly onto a preparative HPLC (Mobile phase A:
50 mM
NH4HCO3 buffer, pH 7.0; B = ACN. Method: 5-50 B% in 20 min.) for purification
to yield 7.3
mg (18%) EC2464 as a pale yellow solid. Selective 1H NMR (500 MHz, 298 K, D20)
ä 8.623
(s, 1H), 7.666 (b, 2H), 7.089 (s, 1H), 6.780 (b, 3H), 6.687 (s, 1H), 6.492 (b,
2H). MS- (ESI
m/2z) calculated for C115H161N2404952: 1363.02; found 1363.79.
0
ONO ( Aik..... NO2
DCM DIPEA 0
ci 0 5L I. 3.. *¨
0 OH 0
EC2474
To a solution of maleimidoethanol (0.655 mg, 4.64 mM) in dry DCM (5 ml) under
Argon was
added p-nitrophenylchloroformate (1.12 g, 5.56 mM) and DIPEA (1.13 ml, 6.50
mM)
respectively. The reaction was allowed to stir at RT for 18 h. TLC analysis (5
% methanol in
methylene chloride) indicated that the reaction was complete. The reaction
mixture was
145
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
concentrated and purified using combiflash (Si02) column and eluted with 0-
100% Et0Ac in
petroleum ether to yield pure EC2474 (0.78 g, 55%). 1H NMR (500 MHz, CDC13): 6
8.28 (d,
Ji= 9.0 Hz, 2H), 7.41 ((d, Ji= 9.0 Hz, 2H)), 6.77 (s, 2H), 4.41 (t, ./i= 4.5
Hz, .12= 5.5 Hz, 2H),
3.95 (t, ./i= 4.5 Hz, .12= 5.5 Hz, 2H); 13C NMR (500 MHz, CDC13): 6 170.37,
155.40, 152.40,
145.59, 134.36, 125.32, 121.99, 66.15, 36.35
0
NH2CH2CH2OH HN''... 0
DCM, TEA, RT, 30 min
____________________________________________________ )...
ri4N_ \ _0y1.00 NO2
NBoc
LLIO
E
EC2474 C2475
To a solution of aldehyde (158 mg, 0.75 mM) in dry DCM (2 mL) was added MgSO4
(79 mg)
and ethanolamine (67.83 [t.L, 1.13 mM) repectiveley. The reaction was allowed
to stir for 1 h.
In another flask, EC2474 (459 mg, 1.5 mM) was dissolved in dry DCM (2 mL) and
triethyl
amine (0.314 mL, 2.25 mM) was added. Above reaction mixture (step 1) was
slowly added to
this solution and stirred for 20 h. LCMS analysis (20 mM NH4HCO3, pH 7.4)
indicated that the
reaction was complete (only mass no UV). TLC analysis (50 % Et0Ac in petroleum
ether)
indicated that the reaction was complete. The reaction mixture was
concentrated and purified
using combiflash (5i02) column eluting with 0-50% Et0Ac in petroleum ether to
yield pure
EC2475 (158 mg, 50%). 1H NMR (500 MHz, CDC13): 6 6.72 (s, 2H), 4.85-5.30 (m,
3H), 3.95-
4.25 (m, 5H), 3.70-3.95 (m, 5H), 3.25 (br s, 1H), 2.40-2.85 (m, 2H), 1.41 (s,
9H); LCMS (ESI):
(M + H) = Calculated for C20H27N307, 422.18; found 422.39
O 0
,,DIN0
PyBOP DMF TEA
---) TFA/DCM 1 N.,..........0õ11,N,,)
O 0 30 min0
0 <?---0 H
SO3H
õ.
EC2475 EC2476 HO 0 IW N
EC2322
0 NH2 0
0
N ....õ--,0Y1, N --') ..--
O 0 difili 0 0 FL(S 3H
-
--...?---
N Ur IW h
0 N.\,.... EC1579
__________________________________________________________ a-
O NH2 0
EC2477 pH 7 buffer
702H CO2H
0 902H 0, <H 9 f" ki O iO2Hs 0
rc,' r3 T-I'''. \4N 0
HN N
Fill)NrN s ), ,----0AN-, H SO3H
'1\I ' H 11 o 0 NH oNH - NH (:) 0,0
,õOH .õOH .õOH N WI- 0 N.
EC2478 HO' C)E1
''. '' He 'µ. H HOs'. '''C'H 0 NH2 0
HO HO HO
OH HO HO
146
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
EC2475 (10.0 mg, 0.025 mM) was treated with the mixture of TFA/
dichloromethane/TIPS
(1.0 mL/1.0 mL/ 0.06 mL) and stirred for 30 min. LCMS analysis (20 mM NH4HCO3,
pH 7.4)
indicated that the reaction was complete. The reaction mixture was
concentrated to dryness, co-
evaporated with DCM (3 times) and dried under high vacuum for lh to yield
EC2476. In
another flask, EC2322 (13 mg, 0.02 mM) was dissolved in dry DMF (1 mL). PyBop
(11 mg,
0.02 mM) and TEA (29.5 [tL, 0.21 mM) were added respectively. Stirred for 5
min, EC2476
(prepared earlier) in DMF (1 mL) was added, and stirred for lh. LCMS analysis
(20 mM
NH4HCO3, pH 7.4) indicated that the product EC2477 was formed. EC1579 (50 mg,
0.03 mM)
in phosphate buffer (2 mL) was added and stirred for lh. LCMS analysis (20 mM
NH4HCO3,
pH 7.4) indicated the product formation. The reaction mixture was purified
with prep-HPLC (5
to 80% acetonitrile in 20 mM NH4HCO3, pH 7.4) to yield pure EC2478 (7.5 mg,
12%). 1H
NMR (500 MHz, DMSO-D6 + D20) (selected data): 5 8.60 (s, 1H), 7.56 (d, J=8.0
Hz, 2H), 6.94
(s, 1H), 6.60 (d, J=8.5 Hz, 2H), 6.60 (s, 1H), 6.49 (s, 1H), 6.28 (br s, 1H),
5.06 (s, 1H), 5.01 (s,
1H), 4.90 (m, 2H), 4.45 (s, 4H); LCMS (ESI): [M-2H]2 = Calculated for C1071-
1148N2204852,
1286.28; found 1286.31
The following examples are also described herein. It is to be understood that
radicals of these examples are included in the PBD prodrugs, poly-PBD
prodrugs, mixed PBDs,
conjugates, and conjugates described herein.
0
r\N4
0
0 la NH2 H2N N S¨(
N
0 0
40 N
0 N 0 0 0¨
o\--/
EC1564 EC1592
r\N¨e r\N4C)
0 0
H2N
02N \S¨µ
S
OH 110 1P "1"¨)
N
0
0 0¨ 0 0¨
EC1593 EC1627
147
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
Or2t-t
0 -\-S - 0
µ OMe
H2N N S-0 0--/ 0--,
li 10 N Me0 0 s. \sµ ___)
N S--- /
0 N
0 0- 1 NH2 0 lei
\
EC1628 EC1660
HI H2N. 0
0
0
Me Cc/N-IL SI)\--NI JO 0
Me0 it N "--
S'SfNi
as'
s_7-0 \O . N 0
0*
q
0
NH2 N
EC1672 EC1741
bH2N 0,......õõ--.õ,õ,...-.,õ,õ0 NH2i..._/
0 N W 01 N
0 0
NS-SOAN 0 NFmoc
o\__ j
EC1771
N
I
s's
1\1.
cr N 0 N\
N NO2 0 ....--1..r-
N 1
H
01 . Nµ..... 0
00
0
EC1864
O oh,
om / ON
OS
0 NH2 0
/\ NI
NO
O
N
0 i 00 i
0
IH2N * /¨
N )
ON_____N___N0 )
H
0 (:, NH 2N /....., s-s
YN j NO =
O
N ,S 0 1-rs 1\1µ
C )---S 0/
EC1695
148
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
N
S,s
le t\H2N i& c No l/
0....---,---...õ..õ.0 0 N H2
N OMe Me0 0
0 , 0 0
AI
O N "o
Li
S40,s
N
EC1703
CO2H CO2H
)
0 CO2H 0 ) n H_ ,H,_,r HOCO2H
N 7 NNA N
4 pi N7IL )INSH
0 l E pli i inf
0 0 0
HN)cxNrN
), 1 ==
C;)\ NH (-1 )
H2N N N H - NH - NH
.00H ...40H (.OH
,,,OH H 00... .,,00 H Hossõ-
...,0 H
He
HO HO HO
OH HO HO
EC1579
HNyNH2
NH
0 CO2H H 0 0
H jt... (CO2H
1.
N N CO2H
0 ill C)r N 11 CO1 ill
\ H
CO2H CO2H
H2N N N NH2 0 S
/ =N
¨0 o oi)
EC1569
The following conjugates of PBD prodrugs, poly-PBD prodrugs, or mixed PBDs
are described herein. The conjugates are prepared according to the processes
described herein
and conventional processes.
149
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
HN. NH2
NH
CO2H
0 CO2H H 0 ----0
H 9H
CO2H
N N ip
0 INIOrNY11 0
--11.õ-N,,,..õ..--.., 0 0
1
HN 1 N 0 CO2H CO2H S¨S
i
=0
H2NNN H
0 N
ON C...5 0 H2N
EC1629
HN. NH2
NH
CO2H
0 = 0 0 CO2H
ri,)L ,cr NuL L,H
CO H
0 0 hi . N 2
0 1-1 0 i N H
FIN)Ci NN 0 \s
I , H -CO2H -CO2H / 0 0 NH2
H2N NI\I S
=
Ck ?--.0
OMe
OMe
O
EC1673
\11H2N
H
ilk n24_
J-0 ,
0 Fr R
).
HO2C /s s 0.,N1,./
1
HN
HO2CL..o r0
s--S)
NH
H2N
C),,,,/CO2F1 HO2C,.01
HN---NH
HN. HO2CHN
0
ONJH CO2H
/
o..NH
HN 0
HN H
0 H2N N
II NH CO2H
NH O's"I
HO2C,,.
HN,.0
NH
O
111
Ho2o NH
NH 0 0
NH
NS---- YI\J
0 N N
HN-'
ON N H2
NH2 H
EC1866
150
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
NH2
\ NH
5-N 0
HN¨'
HN
HO2C,
f--NH CO2H
O HN---1\
HO2C--_,
0
--"F-N)H¨S
HN
S
NH
H2N
1_4 0/
N..2
No 0
t\NH2N = OMe Me0 0
0 .
-\\
0 N 0 =
NH2
HN CO2H CO2H S
SA1N¨k
NH
0
HN¨
HN¨¨CO2H
<
Ho2c [4 ¨CO2H
- 2
o %
NH
NH
HNSN
H2N
EC1704
151
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H2N H2N
N1)=t0 1\1)_t0
N N N N
HN HN
41, *
0 0
HN HN
uniCO2H -,,CO2H
O 0
NH NH
/II. /h.
HO2C 0 HO2C 0
HN HN
O¨\ NH 0¨\ NH
NH HN¨ NH HN¨
/III" NH2 iiih. NH2
HO2C 0 HO2C 0
HN HN
O---n\CO2H
0002H
NH
S NH
tii..(
S---S CO2H 5 \SCO2H
0
/.0
CD(:)
r H 0
0
\---0 )-3
NH2
NH2
* 0*
0 \ 50
\ 0
0 0
0 * 0 *
NH ro N NH2
N
p..."µ
LN
0
Fritcq
EC1744 EC1772
152
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H2N
)/¨NH
NO
N N
H2N)/¨NH
HN NO
* N N
S
HN
0
HN
41
..HICO2H
0
HN
.00O2H
0
NH
1....
HO2C/ 0 NH
HN
r
__,
/NH " HN
0 ¨\ NH H C) El C) /NH HN
?i"
OH 0 " \¨CO2H
NH HN¨NFI
HO¨/ a
OH NH
el..
2 0 I""
HO2C 0 / / c0
HO
HN
0\CO2H '
7) _________________________________________ / /
"OH C) \¨CO2H
---..1a
HO OH/ ,,,,. IlHo
NH
/1""( HO
0 S 002H --; rNH HN
C) HON / azm tCO2H
N---1
HO-2 30H S
1
S
N 0 /---I
NH2 --0
0 r¨N
* 0
N
0
0
H2N II 0
0\
\
0
ci 0
* 0
N H2N
110 0/
0 V ¨\N
Y ---- 0
FmocNt
EC1788 EC1884
153
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
H2N
)/-NH H2N
N1)_t0 )/-NH
N N N 0
SN N
HN S
= HN
0
e
HN
...CO2H
o
HN
offiCO2H
0
NH
0.._7,.". o
HO, i-N o H HN NH
HO ) __ !,,,
_) ______________ OH 0 CO2H Ho, o
HO IDFI NH --, ,/-NH HN
0 CO2H
C::)_/ ________________________________________ .
/-NO H
VIH""No '701-1
HR, HO --OH NH
HO\ ____________
( C,F1 O''''' \-CO2H (:) /1""
0
HO---/ 1:)H NH OH HO HO ! i-NH HN
0
.)
HO /-
NH HN
HO ) ____________ c
N
)o,,,.. N/(:;/ts CO. 2H 0 HO HO ( o 01-1 0 CO2H
OH NH
OH CD
0
HO OH S HO, )-NH HN
I
HO\ ) _________________________________________ !, CO2H
,--1 1)F1 S
I
O ,--o
H2N * o CN)
\ o
n(IY.
o o
H2N' * 0
0 \
0
.
N1-.
0NH o
*
N ' NH
0 ____________________________________________ ........N \ /
- --- N
c-N\
HO N 0
N-7
0 0
EC1879 EC1904
154
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H2N H2N
)7-NH )/-NH
N___,r) NIt0
_
N N N N
S
HN HN
*
*
0
HN 0
....0O2H HN
...0O2H
0
NH 0
C
No
HO 0
NH HN .....
2-V HN
O
HO
HO '30H 0 \--CO2H
HO
2 _____________________________________________ .!,s,
',._ H NH
HO _ :HNFi C)
H
CO2H
0,/'cO HO) __ OH ,,,..N
NH
-1
_)1_0?--NH I-HNo/
n
0
\-CO2H HO,
OH `-'
______________________________________________ (
HO OH
0.j""'
0 HO . OH (
4
'0
OH CO2H-
NH
HO NH HN
CO2H 0
HO '. HR, /-NH HN
'OH
bH S H ON __ c tCO2H
HO OH
,---.0 HO--/ .'
OH S
$ 0
0./ 0
)õ,..(NH
CN)
HN ,-, v-,
0 NH2
Oys.,,,
NH
=111101 0* 0
/
\
0,r,0 r_e
N
Q"µ"?
H2N 0 0 0
it *
0 0 0 NH2
/
\ L-N
0
0 O
# 0
0 S
H2N S/
N)/-)FmocN
EC1911 EC1949
155
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H2N
)1¨NH
NCD
N N
\ I"
H2N HN
)/¨NH
NO
N N qo
HN
HN
0
NH
qo
HN 0
HO NH HN
OH 0 \ ¨CO2H
0 HO 'OH NH
NH 0\ __/1..,=0
0 HO:(3)--FNH HN),..,,
HO NH HN
OH 0 NH\ ¨CO,H
HO C HO 4 \ ¨CO2H , _.2--
OH
HO OH NH Oj
o Ho,NH HN
Ho, NH HN HO '' , tCO21-1
HO '' , ,..q \ õ OH
OH 0 \ ¨CO2H HO OH
HO 'OH NH
O_JO 4
HO
3--FNH HN
tCO2H
, OH 0
HO-1 -OH S HN
cy 0.;.1s.. 0
HNC) OS
0
0
S
0
0
0 HN, /
5 (q--..
0 NH
HN HN
0
0 ).....<
NH
0 0
HN 0
t? CI
0,1
0
/0 H2N
'--0
r-N \
N
ONH2
0
(3\ 0
55,..NH
(7
L-- NH
AH S''.-)
(--N,
/N---/
EC2074 EC2080
156
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
H,N
)-NH
H2N N)__O
),-NH
N0 N N
N N
\I"HN
HN
qo
HN
-nCO,H
.q0
HN
0
..,CO2H NH
0,_/....0
0 HO NH HN
NH
FID)-OH (4 \-co2H
o)_./ ...
NH HN 0 HO OH NH
Ho,
7
) j¨C. ID_/,..
% OH C)."" \--CO2H HS NH HN
HO 'OH NH H ' \-
0 CO,H
C/,...
0 HO OH NH
HS NH HN )--/".<0
HO, NH HN
H_C:)_)--C
OH 0 \-CO2H HO '' ,, 1-1
tCO3 OH
HO-' OH NH HO -J
'OH ,.....(L
0
HO, NH HN =--r
0 )
HO--,=CO2H
õ. bH 0
HO
OH S HN
0
0
ito
S
0
HN
$
0
0
S 0
0
0
HN\_./
0 Cl \
S NH
0
HN
0
HN
04-<
0
NH 0
HN N
q
0 s1H2 ' oCNFmoc
0 0
C)--.F-N. \
N
0
(:) -- 0 0 0
NH,
0
daiNi 0 N
0 111" o
O
C3.,1 NH2
PMOC
NO2
EC2103 EC2127
157
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H2N
),¨NH
NO
H2N
)/¨NH N N
$1 NO
N N HN
HN
qo
HN
= .,CO2H
qo
HN
0
NH
0 0._/,'..
NH HO NH HN 0
Ho, NH HN o,.-
0 '-.
bH 0.''' \¨CO2H
HO 'OH NH
'OH 0 \¨CO2H
:
HO OH NH 0
V".=0 HQ, NH HN
Ho, NH HN , bH 0 \¨0O2H
H})¨/¨
;., ....1
0 CO2H
HO 'OH NH
, OH \¨
HO OH NH
Ho,
NH HN 0 HQ
= 'OHNH HN
-'.0O2H
10)=/¨r --..0O2H
HO 'b H S
HO OH S
0
0 )
0
HN 0
HN
0
0 0
EC2110
0
S 0
0
0 0
HI\1?....<
0
NH
0 0
HN
----k
0
0\
<..) 0c)
0
o/ ¨N
,--N,
N'l 6I IT 0
H2N
* ,,...;0
HN
0--
--0 0
0 0
S
HN
0
g 0
/0 0 NH
N..
O
0540
N
\¨C1
Cl ----c
EC2130 EC2110
158
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
HNy NH2
NH
CO2H
0 CO2H
N N H 0 H 0
T
N.,...A. N.,...)... NrciA CO H
0 ril ,.
0 ,. -
i H .,....- 2
E 0
.. H 0 =.,. 0 =,s,o,11,Nõ.
HN)I/r 111111fr CH CH s
H
,,k,. .....
H2N N N 0 N H2
* C)N= \.õ.N.0
=
=
4 NH
4 Fri
11\1 *
N
c-N
HN,y.NH2
NH
CO2H
0 go 2H H o o
H H
0 0 NrN......,,-A,N N.......),,N.f,r.NCO2H
H ! H ! H
0 7,.. 0 7,.. 0
HN....11.1NrN CO2H CO2H
....4 I H SI HN¨t.
H2N N N
OC) * H2N 1\fl
r---N
0,......N 0 * 0/ ---O
II 0
0 ..N. j
0
H N. N H2
NH
CO N 2H
0 CO2H H
O
0 0
H frH
N CO2H 0
4N
HNAINrN \CO2H 0 7......
, , H CO2H S
H 2
0 0
H2N N N
NF_I
Nv_ zH HN
0
1-1 <
0 --- \ 0
0 .t?
..N
0
\ (:)
0...'N .....-0 0 (
0". \ ........... \ N. ......... \ * N ..S.
>1.........- 0
0
NH2 9 0
H N. N H2
NH
CO 2H
0
0 CO2H H
l i H 0
H
0 i,.."....õ.....".N.........A: i\ilid/c N C04H O
0
N 0 \
002H 002H s 0
)..., , H
N?1"-N H 2
H2N N N
NH HN<
0
.'N
a., * ON
*:N0 CC
....-0
No
0
* N , r....,
0 1 0
NH2
159
CA 02979527 2017-09-12
WO 2016/148674 PCT/US2015/020397
H N. N H2
NH
CO 2H
0 CO2H H 0
H
'NI ..õõ),,C) N CO 2H 0
4
0 \ 0 _....õ 0 N
HN -11.1NrN 002H 002H s 0
H2
H2N N N"-NH
0
0 0 t?.
.'N
N 0 CD/
H\ ----N
0-"" \,..w....., * N
0 t? 0
NH 2
HNyNH2
NH
CO2H
0 CO2H H 0 0
H H
0 0 N/===,,,,,...y.,,õ,AN N ,)LNiNCO2F-4
0
H H . -=,,. 0 7,, N
HN -itfrN 002H 002H H 0
-s 0
H2
H2N N N--NH
0 ---- \
N 0 0 t?
*.--1
FMOCN-c * ON
cr0 H2N
µ--N D
* N .s. )r....,
0 0
NH 2
HNyNH2
NH
CO2H
0 CO2H
N H 0
H w rH
N CO 2H 0
NIr ,4
0 NCO2H 0 -CO2H 0 's N
al 'ill r.
H2N N N
NH H
N..........
0
.)---- ri
----\ 0 0= E
N \ 0
0 ".0 is q
*C)c)= NH
0
FMOCN---No H2N
Li
160
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
HNyNH2
NH
CO2H
O CO2H H 0 0
H H 0
0 0 N -
N.,.....),,N4NILN,...(1,,N,,,..0O24
H H = H
H L...,N....11,11N N 07,õ 0 7,õ 0 Nõ N
CO2H CO2H S
H
0 ----\-.....\......)"...
H2N N N....?
0
=Si----% rA,,
-----\ 0 0
0
Nq
O #NH2
O 0- 0
,r_NH
0
HNyNH2
N
.. H"
CO2H
O CO2H H 0 0
H H
fir fõir,
0
N..õ,1 0 \CO2H 0 7,,CO2H 0
HN,,.
)11 ", N S
H
)..,õ.,
H2N N N
0
---J---1 r--\,,
\
0 N,
0
Nq
O #NH2
O 0- 0
HNyNH2
NH
.."
CO2H
O CO2H H 0 0
H H
N.õ,...,K Xi, C0 214
0
HN)11N CO2H 7,,CO2H 7,õ N
`=== N 0 S
H
)..,õ.,
0 \ 0
H2N N N
0
---J---1 r--\,,
\
N '-' 0
0 c
0
Nq
O #NH2
O 0- 0
...y it 0
',-.-===NH
161
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
HNyN H2
NH
CO2H
0 CO2H H 0
H =
Nj= NN)L rN= CO21-4
0 Er
H2N
0 \CO2H 0 CO2H 0 =s
N
0
NIN
n
0
00 N\O
= F
0,
0
H N '-C)
H04 ).(:)\Ar:1***(N"*.N-'1\ H2N o/ NH2
METHOD EXAMPLES
General. The following abbreviations are used herein: partial response (PR);
complete response (CR), biweekly (M/F) (BIVV), three times per week (M/W/F)
(TIVV). A PR
is observed where tumor volume, as defined herein, decreases from a previous
high during the
observation period, though regrowth may occur. A CR is observed where tumor
volume, as
defined herein, decreases to zero during the observation period, though
regrowth may occur. A
cure is observed where tumor volume, as defined herein, decreases to zero, and
does not regrow
during the observation period.
METHOD. Relative Affinity Assay. The affinity for folate receptors (FRs)
relative to folate was determined according to a previously described method
(Westerhof, G. R.,
J. H. Schornagel, et al. (1995) Mol. Pharm. 48: 459-471) with slight
modification. FR-positive
KB cells were heavily seeded into 24-well cell culture plates and allowed to
adhere to the
plastic for 18 h. Spent incubation media was replaced in designated wells with
folate-free RPMI
(FFRPMI) supplemented with 100 nM 3H-folic acid in the absence and presence of
increasing
concentrations of test article or folic acid. Cells were incubated for 60 min
at 37 C and then
rinsed 3 times with PBS, pH 7.4. Five hundred microliters of 1% SDS in PBS, pH
7.4, was
added per well. Cell lysates were then collected and added to individual vials
containing 5 mL
of scintillation cocktail, and then counted for radioactivity. Negative
control tubes contain only
the 3H-folic acid in FFRPMI (no competitor). Positive control tubes contain a
final
concentration of 1 mM folic acid, and CPMs measured in these samples
(representing non-
specific binding of label) were subtracted from all samples. Relative
affinities were defined as
the inverse molar ratio of compound required to displace 50% of 3H-folic acid
bound to the FR
on KB cells, where the relative affinity of folic acid for the FR was set to
1.
EXAMPLE. The conjugates described herein show high binding affinities
towards folate receptors as determined by an in vitro competitive binding
assay that measures
162
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
the ability of the ligand to compete against 3H-folic acid for binding to cell
surface folate
receptors (FR). Without being bound by theory, it is believed herein that the
high binding
affinity of the conjugates described herein allows for efficient cellular
uptake via FR-mediated
endocytosis.
METHOD. Inhibition of Cellular DNA Synthesis. The conjugates described
herein were evaluated using an in vitro cytotoxicity assay that predicted the
ability of the drug
to inhibit the growth of the corresponding targeted cells, such as, but not
limited to the
following
Cell Line
KB Human cervical carcinoma
NC1/ADR-RES-C12 Human ovarian carcinoma
IGROV1 Human ovarian adenocarcinoma
MDA-MB-231 Human breast adenocarcinoma (triple
negative)
A549 Human lung carcinoma
H23 Human lung adenocarcinoma
HepG2 Human hepatocellular carcinoma
AN3CA Human endometrial adenocarcinoma
It is to be understood that the choice of cell type can be made on the basis
of the susceptibility
of those selected cells to the drug that forms the conjugate, and the relative
expression of the
cell surface receptor or target antigen. The test conjugates were conjugates
of a cell surface
receptor or target antigen binding compound and PBD prodrugs, poly-PBD
prodrugs, and
mixed PBDs, as described herein. The test cells were exposed to varying
concentrations of the
conjugates, and optionally also in the absence or presence of at least a 100-
fold excess of the
unconjugated cell surface receptor or target antigen binding compound for
competition studies
to assess activity as being specific to the cell surface receptor or target
antigen.
EXAMPLE. Conjugates of PBD prodrugs, poly-PBD prodrugs, and mixed
PBDs described herein were active against KB cells. The activity was mediated
by the folate
receptor as indicated by competition experiments using co-administered folic
acid. KB cells
were exposed for up to 7 h at 37 C to the indicated concentrations of folate-
drug conjugate in
the absence or presence of at least a 100-fold excess of folic acid. The cells
were then rinsed
once with fresh culture medium and incubated in fresh culture medium for 72
hours at 37 C.
Cell viability was assessed using a 3H-thymidine incorporation assay. For
conjugates described
herein, dose-dependent cytotoxicity was generally measurable, and in most
cases, the IC50
values (concentration of drug conjugate required to reduce 3H-thymidine
incorporation into
newly synthesized DNA by 50%) were in the low nanomolar range. Though without
being
bound by theory, when the cytotoxicities of the conjugates were reduced in the
presence of
163
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
excess free folic acid, it is believed herein that such results indicate that
the observed cell death
was mediated by binding to the folate receptor.
Example IC50KB Cells
(nM)
EC1628 383
EC1628 + DTT (a) 11
EC1629 + DTT (a) >10
EC1630 2.7
EC1673 >1 [t.M
EC1695 >100
EC1695 + DTT (a) 1
EC1704 0.46
EC1744 1.2
EC1772 0.33
EC1788 0.18
EC1879 0.56
EC1884 0.36
EC1904 >50
EC1911 0.7
EC1949 1.49
EC2074 3.6
EC2080 0.2
EC2103 3.5
EC2127 1.34
(a) Co-administered with dithiothreitol (DTT).
METHOD. In vitro activity against various cancer cell lines. IC50 values were
generated for various cell lines. Cells were heavily seeded in 24-well Falcon
plates and allowed
to form nearly confluent monolayers overnight. Thirty minutes prior to the
addition of the test
compound, spent medium was aspirated from all wells and replaced with fresh
folate-deficient
RPMI medium (FFRPMI). A subset of wells were designated to receive media
containing 100
[t.M folic acid. The cells in the designated wells were used to determine the
targeting
specificity. Without being bound by theory it is believed herein that the
cytotoxic activity
produced by test compounds in the presence of excess folic acid, i.e. where
there is competition
for FR binding, corresponded to the portion of the total activity that was
unrelated to FR-
specific delivery. Following one rinse with 1 mL of fresh FFRPMI containing
10% heat-
inactivated fetal calf serum, each well received 1 mL of medium containing
increasing
concentrations of test compound (4 wells per sample) in the presence or
absence of 100 [t.M free
folic acid as indicated. Treated cells were pulsed for 2 h at 37 C, rinsed 4
times with 0.5 mL of
media, and then chased in 1 mL of fresh medium up to 70 h. Spent medium was
aspirated from
all wells and replaced with fresh medium containing 5 p.Ci/mL 3H-thymidine.
Following a
164
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
further 2 h 37 C incubation, cells were washed 3 times with 0.5 mL of PBS and
then treated
with 0.5 mL of ice-cold 5% trichloroacetic acid per well. After 15 min, the
trichloroacetic acid
was aspirated and the cell material solubilized by the addition of 0.5 mL of
0.25 N sodium
hydroxide for 15 min. A 450 [t.L aliquot of each solubilized sample was
transferred to a
scintillation vial containing 3 mL of Ecolume scintillation cocktail and then
counted in a liquid
scintillation counter. Final results were expressed as the percentage of 3H-
thymidine
incorporation relative to untreated controls.
METHOD. Inhibition of Tumor Growth in Mice. Four to seven week-old mice
(Balb/c or nu/nu strains) were purchased from Harlan Sprague Dawley, Inc.
(Indianapolis, IN).
Normal rodent chow contains a high concentration of folic acid (6 mg/kg chow);
accordingly,
test animals were maintained on a folate-free diet (Harlan diet #TD00434) for
about 1 week
before tumor implantation to achieve serum folate concentrations close to the
range of normal
human serum, and during the Method. For tumor cell inoculation, 1 x 106 M109
cells (a
syngeneic lung carcinoma) in Balb/c strain, or 1 x 106 KB cells in nu/nu
strain, in 100 [t.L were
injected in the subcutis of the dorsal medial area (right axilla). Tumors were
measured in two
perpendicular directions every 2-3 days using a caliper, and their volumes
were calculated as
0.5 x L x W2, where L = measurement of longest axis in mm and W = measurement
of axis
perpendicular to L in mm. Log cell kill (LCK) and treated over control (T/C)
values were then
calculated according to published procedures (see, e.g., Lee et al., "BMS-
247550: a novel
epothilone analog with a mode of action similar to paclitaxel but possessing
superior antitumor
efficacy" Clin Cancer Res 7:1429-1437 (2001); Rose, "Taxol-based combination
chemotherapy
and other in vivo preclinical antitumor studies" J Natl Cancer Inst Monogr 47-
53 (1993)).
Dosing was initiated when the s.c. tumors had an average volume between 50-
100 mm3 (to), typically 8 days post tumor inoculation (PTI) for KB tumors, and
11 days PTI for
M109 tumors. Test animals (5/group) were injected intravenously, generally
three times a
week (TIVV), for 3 weeks with varying doses, such as with 1 p.mol/kg to 5
iimol/kg, of the drug
delivery conjugate or with an equivalent dose volume of PBS (control), unless
otherwise
indicated. Dosing solutions were prepared fresh each day in PBS and
administered through the
lateral tail vein of the mice.
METHOD. General 4T-1 Tumor Assay. Six to seven week-old mice (female
Balb/c strain) were obtained from Harlan, Inc. (Indianapolis, IN). The mice
were maintained
on Harlan's folate-free chow for a total of three weeks prior to the onset of
and during the
method. Folate receptor-negative 4T-1 tumor cells (1 x 106 cells per animal)
were inoculated in
the subcutis of the right axilla. Approximately 5 days post tumor inoculation
when the 4T-1
165
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
tumor average volume was ¨100 mm3 (to), mice (5/group) were injected i.v.
three times a week
(TIVV), for 3 weeks with varying doses, such as 3 i.tmol/kg, of drug delivery
conjugate or with
an equivalent dose volume of PBS (control), unless otherwise indicated herein.
Tumor growth
was measured using calipers at 2-day or 3-day intervals in each treatment
group. Tumor
volumes were calculated using the equation V = a x b2/2, where "a" was the
length of the tumor
and "b" was the width expressed in millimeters.
METHOD. Drug Toxicity. Persistent drug toxicity was assessed by collecting
blood via cardiac puncture and submitting the serum for independent analysis
of blood urea
nitrogen (BUN), creatinine, total protein, AST-SGOT, ALT-SGPT plus a standard
hematological cell panel at Ani-Lytics, Inc. (Gaithersburg, MD). In addition,
histopathologic
evaluation of formalin-fixed heart, lungs, liver, spleen, kidney, intestine,
skeletal muscle and
bone (tibia/fibula) was conducted by board-certified pathologists at Animal
Reference
Pathology Laboratories (ARUP; Salt Lake City, Utah).
METHOD. Toxicity as Measured by Weight Loss. The percentage weight
change of the test animals was determined on selected days post-tumor
inoculation (PTI), and
during dosing. The results were graphed.
EXAMPLE. In vivo activity against tumors. Conjugates described herein
showed high potency and efficacy against KB tumors in nu/nu mice. Conjugates
described
herein showed specific activity against folate receptor expressing tumors,
with low host animal
toxicity.
EXAMPLE. EC1629 in vivo activity against tumors. As shown in FIG.1,
EC1629 (*) dosed at 2 p.mol/kg TIVV for two weeks decreased KB tumors in test
animals
compared to untreated control (411 ). Toxicity was not observed, as evidenced
by test animal total
body weight.
EXAMPLE. EC1744 and EC1788 in vivo activity against tumors. As shown in
FIG. 2 EC1744 (N) dosed at 2 p.mol/kg TIVV for two weeks and EC1788 ( A )
dosed at 0.2
p.mol/kg TIVV for two weeks decreases KB tumors in test animals compared to
untreated control
(411 ). Moreover, EC1788 gave a complete response. Toxicity was not observed
for EC1744, as
evidenced by test animal total body weight. Minor toxicity was observed for
EC1788, as
evidenced by test animal total body weight; however, test animal total body
weight steadily
increased after the last dosing day.
EXAMPLE. EC1884, EC1879, and EC1788 in vivo activity against tumors. As
shown in FIG. 3, EC1884 (d) dosed at 2 p.mol/kg TIVV for two weeks decreases
KB tumors in
test animals compared to untreated control (a). Toxicity was not observed for
EC1884, as
166
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
evidenced by test animal total body weight. FIG. 3 also shows and that EC1879
(c) dosed at 2
p.mol/kg TIVV for 1 week decreased KB tumors in test animals compared to
untreated control
(a). Moreover, EC1879 gave a partial response. Minor toxicity was observed for
EC1879, as
evidenced by test animal total body weight. FIG. 3 also shows and that EC1788
(b) dosed at
0.4 p.mol/kg BIVV for 2 weeks decreases KB tumors in test animals compared to
untreated
control (a). Moreover, EC1788 gave a complete response, and cure. Minor
toxicity was
observed for EC1788, as evidenced by test animal total body weight; however,
test animal total
body weight increased after the last dosing day.
EXAMPLE. EC1879 in vivo activity against tumors. As shown in FIG. 4,
EC1879 ( A ) dosed at 2 p.mol/kg TIVV for two weeks decreases KB tumors in
test animals
compared to untreated control (N). Moreover, EC1879 gave a complete response
in 5/5 test
animals, and cure in 5/5 test animals. Toxicity was not observed for EC1879,
as evidenced by
test animal total body weight.
METHOD EXAMPLE. TNBC Tumor Assay. Triple negative breast cancer
(TNBC) is a subtype characterized by lack of gene expression for estrogen,
progesterone and
Her2/neu. TNBC is difficult to treat, and the resulting death rate in patients
is reportedly
disproportionately higher than for any other subtype of breast cancer. A TNBC
xenograft
model was generated in an analogous way to the KB and M109 models described
herein by
implanting MDA-MB-231 breast cancer cells in nu/nu mice. Dosing was initiated
when the s.c.
tumors had an average volume between 110-150 (generally 130) mm3 (to),
typically 17 days
post tumor inoculation (PTI). Test animals (5/group) were injected
intravenously, generally
three times a week (TIVV), for 2-3 weeks with varying doses, such as with 1
p.mol/kg to 5
iimol/kg, of the drug delivery conjugate or with an equivalent dose volume of
PBS (control),
unless otherwise indicated. Dosing solutions were prepared fresh each day in
PBS and
administered through the lateral tail vein of the mice.
EXAMPLE. EC1744 in vivo activity against tumors. As shown in FIG. 5,
EC1744 (=) dosed at 2 p.mol/kg TIVV for two weeks decreased triple negative
breast cancer
(TNBC) MDA-MB-231 tumors in test animals compared to untreated control (0).
Moreover,
EC1744 gave a complete response in 5/5 test animals, and cure in 4/5 test
animals. Toxicity
was not observed for EC1744, as evidenced by test animal total body weight.
METHOD. Human cisplatin-resistant cell line. A human cisplatin-resistant cell
line was created by culturing FR-positive KB cells in the presence of
increasing cisplatin
concentrations (1002000 nM; over a> 12 month period). The cisplatin-resistant
cells, labeled
as KB-CR2000 cells, were found to be tumorigenic, and were found to retain
their FR
167
CA 02979527 2017-09-12
WO 2016/148674
PCT/US2015/020397
expression status in vivo. KB-CR2000 tumors were confirmed to be resistant to
cisplatin
therapy. Treatment with a high, toxic dose of cisplatin (average weight loss
of 10.3%) did not
produce even a single partial response (PR).
METHOD. Human serum stability. Conjugates described herein may be tested
in human serum for stability using conventional protocols and methods. The
test compound
may be administered to the test animal, such as by subcutaneous injection. The
plasma
concentration of the conjugate, and optionally one or more metabolites, may be
monitored over
time. The results may be graphed to determine Cmax, Tmax, half-life, and AUC
for the test
compound and metabolites.
METHOD. Plasma clearance. In vivo studies include a minimum of 3 test
animals, such as rats, per time point. Illustratively, female Lewis rats with
jugular vein
catheters (Harlan, regular rodent diet) may be given a single subcutaneous
injection of test
compound. Whole blood samples (300 [t.L) may collected at the following time
points: 1 min,
10 min, 30 min, 1 h, 2 h, 3 h, 4 h, 8 h, and 12 h after injection. The blood
samples may be
placed into anti-coagulant tubes containing 1.7 mg/mL of K3-EDTA and 0.35
mg/mL of N-
maleoyl-beta-alanine (0.35 mg/mL) in a 0.15% acetic acid solution. Plasma
samples may be
obtained by centrifugation for 3 min at ¨2,000 g and stored at -80 C. The
amounts of test
compound in the plasma and any metabolites were quantified by LC-MS/MS.
168
